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Abstract
Sequential procedures were originally designed for use in an industrial 
context. However the flexibility and efficiency of sequential methods made them 
attractive to those involved in medical experimentation.
The earliest sequential designs for clinical trials were fully sequential, that is 
they required an analysis to be conducted after every patient response. More 
recently the emphasis has been on group sequential designs, where analyses are 
carried out after groups of patient responses.
One of the distinguishing features of sequential procedures is that the 
required sample size is a random variable. For fixed group sizes, a given 
maximum number of analyses and given error constraints, group sequential tests 
can be designed which minimize a given function of expected sample size. We 
term such procedures optimal group sequential tests.
In this thesis we introduce a computationally efficient and numerically stable 
method for the computation of optimal group sequential tests. Although we 
approach this problem from a frequentist perspective, our method makes use of 
both Bayesian decision theory and dynamic programming.
In Chapters 3 and 4 we consider computing optimal one-sided and two-sided 
tests respectively. The two-sided tests permit the rejection of the null hypothesis, 
H0, at any analysis, but they only allow H0 to be accepted at the final analysis. 
In Chapter 5 we consider computing optimal wedge tests which, like two-sided 
tests, test Hq against a two-sided alternative, but, unlike two-sided tests, allow H0 
to be accepted or rejected at each analysis.
In Chapter 6 we consider some of the Bayesian and Bayes decision theoretic 
procedures proposed in the literature. Finally, in Chapter 7, we look at a number 
of ideas for future research as well as some relevant topics which have not been 
considered elsewhere in the thesis.
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1. Sequential Methods: An Introduction.
1.1 Introduction.
Johnson (1961) defined a sequential method to be ’... any statistical 
procedure in which the final pattern (including the number) of observations is not 
determined a priori but depends, in some way or other, on the values observed in 
the course of the work’. Johnson’s definition covers the theory, methods and 
examples of this thesis.
1.2 The History of Sequential Methods.
The first sequential test can be traced back to 1929 when a paper by Dodge 
& Romig entitled ’A Method of Sampling Inspection’ was published in the Bell 
System Technical Journal. Dodge & Romig proposed a double sampling 
inspection procedure for use in acceptance sampling.
It was in April 1943 that Abraham Wald introduced the sequential 
probability ratio test (SPRT) (which we describe in detail in §3.4). The SPRT 
laid the foundations for many of the recent developments in the theory of 
sequential analysis. At about the same time as Wald, G.A. Barnard was carrying 
out war-time work in Britain of a sequential nature.
The main motivation for the work of Wald and Barnard came from industrial 
problems such as quality control. As an example, consider the following 
problem: a random sample of size n is drawn from a batch of manufactured goods. 
A rule is applied so that if r  (< n) of the sample are in some sense ’defective’ we 
reject the batch; otherwise the batch is accepted.
Clearly, in the majority of cases, it will prove quite unnecessary to inspect all 
n items in the sample before coming to a decision. Hence the total number of 
items inspected will not be fixed, but a random variable taking values in the range 
[r,n].
This simple example highlights many of the properties of sequential 
methods:-
(i) the method is efficient in the sense that it employs as few observations as 
possible before coming to a decision;
(ii) the sample size is not fixed, but a random variable;
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(iii) the method leads to savings both in terms of time and money over the 
corresponding fixed sample size procedure.
Sequential Methods in Clinical Trials.
More recently researchers have been interested in employing sequential 
methods in clinical trials. The nature of clinical trials is such that patients respond 
gradually over time. The investigator will naturally want to analyse the resulting 
data as it becomes available in order that the trial may be stopped as soon as an 
important difference between treatments becomes apparent. However the 
sequential nature of such an analysis must be borne in mind when deciding 
whether or not to stop the trial.
Armitage (1960) was one of the pioneers in the field of sequential clinical 
trials. Later, Armitage, McPherson & Lowe (1969) introduced the notion of 
repeated significance testing at a constant nominal significance level. These early 
procedures were fully sequential, that is they required an analysis to be carried out 
after every patient response. Such an approach is, of course, likely to prove 
impractical in the context of most clinical trials.
Pocock (1977) and O’Brien & Fleming (1979) were among the first to 
propose group sequential tests, where analyses are conducted after a group of 
patient responses. Both of these papers concentrated on the two-sided testing 
problem, where a null hypothesis, H0, is tested against a two-sided alternative, H l . 
Rejection of H0 in favour of H1 is permitted at any analysis by these designs, but 
acceptance of H0 is only allowed at the final analysis. More recently Fleming, 
Harrington & O’Brien (1984) and Wang & Tsiatis (1987) have also proposed 
two-sided group sequential tests.
Gould & Pecore (1982), Gould (1983) and Emerson & Fleming (1989) have 
proposed group sequential wedge tests, where again we are testing H0 against a 
two-sided alternative, but this time H0 can be accepted or rejected at each 
analysis. DeMets & Ware (1980), (1982), Whitehead (1983), Jennison (1987) and 
Emerson & Fleming (1989) have proposed one-sided group sequential tests.
The big advantage of a group sequential test over a fixed sample size test lies 
in the fact that, on average, it will normally require fewer patients. This is 
particularly the case when treatment differences are large.
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Recently there have been a number of papers in the literature relating to the 
computation of optimal group sequential tests. For a given problem with fixed 
group sizes, a fixed maximum number of groups and given error constraints, the 
optimal test minimizes a chosen function of expected sample size.
Jennison (1987) used a constrained numerical search method to compute 
optimal one-sided tests. Unfortunately his method suffered from a number of 
computational problems (see §3.5 for a description of these problems).
Wang & Tsiatis (1987) considered a family of two-sided tests indexed by a 
single parameter, A, say. They then searched over A for the optimal test within 
their family. Their approach was computationally efficient and gave near optimal 
tests for any given problem.
Emerson & Fleming (1989) used an analogous approach to that of Wang & 
Tsiatis in order to compute near optimal one-sided tests.
In this thesis we introduce an improved method for the computation of 
optimal group sequential tests. Unlike the approach of Jennison (1987), our 
method is computationally efficient and numerically stable. Further, unlike the 
approaches of Wang & Tsiatis (1987) and Emerson & Fleming (1989), our method 
gives the overall optimal test for a given problem.
Despite the obvious attractions of group sequential tests and, in particular, 
optimal group sequential tests, O’Brien & Fleming (1979) have noted a reluctance 
to use formal sequential methods on the part of clinicians. They gave 3 main 
reasons for this:
(i) the analysis of fixed sample size tests is well known and generally thought to 
be efficient;
(ii) the complex nature of some study protocols for sequential trials;
(iii) the experimenter may wish to stop the trial for reasons unrelated to treatment 
differences (for example, the development of a new, seemingly better, treatment).
A number of papers in the literature have proposed less rigid, more flexible, 
sequential methods for use in practice. For example, Lan & DeMets (1983), 
(1989) and Jennison (1987) have suggested methods for use when group sizes 
and/or the maximum number of groups are unpredictable. We also note that 
Pocock (1977) showed that his two-sided tests are robust to departures from the 
usual normality and known variance assumptions, as well as being robust to small
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changes in the planned group sizes.
Jennison & Turnbull (1984), (1989) have proposed an extremely flexible 
procedure known as the repeated confidence interval (RCI) approach. The RCI 
approach allows a trial to be stopped early for reasons unrelated to treatment 
differences, while not invalidating any inferences which might be made concerning 
the size of treatment differences.
Bayesian and Bayes Decision Theoretic Sequential Methods.
The emphasis in this thesis is on frequentist sequential methods. A number 
of Bayesian sequential methods have been proposed in the literature by, for 
example, Berry (1987) and Freedman & Spiegelhalter (1989). Bayesian decision 
theory approaches have been suggested by, among others, Anscombe (1963), 
Chemoff & Petkau (1981) and Berry & Ho (1988).
1.3 Summary of the Thesis.
The examples and motivation for the work presented in this thesis come from 
the area of medical statistics. As an introduction to this topic we consider the 
design of clinical trials in Chapter 2.
Chapters 3, 4 and 5 deal with the one-sided, two-sided and wedge testing 
problems respectively, from a frequentist perspective. In each chapter we give a 
computationally efficient and numerically stable method for computing optimal 
group sequential tests.
Chapter 6 considers some of the Bayesian and Bayes decision theoretic 
procedures proposed in the literature. We look in detail at the frequentist 
properties of one of these procedures and compare them with the frequentist 
properties of some of our optimal tests.
Chapter 7 looks at a number of ideas for future research as well as some 




Pocock (1983) defined a clinical trial to be any form of planned 
experiment which involves patients to elucidate the most appropriate treatment of 
future patients with a given medical condition’. Much of this thesis will be 
concerned with comparing different designs for clinical trials. In this chapter we 
consider some of the more general aspects of clinical trial design.
2.2 Designing Clinical Trials.
An Example
Consider comparing the relative effectiveness of a new drug, N, say, with 
that of a standard, S, for reducing the blood pressure level in patients suffering 
from hypertension. Before such an experiment is conducted the new drug will 
have passed through a number of preliminary checks and pilot studies concerning 
its safety and efficacy. Initially these checks will be carried out in test tubes or on 
animals. Eventually, however, the drug will have to be tested on humans. 
Following Pocock (1983), this stage of the experiment, the clinical trial, can be 
divided into four distinct phases:-
Phase I: Clinical Pharmacology and Toxicity.
Here the main concern is with drug safety rather than drug efficacy. Phase I 
trials are normally conducted on healthy human volunteers. Typically these trials 
require between 20 and 80 volunteers, although separate studies in this phase may 
require as few as 6 volunteers.
Phase II: Initial Clinical Investigation for Treatment Effect
Here relatively small scale investigations are conducted into both the efficacy 
and safety of a new drug. This phase is useful for two main purposes:
(i) to screen out any drugs which are seen to be either ineffective or over-toxic;
(ii) to obtain an optimum treatment policy in terms of doses and schedules.
Phase II trials rarely require more than 100-200 patients per drug.
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Phase III: Full-Scale Evaluation of Treatments.
When people talk of clinical trials they are often referring to Phase ID trials. 
Here a new drug which has passed through the first two phases of experimentation 
is compared with a standard drug, a placebo or another new drug. A "substantial 
number” of patients will be required by a typical Phase HI trial.
Phase IV: Post-Marketing Surveillance.
After a new drug has been approved for marketing it will continue to be 
assessed in terms of both long-term morbidity and mortality effects. This is 
formally termed Phase IV of a clinical trial.
Primarily we shall be concerned with Phase in  trials in this thesis.
The Legal Requirement for Clinical Trials.
Up until the 2nd World War there were no formal requirements for clinical 
trials before a drug could be freely marketed. However the thalidomide disaster in 
the early 1960s led to a tightening up of the legislation in both the U.S.A. and this 
country.
In the U.K. a Committee on Safety of Drugs was set up in 1963 with the aim 
of considering all new drugs before they were tested or marketed. However 
pharmaceutical companies were not legally bound to seek this Committee’s 
approval. In 1968 the Medicines Act was passed. Part of this Act set up the 
Committee on Safety of Medicines (CSM). Any new drugs had now to be 
approved by the CSM before being included in clinical trials and before being 
placed on the market.
The Design of Clinical Trials.
Randomization.
On entry to a trial a patient is randomly assigned to one of the available 
treatments. There are two main reasons for randomization:
(i) to guard against bias;
(ii) to provide a basis for standard frequentist techniques such as significance tests.
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A naive way of randomly allocating patients to treatments would be to toss a 
coin and to assign the patient to the new treatment if the coin falls "heads" and to 
the standard treatment if the coin falls "tails". Alternatively a table of random 
numbers could be used in place of the coin. Unfortunately such approaches do 
not guarantee equally sized treatment groups. Indeed, especially in the case of a 
small trial or of a group sequential test, serious imbalances might occur in the 
sizes of different treatment groups.
One way of ensuring treatment group balance is to use a matched pairs 
design. Here a pair of patients who are similar in terms of such characteristics as 
age, sex and social class, are entered on to a trial with one of the pair being 
randomly assigned to the new treatment and the other to the standard treatment. 
One logistical problem with a matched pairs study concerns the difficulty in 
pairing patients, particularly near the end of a study.
Restricted randomization offers an alternative way of achieving equally sized 
treatment groups. Whitehead (1983, Ch.2) suggested two methods of restricted 
randomization, random permuted blocks and biased coin designs. Both of these 
methods are described in detail by Whitehead.
Historical Controls.
An alternative to randomization would be to use historical controls. Here 
all the patients in a trial receive the new treatment and their responses are 
compared with the historical responses of patients who had received the standard 
drug before the start of the trial.
Whitehead (1983, Ch.2) has strongly attacked the use of historical controls. 
He argued that the historical data would have come from patients who had ’... 
been treated during a different time period when the provision of secondary 
treatments, the standard of care and staffing, the administrative policy of the 
hospital or clinic and many other aspects of their welfare would have been 
different.’ He went on to note that ’... the record forms of the controls would not 
have been filled in for the purpose of the trial and might be incomplete, inaccurate 
or just inadequate for making the observations that can be recorded as they occur 
for the treatment group.’
There is much agreement with Whitehead. Available evidence suggests that 
inferences based on trials using historical controls tend to inflate the value of a
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new treatment
This does not mean that historical data is of no use. On the contrary this 
data can be used when planning a trial to estimate such design parameters as the 
variance of patient responses and the required sample size.
Within and Between Patient Studies.
In a within patient study each subject receives every one of the treatments 
being tested. This is achieved either by administering the treatments 
simultaneously or by administering them sequentially. For example, if we were 
comparing two treatments for earache we could simultaneously administer one 
treatment to a patient’s left ear and the other treatment to a patient’s right ear. 
Obviously logistics will often rule out a simultaneous within patient study. The 
alternative approach is to randomly assign a patient to one of the treatments. 
Then, after a suitable length of time, the patient is taken off this treatment and a 
"wash out" period follows to remove any lingering effects of the treatment The 
patient is then given the other treatment (or randomly assigned to another 
treatment in cases where more than two treatments are to be compared). Such a 
design is known as a crossover trial.
The big advantage of a within patient study is that each patient acts as his or 
her own control. Also the theory behind crossover trials is relatively simple.
Disadvantages include the impossibility of within patient studies for certain 
trials (consider comparing a treatment involving surgery with one that does not, 
for example). Also crossover trials should be avoided if there is any possibility 
that treatment effects could be carried over from one course of treatment to the 
next.
In a between patient study each subject receives only one of the treatments 
being tested. Patient responses on the first treatment are then compared with 
patient responses on the second treatment and so on. Between patient studies are 
much more common than within patient studies. Gore (1982) noted that ’... of 38 
clinical trials reported in the Lancet over six months, 28 compared treatments 
between groups of patients’.
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Blindness.
There are various degrees of blindness. In a single-blind trial the patient 
does not know which treatment he or she is receiving. In a double-blind trial both 
the patient and the doctors involved with the trial do not know which treatment 
the patient is being given. If at all possible a double-blind trial should be 
employed as knowledge of the treatment to be allocated might effect the patient 
psychologically and the doctors’ decision to admit patients on to the study.
Fixed Sample Size and Group Sequential Designs.
Traditionally clinical trials have required a single sample of patients. 
Standard statistical techniques are then used to analyse the responses of these 
patients. The desire for a greater degree of flexibility in clinical trial designs has 
led to a number of group sequential procedures being proposed in the literature. 
Here an analysis of the accumulated data is carried out after a group of patients 
has responded. The trial is stopped if there is significant evidence to suggest that 
one of the treatments is superior to the other(s). Otherwise the next group of 
patients is admitted on to the trial. The trial is terminated at the ATth analysis.
Care has to be taken when designing group sequential tests in order to 
ensure that the Type I and Type II error rates are preserved. In the rest of this 
thesis we shall consider the design of group sequential tests for clinical trials. We 
shall pay particular attention to the design of optimal group sequential tests which 
minimize chosen functions of expected sample size over tests satisfying the 
required error rates.
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3. Optimal One-Sided Group Sequential Tests.
3.1 Introduction.
In this chapter we consider one-sided hypothesis tests on the mean of a 
normal distribution with known variance. In §3.2 we consider the fixed sample 
size approach to this problem. In many areas of application, for example clinical 
trials, there exist strong arguments for employing a group sequential rather than a 
fixed sample size approach. A formal description of a one-sided group sequential 
test is given in §3.3, while the literature on one-sided sequential tests is reviewed 
in §3.4.
In §3.5 we introduce optimal one-sided sequential tests or, more simply, 
optimal tests. Jennison (1987) described a constrained numerical search method 
for computing these optimal tests. Unfortunately his method suffers from a 
number of computational problems. So as a compromise between computational 
considerations and optimality, Jennison (1987) proposed a second, computationally 
efficient, method for computing near optimal tests. Emerson & Fleming (1989) 
also proposed a computationally efficient method for computing near optimal tests.
In §§3 .6-3 .8  we describe an improved method for computing optimal one­
sided group sequential tests. Our method has a number of important numerical 
and computational advantages over Jennison’s original approach. Furthermore, 
unlike the second approach of Jennison and that of Emerson & Fleming, our 
method does give the actual optimal test for a given problem.
In §§3.9 and 3.10 we give some results for our method, while in §3.11 
examples of optimal one-sided tests are considered. Practical problems associated 
with group sequential experiments are addressed in §§ 3.12 and 3.13.
Before proceeding we note that although the motivation for this work comes 
from a clinical trials problem, the implications and applications of optimal tests go 
much wider.
3.2 The Fixed Sample Size Test
Consider a clinical trial designed to compare the relative efficacies of an 
experimental treatment (which we shall denote by E) and a control treatment or 
placebo (which we shall denote by C). The fixed sample size approach to this
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problem requires a total of Nf pairs of patients. On entry to the trial one patient 
in each pair is randomly assigned to treatment C with the other being assigned to 
treatment E. Let the random variable Xg (i=  1, 2 ,..., Nf)  denote the difference 
in response between the ith patient on treatment E and the ith patient on treatment 
C, and suppose that the Xg's are independent and normally distributed with 
unknown mean n  and known variance a 2. We wish to test
H0: n<  0 vs H i : [i > 0
with error rates
Pr (.#! | // = 0) = or (3.2.1)
and
Pr C^ b \ fi = 8) = p  (3.2.2)
where Jfy and ^  denote the acceptance of hypotheses H0 and H1 respectively.
The Type I error or size of the test, a , Type II error, ft and 8 - termed the
reference improvement by Whitehead (1983, Ch.4) - are under the control of the 
experimenter. The number of pairs of patients required by the test, N f , is then a 
function of a, /?, a 2 and 8 and is given by equation (3.2.3)
Nf = { 0 -x( l - « )  + <I>-1(l->9) }2. (3.2.3)J ^2
The test accepts H0 if
n;  ______
V  = X xj * y Nf « 2 ^ ‘( l - a )
;=i
and rejects H0 in favour of Hx otherwise.
In the context of a clinical trial there are a number of reasons for adopting a 
group sequential rather than a fixed sample size approach to the above hypothesis 
testing problem.
To begin with patients generally enter a trial sequentially over time and so 
patient responses tend to accrue gradually over several months or years. The 
natural curiosity of the experimenter often leads to a desire to conduct periodic 
analyses of the available data. The trial is stopped at any one of these analyses if
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a "large" treatment difference is observed. Unfortunately, if the interim analyses 
are unplanned, the overall error rates of the test may be greatly increased. A 
properly designed group sequential test gives the experimenter the flexibility to 
carry out early analyses of the data, while at the same time controlling the 
probabilities of making errors.
Secondly, in the case of a "large" treatment difference, it is desirable to stop 
a trial at the earliest possible opportunity in order to minimize the number of 
patients who will receive the inferior treatment. Group sequential tests can be 
designed which, on average, allow for a study to be stopped earlier than a fixed 
sample size test with the same error rates. There is, therefore, an ethical argument 
for adopting a group sequential approach in clinical trials.
Thirdly, there is an important economic argument for employing a group 
sequential test Clearly clinical trials are very expensive to run and in general it 
will be far more cost effective to offer a patient the standard treatment than to 
admit him or her on to a trial. An approach that attempts to minimize the number 
of patients entering an experiment will, therefore, be desirable from an economic 
perspective.
3.3 One-Sided Group Sequential Tests.
In this section we give a formal description of a one-sided group sequential 
test on the mean of a normal distribution with variance, a 2, assumed known.
Consider again the one-sided hypothesis testing problem described at the start 
of §3.2. This time, however, a maximum of K  groups of n pairs of patients are 
available for entry on to the trial with one patient in each pair being randomly 
assigned to treatment C and the other to treatment E.
Let Sin = Xt +X2 + ... +Xin (i = 1 ,2 , denote the sum of responses
from the first i groups. Clearly Sin is normally distributed with mean inji and 
variance ino2. At analysis i (i= 1 ,2 ,.. . ,  K)  we decide on the basis of 
whether to either stop the trial with the acceptance or rejection of HQ, or to 
continue entering patients on to the study. At analysis K  the trial is terminated 
with H0 either being accepted or rejected.
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We shall consider stopping rules of the general form:-
At analysis i (1 < / < K - 1),
if -  ci st0P entering patients on to the trial and accept H1; 
if -  ci st0P entering patients on to the trial and accept H0; 
if c{ < Sin < Ci enter the next group of n pairs of patients on to the 
trial.
At analysis K,
if SKn > cK stop entering patients on to the trial and accept H l ; 
if SKn < cK stop entering patients on to the trial and accept H0 .
The set of critical values or boundary points of the test, 
{(cj , C j ) , (cK_i ,cK_i) ,cK], is chosen to satisfy the error constraints (3.2.1) 
and (3.2.2). That is we determine critical values such that:
£2  Pr(c! <Sn< Ci <50 _1)n<cy_1, Sjn> Cj\ n  = 0) = a  (3.3.1)
; = i
2  P r(c1/<5/I< c 1,...,c;_1'< 5 0 _1)n<c;_1, Sjn<Cj' \n=8)  = p. (3.3.2) 
; = i
The joint probabilities in the above equations can be expressed in terms of 
multiple integrals:
Pr (c{< Sn< Ci 9_i'<S0 _,)„<c;_1 ,Sjnerj \ n )
C j-1  C\
=  J J , — f'futeO—fptej-Xj-O dxi — dXj-x dxj
rj  Cj- 1 C\
where r;- = (-oo,^] or [c;-,°o) and f M(x)  is a normal density with mean nfi and 
variance n c1. These multiple integrals may then be evaluated numerically using 
an approach based on Simpson’s rule (see Appendix 3.1 for details).
We shall term any set of critical values satisfying the error constraints (3.2.1) 
and (3.2.2) a feasible set and the corresponding test a feasible test. For K > 2 
there are infinitely many feasible sets of critical values satisfying equations (3.2.1) 
and (3.2.2) for fixed «, p, S and n.
- 14-
Unlike fixed sample size tests the sample size of a sequential test is not 
determined a priori but is a random variable with a corresponding probability 
distribution. Of particular interest are the expected number of pairs of patients 
required by a test under some treatment difference p  (denoted by E { N \p )) and 
E{N\p)  averaged over some prior distribution for p. For the stopping rule 
defined earlier E(N\p)  is given by equation (3.3.3)
E (N \p )  =
K
rc£ y P r(c i <Sn<cl ,...,cj _l <S(j_1)n<Cj_l ,Sjn&(cj  , c j ) \p ) .  (3.3.3)
7=1
The joint probability in equation (3.3.3) can be expressed as a sum of multiple 
integrals which can be evaluated numerically (see Appendix 3.1 for details).
A further important property of a sequential test is its maximum sample size. 
In our example a maximum of Kn pairs of patients are admitted on to the 
experiment. It is clear that Kn must exceed the corresponding fixed sample size, 
N f , given by equation (3.2.3). Logistical considerations will often restrict our 
attention to group sequential tests with Kn only a few percent greater than N f .
For a given pair of error constraints (3.2.1) and (3.2.2), feasible tests may be 
compared in terms of their expected and maximum sample sizes. We shall 
consider such a comparison in later sections.
3.4 A Review of the Literature on One-Sided Sequential Tests.
Fully Sequential One-Sided Tests.
There have been a number of one-sided sequential tests proposed in the
literature. The earliest was the sequential probability ratio test (SPRT) of
Abraham Wald (1947). The SPRT was designed for use when testing the quality
of batches of industrial components and it is fully sequential (i.e. a test is
conducted after every observation). The boundaries of the test are given by
iS , a 2 . . ci = — + —  In A 1 2 8
and
i8 o 2 . „
Ci = T  T lnB'
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where the constants A andB (0<A<B)  are chosen to give a feasible test. Wald 
showed that choosing
A = ^  and B = (1~ ^ )
(1 - a )  a
led to a test with error rates approximately equal to a  at /z = 0 and p  at /z = 5.
As can be seen the continuation region of the SPRT is defined by a pair of 
parallel lines of slope 5/2. Although there is no upper bound on the maximum 
sample size of the test, Wald showed that the SPRT will terminate after a finite 
number of observations with probability one. Wald & Wolfowitz (1948) proved 
that the SPRT is optimal in terms of minimizing both £(A|/z=0) and E(N\fi=S) 
over the set of feasible tests. Clearly, though, the infinite maximum sample size 
together with the requirement that data monitoring is fully sequential makes the 
SPRT most unsuitable for use in clinical trials.
Anderson (1960) noted that the SPRT is sub-optimal in terms of its expected 
sample size for /z in the range (0,5). Indeed the SPRT may, on average, require 
more observations than the corresponding fixed sample size test here. Anderson 
considered designing fully sequential tests which, compared with the SPRT, 
reduced E(N\{i) for /z e (0,5) while not leading to substantial increases in 
£(A|/z=0) and £(A|/z=5). He was particularly interested in tests which reduced 
£(A|/z=5/2) compared with the SPRT.
To this end he considered a family of tests with critical values of the form
c i  =  a i  + t>i i
and
^  = a2 + b2 i
where flj < 0 < a2. To ensure that the experiment stops after a finite number of 
observations, sampling is terminated after K  observations with the acceptance of 
H0 if Xj + ... +XK < c, a constant, and the rejection of H0 in favour of H l if 
Xi + ... +XK > c. It would seem intuitively reasonable to have b2<0<bi  in 
order that the lines defining the continuation region of the test are converging 
towards each other.
Of course, for fixed a lt b±, a2, b2, K and c, we could easily calculate the 
error rates and expected sample size for the Anderson test using the numerical
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methods described in Appendix 3.1. Back in 1960, however, the calculation of 
error probabilities and expected sample sizes for sequential tests was a major 
computational problem. Anderson overcame this problem by considering an 
analogous problem in continuous time. He replaced the test statistic by a Wiener 
process, X{t)y which is a gaussian process such that E(X(t)) = //t, Var(X(t)) = t 
and Cov(X(t'),X(t'+t)) = / ' for any t, t ' >0. The stopping boundaries for the 
continuous time problem are given by ax + bl t and a2 + b2 t, with sampling 
being terminated at some time T.
Anderson gave formulae for calculating the error rates and the expected 
sample size of his continuous time problem. These formulae can be used to give 
good approximations to the error rates and expected sample size for the original 
problem with its integer group sizes.
The most important test considered by Anderson was the triangular test, 
which has critical values given by
2a2
C -,  ---- — In 1a+ p
3 Si
and
2a2 c; -  —— In
a+P 4
The triangular test is very efficient in terms of its expected sample size under
H =  8/2.
Group Sequential One-Sided Tests.
More recently a number of one-sided group sequential tests with finite 
maximum sample sizes have been proposed in the literature.
DeMets & Ware (1980) proposed a group sequential version of the SPRT 
with a maximum of K  groups of n pairs of patients. The critical values of their 
test for i -  1 ,2 ,. . . ,  K—l are given by
inS a 2 .




Ci = ^ :  + ~t zv
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with
KnS a 2 
C K = C K = —  +  — Z v
They chose zu to give a test of size a  and the group size, n, to give a test with 
Type II error p  at ju = S. The resulting test leads to substantial savings in both 
E(N\fi=0) and E(N\ji=8) over the corresponding fixed sample size test.
DeMets & Ware (1980) proposed two further one-sided group sequential 
tests. The first of these is a one-sided version of two-sided group sequential test 
of Pocock (1977), which we describe in detail in §4.4. DeMets & Ware termed 
this test the one-sided group sequential method. The critical values of the test 
are of the form : ct = Vm'cr2 z and c /  = - q  (i < K ), with cK = cK = VKna2 z. 
Again z is chosen to give a test of size a  and n to give a test with Type II error p  
at = 8.
Clearly the one-sided group sequential method has only a small probability of 
stopping early under // = 0. However savings in E{N\fi=8) over the 
corresponding fixed sample size test are quite substantial.
The asymmetry inherent in the one-sided problem led DeMets & Ware to 
consider a third test with an asymmetric stopping rule. Somewhat predictably they 
termed this test the asymmetric group sequential method. DeMets & Ware 
pointed out that in most clinical trials less evidence is required to stop sampling 
and accept the null hypothesis (i.e. accept that the control treatment is no worse 
than the experimental treatment) than to reject it in favour of the alternative 
hypothesis. With this in mind they recommended choosing ci = ylin<r2 Zu and 
c ,' = -*Nlina2 zL, (i = 1, 2 ,.. . ,  K - l )  with cK' = cK = ^Kna2 zjj. Here zL (<Zy) is 
free to be chosen by the experimenter and Zu (> z{) is subsequently chosen to 
give a test of size a. Again the group size, n, is chosen to give a test with Type 
II error p  at fi = 8.
For fixed K, a  and p, the expected sample size under fi = 8 for this test is 
similar to that for the one-sided group sequential method. However E(N\{i=0) is 
in general smaller for the asymmetric test.
In comparing their 3 tests DeMets & Ware noted that the group sequential 
version of the SPRT requires, on average, fewer analyses under = 0 and ju = 8 
than the other two tests. However it also requires larger group sizes in order to 
satisfy the Type II error constraint. Overall the group sequential version of the
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SPRT was viewed as the best of the three tests because it led to large savings in 
E(N\n=0)  and small savings in E(N\ju=8) compared with the other two tests.
In a later paper DeMets & Ware (1982) proposed a test with the same lower 
boundary as the group sequential version of the SPRT and the same upper 
boundary as the one-sided version of the O’Brien & Fleming (1979) test (the 
two-sided O’Brien and Fleming test is described in §4.4). The critical values of 
this test are given by c{ = zobf
.2inS , <r . 
C;  = —— + ——In 
'  2 8
P
(1 - a )
for (i = 1, 2 ,.. . ,  K - 1) and cK' = cK = zobf• The constant zobf chosen to give 
a test of size or, while the group size, n, is chosen to give a test with Type II error 
p  at fi = 8. The resulting test has a relatively large probability of stopping early to 
accept H0. However the probability of the test stopping early to reject H0 in 
favour of Hx is small.
DeMets & Ware (1982) claimed that their test was in tune with the views of 
many clinicians. Trials involving unpromising experimental treatments are 
stopped as quickly as possible in order to minimize the use of experimental 
resources. On the other hand, trials involving promising experimental treatments 
are allowed to continue so as to enable secondary issues, such as treatment side 
effects, to be assessed.
Whitehead & Stratton (1983) (also Whitehead (1983, Ch.4)) have described a 
group sequential version of the triangular test of Anderson (1960). In defining 
their stopping rule, Whitehead & Stratton made use of a continuity correction due 
to Siegmund (1979) and Cuzick (1981). The critical values of the group 






Sin 2a . C: = —  + —— In
a+P -  0.583Vn.
The test is very efficient in terms of its expected sample size under n = S/2.
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Clearly there is a good deal of interest in the literature in designing feasible 
sequential tests which are efficient in terms of the expected number of patients 
entering a trial under some given treatment difference, fi. The advent of modem 
computers allows us to consider tests which minimize given functions of expected 
sample size over feasible stopping rules. We shall consider the computation of 
such tests in §3.5.
3.5 Optimal One-Sided Sequential Tests.
For a given problem with n, K, or, fi and 8 fixed, we are often interested in 
computing the sequential test which minimizes some given function of expected 
sample size known as an objective function. We shall term such a test an optimal 
sequential test, or, more simply, an optimal test. Jennison (1987) pointed out 
that the computation of stopping rules for optimal tests is eased if we choose the
Type II error of our test, fi, equal to the Type I error, a. Jennison also
concentrated on the following symmetric testing problem:
0 vs Hl+: f i>0
with error rates
Pr ( ^ ~  \ (i = 8) = a  (3.5.1)
and
P r ( V |  n = - 8 )  = a  (3.5.2)
where and Six+ denote the acceptance of hypotheses H{~ and 7/1+
respectively. Stopping rules for this problem are of the general form:
At analysis i (1 < i < K - 1),
if Sin > ct stop entering patients on to the trial and accept / / 1+; 
if Sin < -Ci stop entering patients on to the trial and accept H{~\ 
if -Ci < Sin < ct enter the next group of n pairs of patients on to 
the trial.
At analysis K,
if SKn > 0 stop entering patients on to the trial and accept H{+; 
if SKn < 0  stop entering patients on to the trial and accept H{~ .
There is no major loss in generality from considering symmetric tests. For 
fixed K  and a , the group size, n, and critical values of the optimal test 
{cx, c2, cK], are easily rescaled to give an optimal test for problems with 
different values of 8 and <7 2 (details of the necessary rescalings are given in 
Appendix 3.2).
The fixed sample size test for the symmetric problem requires Nf pairs of 
patients, where Nf is a function of or, 8 and cr2 and is given by equation (3.5.3)
Nf  = 4-{<J>-1a - a ) } 2- (3.5.3)J 82
The test accepts Hx* if SNf > 0, while it accepts Hl if SNf < 0.
Optimal Fully Sequential Tests.
Lai (1973) was one of the first to consider the computation of optimal tests. 
He considered minimizing £(Af|/r=0) over feasible fully sequential tests with no 
bound on the maximum sample size. Weiss (1962) showed that a feasible test, T, 
minimizes E(N\p=0) if, for some p  e (0,1), T  minimizes
«F(«T,p) = y P r  ( V I /* = -* )  + (l-/> )£ (iV |/i = 0) + |- P r  | M = 5).
Lai used the result of Weiss to obtain a system of equations which can be 
solved numerically to give the desired optimal test. Clearly this approach could 
be extended in order to minimize other objective functions. Lai did not give any 
results for his method. Indeed Lorden (1976) in discussing Lai’s approach noted 
that ’... heavy computational work is required to carry out this algorithm, 
rendering it unsuitable for routine use’.
Lorden did, however, use Lai’s algorithm to obtain results with which his 
fully sequential 2-SPRT test could be compared. The 2-SPRT stops sampling 
after i observations and accepts H{~ if
S, = X, +X2 + ... + Xj < ^ - l n A  + j .
Similarly it stops sampling after i observations and accepts Hx+ if
-  2 1  -
To obtain error rates close to the desired a  at (i = ±8, Lorden suggested 
choosing
A =  “ ______________
0.4996 -  0.286455+0.069652
He reported that for a  between 0.001 and 0.1 the attained error rates based on this 
formula for A are accurate to within 1/5000 for 8 between 0.1 and 0.5 with a 
slight loss in accuracy as 8 increases beyond 0.5.
The 2-SPRT is close to optimal in terms of minimizing E(N\fii=Q). To 
demonstrate this point Lorden considered a range of values of 8 and a  and noted 
that the test was always within 1% of the overall minimum of this objective 
function.
Optimal Group Sequential Tests.
Jennison (1987) considered computing optimal group sequential tests for the 
following four objective functions:




F4 : j  {E(N\/i=0) + E(N\(1=3/2) + E(N\(i=S)+ E(N\(i=3S/2) + E(N\(i=2S)}.
Clearly, for stopping rules symmetric about zero, objective function F2 is identical 
to E(N\fi=-8), F3 is identical to E(N\ti=-2S),  and so on.
For a given objective function, F, and for fixed K, n, a , 8 and <72, Jennison 
employed a constrained numerical search method to compute his optimal tests. 
(We note here that Jennison considered the rather special set of problems with 
a 2 -  I and ^ = <I>-1( l - a )  so that A -^= 1. He went on to consider an analogous 
problem in continuous time. However the critical values of his stopping rules are 
easily rescaled to give stopping rules for tests with other values of 8 and a 2.) The 
search was conducted over the first K -2  critical values with cK_x being 
constrained at each stage of the search to give a feasible stopping rule. A simple 
bisection search gave the relevant cK_\. In cases where no such cK_x existed, F
-  2 2  -
was assigned a "large" positive value in order to move the search away from 
infeasible regions.
The search algorithm employed was dependent upon the dimensionality of 
the minimization problem. When K  = 2, assuming a sensibly formulated problem, 
there is a unique test satisfying the group size and error constraints. When K — 3 
there is a single unconstrained critical value, cl9 and the minimization problem is 
one-dimensional. The Golden Section Search algorithm was used in this case. 
When K > 3 the minimization problem is multi-dimensional and the simplex 
algorithm of Nelder & Mead (1965) was used.
Unfortunately Jennison’s approach is both computationally expensive and 
numerically unstable. For instance with K -  10 it can take up to 12 hours on a 
Sun-4 to converge to an optimal test. Further the Nelder & Mead algorithm is not 
particularly powerful in more than about 7 dimensions (i.e. K -  9) and does not 
guarantee convergence to the global minimum of F.
To overcome these problems Jennison considered the error spending 
functions of his optimal tests. An error spending function is simply the rate at 
which a test spends its Type I error expressed in a functional form. For his 
optimal tests Jennison noted that the error spending functions are sigmoid shaped 
and therefore are of the general parametric form
f ( i ;a ,b ) =
b b
o[l+exp{-(—r~+ ■ 2 +b3in+b4)}\~1 1 <i<K
in (K -i  )n
a  i=K.
Here b = (b i ,b 2,b 3, b4), bi and b2 are constrained to be positive and f ( i ;a ,b ) 
gives the total Type I error spent by analysis i. Given f ( i;a ,b)  (/ = 1 ,2 ,..., K - 1) 
the corresponding set of critical values are computed by numerical integration and 
the bisection method. Again cK equals zero.
For a given problem an objective function, F, can be minimized over the 
family of error spending functions of the above parametric form. The requirement 
that f (K;a ,b)  = a  reduces the number of free parameters in this minimization 
problem from 4 to 3. Therefore the Nelder & Mead simplex algorithm is used to 
search over (In bx , \n b 2,b3) e R3 while b4 is constrained at each stage of the 
search to give a feasible test.
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Jennison reported that the test minimizing F over this family of error 
spending functions is very close to the overall optimal test. Also, for fixed K, a  
and F, varying the group size, n, leads to only small changes in the values of 
bx, b2 and b3 for the optimal error spending function (although b4 might vary 
quite considerably). Jennison tabulated the values of bi9 b2 and b3 leading to 
optimal error spending functions for each of the objective functions Fx, F2, F3 
and F4, for a  = 0.01 and 0.05, K -  5 and 10, and with group size nopt (the group 
size which minimizes F  when everything else is fixed). This table can be used to 
give near optimal stopping rules for other group sizes and values of K. For the 
examples considered by Jennison, attained minima were never more than 0.7% of 
the fixed sample size from the overall minima.
Emerson & Fleming (1989) considered minimizing objective functions Fx 
and F2 over stopping rules with critical values of the general form
Ci = (in)Az~ inS  ( /= l ,2 ,. . . ,A f ) .
Given K, a  and S, Emerson & Fleming searched over A for the minimum of the 
chosen objective function. At each stage in the search z was constrained to give a 
feasible stopping rule and n was constrained so that cK = 0.
Clearly the Emerson & Fleming approach is more computationally efficient 
than the original approach of Jennison. For £ < 1 0  and a  = 0.01 or 0.05 Emerson 
& Fleming showed that their tests were approximately 1% of the fixed sample size 
from the overall minima for F2 and approximately 0.5% of the fixed sample size 
from the overall minima for Fx. The Emerson & Fleming approach can be seen 
to be a one-sided version of that of Wang & Tsiatis (1987) described in §4.5.
In §3.6 we propose a new method for the computation of optimal one-sided 
group sequential tests. Our new method is an improvement upon that of Jennison 
(1987) in terms of both computational efficiency and numerical stability.
Our approach considers a family of group sequential problems in Bayesian 
decision theory with a common prior distribution and cost of sampling function. 
The forms of the prior and cost function are determined by the objective function 
we are interested in minimizing. Individual problems within the family differ in 
their loss function. These loss functions are indexed by a single parameter, d. 
We show that by searching over d we obtain a loss function which gives a Bayes
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decision problem with an associated Bayes rule which has errors a  at // = ±8, and 
which minimizes our chosen objective function over the set of all decision rules. 
This Bayes rule can equally be viewed as an optimal stopping rule for our original 
frequentist problem.
In §3.6 we describe our improved method for objective function
F2: E(N\ju,=8). In §3.7 we indicate how to adapt our approach when minimizing
other objective functions.
3.6 An Improved Method for the Computation of Optimal One-Sided
Group Sequential Tests.
Consider again the clinical trial problem outlined in §3.5 with a maximum of 
K equally sized groups of n pairs of patients. The random variable Xt 
(/=  1 ,2 ,. . . ,  Kri) denotes the difference in response between the ith pair of 
patients and is normally distributed with unknown mean fi and known variance
CT2 .
Here we wish to make a choice between the decisions :
D{~: ii< 0 and D1+: / / > 0 .
We shall consider a family of Bayes decision theory problems with a 
common prior distribution for n  given by n ( -8 )  = k {8) = 1/2 with x(f i)  = 0 
otherwise, and a common cost of sampling function given by c ( - 8 ) = c(8) = 1 
with c(fi)  = 0 otherwise. Individual problems within the family differ in their 
loss functions, L ( D , n \  which are indexed by a single loss parameter, d (>0). 
The general form of L(D,fi) is given by L{D{~,8) = L i D ^ ^ - S )  = d with 
L(D ,//) = 0 otherwise.
Suppose for the moment that d is fixed. Consider a general decision rule for 
the above problem which we shall denote by (B. Because our family of Bayes 
decision problems are symmetric about //= 0  we shall only consider decision rules 
which are symmetric about zero.
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So $  is of the general form :
At analysis i (1 </ <K-T),
if Sin > Ci stop entering patients on to the trial and make decision
£ i +;
if Sin < -Ci stop entering patients on to the trial and make decision
» r ;
if - c t < Sin < Ci enter the next group of n pairs of patients on to 
the trial.
At analysis K,
if SKn > 0 stop entering patients on to the trial and make decision
o r ;
if SKn < 0 stop entering patients on to the trial and make decision
or-
The risk associated with (B, which we shall denote by r((B,d), is defined as 
the sum of the total expected sampling cost of the trial plus the total expected loss 
through making a wrong decision. That is
rCM) = c{ -5 )E (N \p = -8 )x { -5 )  + c{8)E{N\n=8)n(8)
+ J  Pr(Di+1//= -£ ) * (-£ )  + dVT{Dl- \ i i = 8 ) x ( 8 ) ,
where Pr(D| ( i) denotes the probability of making decision D under a treatment 
difference fi.
As F2 = E(N\fi=8) = E(N\ji=-8), for symmetric stopping rules, it follows
that
rCB,d) = - j  {2F2 + dPt(D1+\fi=-S) + d P t i D f l ^ S ) } .
The Bayes decision rule for our problem, *B*{d), minimizes this risk over the 
set of all decision rules. Denoting the set of all decision rules by 5, we have
r{*B*{d),d) = min{r((B,d)}
We can compute *B*{d) by dynamic programming (the necessary computations are 
described in §3.8). Using numerical integration we can calculate the error rates 
of
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Suppose these errors are given by
PKZV = Pr(£>r I/*=<*) =
then clearly
r(«*(</),</) = j { 2 F 2 + 2 d  a]
= f2 + d ct.
It follows from the definition of the Bayes rule that there can be no other decision 
rule with errors Ct at // = ± 8 which attains a lower value of F2.
Using a simple bisection search over d we obtain the loss parameter 
giving rise to a Bayes decision theory problem with an associated Bayes rule 
which has errors a  at // = ±8. Now clearly
r(0*(</<a>),</<“>) = F2 + d (a) a
and, from the definition of the Bayes decision rule, there can be no other decision 
rule for this problem with a smaller risk, i.e.
r(B* (</<“>),</<“>) = m in { re M (a))}
<BeS
Moreover there can be no other decision rule with errors Ct at ji = ±8 which attains 
a lower value of F2. Hence ‘B ' i d ^ )  minimizes the objective function F2 over 
the set of all decision rules with errors a  at // = ±<5. By equating decisions Dx~ 
and D1+ with hypotheses H{~ and Hx+ respectively we have computed the 
optimal one-sided group sequential test for our original ffequentist problem.
3.7 Applying our Improved Method to Other Objective Functions.
The method described in §3.6 is easily adapted to compute optimal one-sided 
group sequential tests for other objective functions.
Consider the minimization of Fl : E(N |/J=0). A suitable family of Bayes 
decision theory problems has the common prior distribution for // given by 
7u(-S) = ;r(0) = k{8) = 1/3 with x(fj,) = 0 otherwise, and the common cost of 
sampling function c(0) = 1 with c(fi)  = 0 otherwise. The general form of the 
loss function, L(£),//), is identical to that given in §3.6, with, in particular, 
L(D1- ,//=0) = L(D1+,/z=0) = 0.
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For a fixed loss parameter, d, the risk of a given decision rule, (B, is denoted 
by r((B,d) and equals
c(0)£(tf|jf=0)jr(0) + dVr(D1+\ n = - S )x ( - S )  + d P r i D f l ^ S )  x(S).
That is,
r(V,d) = j ( F !  + dPt(Dl*\fi=-S) + d P t iD f l f i ^ S ) } .
The Bayes decision rule for this problem, <B*(d), minimizes this risk over the set 
of all decision rules, 5, i.e.
r($*(<i),d) = min{r(®,J)}
Suppose (B*(d) has errors given by
Pr(£>1+|//= -5 )  = P d D f \n = S )  = a,
then clearly
r(Q*(d),d) = j { F x + 2dCt]
and, from the definition of the Bayes rule, there can be no other decision rule with 
errors Ct at n  = ±8 which attains a lower value of Fx.
By searching over d (>0) we obtain the loss parameter, d^a\  giving a Bayes 
decision theory problem with an associated Bayes rule, which has errors
a  at // = ±8. Clearly
r C B ^ d ^ . d ^ )  = y  {Ft + 2<*<“>«}•
Again, from the definition of the Bayes decision rule, there can be no other 
decision rule for this problem with a smaller risk, i.e.
r(‘B*(d(a'>),dW) = min{r(®,<*<“>)}
« s 5
Moreover there can be no other decision rule with errors a  at /z = ±8 which attains 
a lower value of F1. By equating decisions D{~ and D{+ with the acceptance of 
the hypotheses H{~ and Hx+ we obtain the optimal one-sided group sequential test 
for our original frequentist problem.
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For the minimization of F3: E(N\fi=28) we consider the family of Bayes 
decision theory problems with the common prior distribution for // given by 
k { - 2 8) = x ( - 8 )  =  k{8)  =  7c{28) =  1/4 with n(n)  -  0 otherwise, and the 
common cost of sampling function given by c(-2S)  = c(2S) = 1 with c({i) = 0 
otherwise. The general form of the loss function, L(D,{i), is identical to that 
given in §3.6 with, in particular, L{D{~,//) = L{DX+,//) = 0 for fi = ±28.
For a fixed loss parameter, d, the risk of a given decision rule, is denoted 
by r(® ,J) and equals
c{ - 2 8 ) E { N \ ^ - 2 8 ) tx{ -28 )  +  c(28 )E (N \m=28)tc(28)
+ + d V x i D ^ l ^ S ) ^ ) .
That is
r ($ ,d)  = i { 2  F3 + d'Pt(Dl+\ii=-8) + ^ Pr(Z>j-1//=<5)}.
The rest of the logic is analogous to that for objective functions Fl and F2 
given earlier. In particular we search over d (>0) for a loss parameter, d^a\  
giving a Bayes decision theory problem with associated Bayes rule, 
which has errors a  at // = ±£. Clearly
= - j  {2f 3 + 2 d a a)  = {F3 + d ^  a) .
From the definition of the Bayes rule, there can be no other decision rule for 
this problem with a smaller risk. Moreover there can be no other decision rule 
with errors a at f i= ±S  which attains a lower value of F3. By equating decisions 
D{~ and Dx+ with the acceptance of the hypotheses H{~ and Hx+ we obtain the 
optimal one-sided group sequential test for our original frequentist problem.
Jennison (1987) considered the minimization of F4 because he wanted to 
compute optimal tests which were optimal, or near optimal, over a range of 
parameter values. Instead of considering the minimization of F4 we will consider
the minimization of E(N |//)  integrated over a normal density with mean 0 and
variance S2. Denoting this objective function by F5, we have:
F5: <p(ti/S)dM.
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A suitable family of Bayes decision theory problems for the minimization of F5 
has the common prior distribution:
Again the general form of the loss function, L (£>,//), is identical to that given in 
§3.6, with, in particular, L(D,/z) = 0 for fi±±S.
For a fixed loss parameter, d, the risk of a given decision rule, ©, is denoted 
by r{*B,d) and is equal to
The rest of the logic is analogous to that for objective functions F1 and F2-
theory problem with associated Bayes rule, which has errors a  at
fi -  ±8. Clearly
rCB*(d{a)) ,d ia)) = - j  {Fs +
From the definition of the Bayes rule, there can be no other decision rule for 
this problem with a smaller risk. Moreover there can be no other decision rule 
with errors a  at n = ± 8  which attains a lower value of F5. By equating decisions 
D{~ and Dx+ with the acceptance of the hypotheses H{~ and H{+ we obtain the 
optimal one-sided group sequential test for our original frequentist problem.
1/3 if fx = ±8
(1/3)8~1<p(n/8) otherwise
and the common cost of sampling function :
1 if // + ±<5 
c (/0  -  o otherwise.
= Jc(/z) E(N\fii) 7t(n) d/i +
J  Pr(ZV |//= -£ ) * (-£ )  + dVi{D{-\LL=S)n{8).
It follows that
rCB(d)) = j \E (N \n )8 ~ l p(ft/8)  dfi + d'Pt(Dl+\fi=-5) + d V t(D f \n = 8 )
=  j { F 5 +  d P r < D 1+ | / i = -< 5 )  +  < iP r (Z > r lF = « 5 )} -
In particular we search over d for a loss parameter, d^a\  giving a Bayes decision
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Clearly our improved method for computing optimal one-sided group 
sequential tests is easily extended to other objective functions not considered here. 
We now go on to consider in detail the dynamic programming algorithm for our 
method.
3.8 The Dynamic Programming Algorithm.
For any given Bayes decision theory problem we compute the Bayes decision 
rule by dynamic programming. In this section we describe the dynamic 
programming algorithm for a general problem. Throughout we shall assume that 
the Bayes rule is monotone. That is at analysis i ( / = 1 , 2 , F - l )  it is optimal 
to make decision D1+ if Sin > ci and decision D{~ if Sin < -c,-, while for 
~ci < Sin < ci ^  1S optimal to sample the next group of n observations. Further, at 
analysis K, it is optimal to make decision Dx+ if SKn > 0 and decision Dx~ if
$Kn -  0*
Lai (1973) proved that optimal tests for objective function Fl are monotone, 
while Brown, Cohen & Strawdermann (1981) proved the monotonicity of optimal 
tests for F2. Although we have no formal proofs to demonstrate the monotonicity 
of optimal tests for F3 and F5, numerical checks support our assumption that these 
objective functions are monotone.
Suppose we have a maximum of K  groups of n observations for choosing 
between the decisions
0 and D1+://>  0.
Further suppose that our family of problems has a common prior distribution 
denoted by k {i i ) which is defined over some parameter space M, and a common 
cost of sampling function denoted by c(//). Finally we shall suppose that our loss 
function is denoted by L{D,fi ) and that it is of the same general form as that 
given in §3.6.
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Suppose the loss parameter d is fixed. Letting p ^ \ j i \ x )  denote the current 
posterior distribution of fi at analysis i (1 <i<K),  given that Sin =x, the loss from 
making decision equals
d p (i)(-S\x)  
and the loss from making decision D{~ equals
d p ^ H s  |jt>.
If we let y (‘\ x )  denote the minimum loss from stopping at stage i 
(i = 1,2, . . . ,K)  and making a definite decision, it follows that
y^l\ x )  = min [dp^(-8 \x )>  d p ^ ( 8 \x ) } .
Clearly
r (i)W  = '
d p (i)(-<5|;t)for;<:>0 
d p ^ i t f x )  forjtcO .
Further, let p^‘\ x )  be the minimum additional risk from sampling the
(i+l)st group (1 = 1 ,2  AT—1) and then proceeding optimally. Denoting the
c.d.f. of 5(/+1)n given that S^ =x  by F (l+1)(S(t+1)n|;c), we ^ave
= » s  c W p V - ' H r i x )  + j  r (K)(sKn) dF<-K\ s Kn\x)
and, for i < K - 1,
pV>(x) = n £  c (p)p«Xp\x)  +
fieM
J min{j3(i+1)(5(i+1)n) ,y (i+1)(5(i+1)„)} dF<i+1>(S(i+1)„|x)
where the summation signs in the above equations are replaced by mixture of , 
summations and integrals for objective functions such as F5.
We compute the critical values of $*(d) by starting at the £th analysis and 
working back.
At analysis K  it is optimal to make decision D±+ for all $Kn ~ X such that
d p m (-S\x) < d p <-K\ 8 \ x ) (3.8.1)
and to make decision D{~ for all $Kn ~ x  such that
d p m (S\x) < d p W \ - 5 \ x ) .  (3.8.2)
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Clearly this is equivalent to making decision Dx+ for x> 0 and decision Dx for 
x<  0.
At analysis K- 1 it is optimal to make decision Z>1+ for all - x  (>0)
such that
d p ^ - 'H - S l x )  < P<K~lHx) (3.8.3)
and to decide to sample the £th group of observations and then to proceed 
optimally for all x  (> 0) such that
f t K~l\ x )  < dp^K~l\ - 8 \ x ) .  (3.8.4)
Here p^K~l^(x) is equal to
p (K~l\ x )  = « X  c ( p ) p {K~l){p\x) 
f i e  M
+ d  {Pr_; (SKn >0 I j O p ^ M * ) }  + d { Pr, (SKn < 0 1 j O p ^ ^ I * ) } .
We use the bisection method to obtain the (AT— l)st critical value, cK_x, as 
the solution, for x > 0, of equation (3.8.5)
d p l K~V(-S  |x) = p W - V w .  (3.8.5)
Clearly it is possible that equation (3.8.5) does not possess a solution for
x > 0. To avoid our algorithm getting in to computational difficulties we can build 
a simple check in to our program. The check tests whether inequality (3.8.4) 
holds for *=(). If this is not the case we set cK_i =0 and go back to the 
(A'-2)nd analysis. Similar checks can be built in at other analyses.
The symmetry inherent in our problem makes it optimal to choose D{~ if 
S(K-i)n -  ~CK-1 to continue sampling if - c K_i < S^K_ ^ n <0.
At analysis K— 2 it is optimal to make decision Dx+ for all Sn K^_2) = x  (>0) 
such that
d p ^ ~ 2H-S\x) < p <K~2,(x)
and to decide to enter the (AT— l)st group of patients on to the trial and then to 
proceed optimally for all jc (>0) such that
P >K~2Hx) < d p iK~2H-S\x).
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Here 2\ x )  is given by
p(K-2)(x ) = n £  c ( n ) p (K~2)(n\x)  +
/*eM
\x)p(K~2\ -S \x ) }  +dlPrs(S(K_l)nZ ~cK_x |x )p (JC' 2)(5|x))
CK-1
+ J dF^K~l\ S ^ i ) n\x),
-Cjf-l
Again the bisection method gives the (K-2)nd critical value, c^_2, as the 
solution, for x > 0, of equation (3.8.6)
dp<-K- 2\ - g \ x )  = p(K- 2)(x). (3.8.6)
The symmetrical nature of our problem makes it optimal to choose D{~ if 
Sn(K-i) -  ~ CK-2 t0 continue sampling if - c K_2 < Sn(K-2)
We work back to the first analysis in a similar fashion. The error 
probabilities of the resulting decision rule are then computed and a test for 
convergence conducted. If convergence has not been achieved a new value of d is 
obtained from the bisection method. The above algorithm is computationally very 
fast and efficient.
3.9 Results and Discussion.
Tables 3.1-3.8 give the minima of objective functions F j , F2, F3 and F5 for 
group sequential tests with equally sized groups, a  = 0.01 and 0.05, K  = 2, 3, 4, 5, 
10, 15, 20, 30, 50, 100 and 200 and t (the ratio of the maximum sample size of 
the sequential test to the corresponding fixed sample size, Nj) equal to 1.01, 1.05, 
1.1, 1.15, 1.2, 1.3, 1.4, 1.5 and 1.6. The minima are expressed as percentages of 
Nj- and are independent of the choice of 5 and a 2 as is verified in Appendix 3.2. 
In each table the minimum over t for fixed K  is shown in bold type.
Tables 3.1 and 3.2 refer to the minimization of objective function 
Fl : E(N\j2=0) for a  = 0.01 and 0.05 respectively. The minimization of F i is 
known in the literature as the Kiefer-Weiss problem. For any stopping rule 
symmetric about zero E{N\n ) is maximized when // = 0. Hence the Kiefer-Weiss
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problem is essentially a minimax problem.
Lorden (1976), building on the work of Lai (1973), used techniques very 
similar to our own to determine the minimum of Fl up to a small discretization 
error. For a  = 0.01 this minimum is equal to 71.1% of the fixed sample size and 
occurs with continuous monitoring of the data and t - 2.33. For a  = 0.05 the 
minimum of F1 is equal to 73.3% of the fixed sample size. It also occurs with 
continuous monitoring of the data but this time with t = 3.37.
Clearly, in the context of a clinical trial, continuous monitoring of the data is 
likely to prove impractical. As we have already seen, Jennison (1987) considered 
minimizing Fl over feasible group sequential tests. Tables 3.1 and 3.2 extend the 
results of Jennison by considering designs with K  = 4, K > 10 and t = 1.01.
In discussing Table 3.1 we begin by considering group sequential tests with 
K - 2 .  Compared with the fixed sample size test satisfying the same error 
constraints, each of the 2 group tests lead to savings in F1. The largest of these 
savings occurs with *=1.1 and is equal to 10.6% of Nf. Note that even if 
logistical considerations restrict us to designs with *=1.01 the expected saving is 
6% of the fixed sample size. In a clinical trial with perhaps hundreds of patients 
this could represent an important saving in both financial and human resources.
As might be anticipated the expected gains in efficiency over the fixed 
sample size test are even more impressive when K  = 3. The largest saving occurs 
with * = 1.15 and is equal to 14.8% of the fixed sample size. When * = 1.01 the 
expected saving equals 9% of Nf.
Pocock (1982) suggested that in practice it would be unlikely for a clinical 
trial to be designed with more than 5 analyses. The most efficient 5 group design 
in our table occurs with * = 1.2 and on average leads to an 18.8% saving over the 
fixed sample size test. This compares favourably with the most efficient 200 
group test in the table and with the approximately optimal test of Lorden (1976).
The most efficient test in Table 3.1 has a maximum of 200 groups and 
*=1.5. For this test £(A|/*=0) is only 0.2% of the fixed sample size greater than 
for Lorden’s (1976) test.
From the table it is clear that, for fixed f, the rate of gain in efficiency in F1 
depreciates as K  increases. For example, when *=1.5 doubling the maximum 
number of analyses from 100 to 200 produces a mere 0.2% of Nf gain in
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efficiency. It is also clear from the table that for each value of K the minima of 
Fi are a U-shaped function of t. This observation was initially made by Jennison 
(1987).
Table 3.1. Minima of Fx: E(N\fi=0) expressed as percentages of the fixed sample 
size, Np for or=0.01, t = 1.01, 1.05 1.1, 1.15, 1.2, 1.3, 1.4, 1.5 and 1.6 and K  = 
2, 3, 4, 5, 10, 15, 20, 30, 50, 100 and 200.
K 1.01 1.05 1.1 1.15
t
1.2 1.3 1.4 1.5 1.6
2 94.0 90.3 89.4 89.5 90.0 91.5 93.3 95.0 96.6
3 91.0 86.8 85.5 85.2 85.3 86.1 87.1 88.0 88.8
4 89.4 84.8 83.3 82.8 82.8 83.2 84.0 84.7 85.2
5 88.3 83.6 81.9 81.3 81.2 81.5 82.0 82.6 83.1
10 86.1 81.0 79.1 78.3 773 77.9 78.1 78.3 78.6
15 85.3 80.1 78.1 77.3 76.9 76.7 76.8 76.9 77.1
20 84.8 79.7 77.7 76.8 76.3 76.1 76.1 76.3 76.4
30 84.4 79.2 77.2 76.3 75.8 75.5 75.5 75.6 75.7
50 84.1 78.9 76.8 75.9 75.4 75.1 75.0 75.1 75.1
100 83.9 78.7 76.5 75.6 75.1 74.7 74.7 74.7 74.7
200 83.8 78.5 76.4 75.4 74.9 74.6 74.5 74.5 74.5
Many of the comments made concerning Table 3.1 are equally applicable to 
Table 3.2. Again the largest expected gains in efficiency come from adopting a 2 
group sequential test rather than a single sample test. For example with K - 2  and 
t = 1.15 an expected gain in efficiency of 13% of the fixed sample size is attained.
By considering a test with 10 groups and t - \ A  an expected gain in 
efficiency of 25.1% of the fixed sample size is obtained. This is only 3.8% of Ad­
less than that for the Lorden (1976) test with a  =0.05. The optimum test in 
Table 3.2 has AT=200 and t -  1.6 which is a mere 0.2% of the fixed sample size 
less than for Lorden’s test.
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Table 3.2. Minima of F1: E(N\ f i=0)  expressed as percentages of the fixed sample
size, Np  for a=0 .05 ,  t = 1.01, 1.05, 1.1, 1.15, 1.2, 1.3, 1.4, 1.5 and 1.6 and K  =
2, 3, 4, 5, 10, 15, 20, 30, 50, 100 and 200.
K 1.01 1.05 1.1 1.15
t
1.2 1.3 1.4 1.5 1.6
2 93.4 88.9 87.3 87.0 87.2 88.3 90.0 91.7 93.6
3 90.6 85.6 83.5 82.7 82.4 82.6 83.3 84.2 85.1
4 88.9 83.7 81.5 80.5 80.1 80.0 80.4 80.9 81.6
5 87.9 82.5 80.2 79.1 78.6 78.4 78.6 79.0 79.5
10 85.7 80.0 77.5 76.2 75.6 75.0 74.9 75.0 75.3
15 84.9 79.1 76.5 75.3 74.5 73.9 73.7 73.7 73.8
20 84.5 78.7 76.1 74.8 74.0 73.3 73.1 73.1 73.1
30 84.1 78.2 75.6 74.3 73.5 72.7 72.5 72.4 72.4
50 83.7 77.9 75.2 73.9 73.1 72.3 72.0 71.9 71.9
100 83.5 77.6 75.0 73.6 72.8 72.0 71.6 71.5 71.5
200 83.4 77.4 74.8 73.4 72.6 71.8 71.4 71.3 713
Tables 3.3 and 3.4 refer to the minimization of objective function 
F2: E{N\fj,=8) for a= 0 .01  and 0.05 respectively. As was seen in §3.4 the 
minimization of F2 has received a great deal of attention in the literature. The 
SPRT of Wald (1947) minimizes F2 over the set of feasible tests, but requires 
continuous monitoring of the data and no upper bound on the maximum sample 
size. With or = 0.01, the expected sample size under n = S  for the SPRT is just 
41.6% of the fixed sample size, while with or = 0.05 it is 49% of the fixed. 
Jennison (1987) considered the minimization of F2 over feasible group sequential 
tests with finite maximum sample sizes. Tables 3.3 and 3.4 extend the results of 
Jennison by including the minima of F2 for tests with K - 4 ,  K> 10 and t -  1.01.
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Table 3.3. Minima of F2: E{N\ f i =8)  expressed as percentages of the fixed sample
size, Nf , for cr = 0.01, t = 1.01, 1.05, 1.1, 1.15, 1.2, 1.3, 1.4, 1.5 and 1.6 and K  =
2, 3, 4, 5, 10, 15, 20, 30, 50, 100 and 200.
K 1.01 1.05 1.1 1.15
t
1.2 1.3 1.4 1.5 1.6
2 72.3 66.7 65.8 66.3 67.4 70.4 73.9 77.8 82.0
3 67.1 60.4 58.1 57.3 57.0 57.6 58.8 60.3 62.2
4 64.3 57.7 55.2 54.0 53.5 53.2 53.6 54.2 55.1
5 62.5 56.0 53.5 52.2 51.6 51.1 51.1 51.4 51.9
10 59.1 52.6 49.9 48.6 47.8 47.0 46.7 46.7 46.8
15 58.1 51.5 48.8 47.4 46.6 45.7 45.3 45.1 45.1
20 57.5 50.9 48.2 46.8 46.0 45.0 44.6 44.4 443
30 57.0 50.4 47.7 46.3 45.4 44.4 43.9 43.6 43.5
50 56.6 50.0 47.3 45.8 44.9 43.9 43.3 43.0 42.9
100 56.4 49.7 47.0 45.5 44.6 43.5 43.0 42.6 42.4
200 56.2 49.6 46.8 45.4 44.4 43.4 42.8 42.4 423
Consider Table 3.3. Again the largest expected gains in efficiency are 
obtained by going from a single sample test to a group sequential test with a 
maximum of 2 groups. These gains are very impressive with the largest occurring 
when t = 1.1 and being equal to 34.2% of the fixed sample size. Even if logistical 
considerations limit us to a test with K=  2 and t -  1.01 the expected gain in 
efficiency is more than one-quarter of the fixed sample size.
With K — 200 and f= 1 .6  we are within 0.6% of the fixed sample size from 
the SPRT minimum. Indeed with as few as 10 groups and with *=1.5 our 
optimal test is just 5.1% of Nf from the SPRT minimum. Clearly the differences 
in efficiency between tests with a maximum of 10 groups and the SPRT are small, 
and so tests likely to be used in practice are impressively efficient.
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Table 3.4. Minima of F2 : E(N\ f i=S)  expressed as percentages of the fixed sample
size, Nft for <*=0.05, t = 1.01, 1.05, 1.1, 1.15, 1.2, 1.3, 1.4, 1.5 and 1.6 and K  =
2, 3, 4, 5, 10, 15, 20, 30, 50, 100 and 200.
K 1.01 1.05 1.1 1.15
t
1.2 1.3 1.4 1.5 1.6
2 80.9 74.5 72.8 72.7 73.2 75.3 78.1 81.2 84.7
3 76.3 69.3 66.5 65.3 64.8 64.8 65.6 66.7 68.2
4 73.8 66.8 63.8 62.4 61.6 61.0 61.0 61.4 62.1
5 72.2 65.2 62.2 60.7 59.8 59.0 58.7 58.8 59.2
10 69.1 62.1 59.0 57.4 56.3 55.2 54.6 54.4 543
15 68.1 61.0 57.9 56.2 55.2 53.9 53.3 53.0 52.8
20 67.6 60.5 57.4 55.7 54.6 53.3 52.6 52.2 52.0
30 67.2 60.1 56.9 55.2 54.0 52.7 52.0 51.5 513
50 66.8 59.7 56.5 54.7 53.6 52.2 51.5 51.0 50.7
100 66.5 59.4 56.2 54.4 53.3 51.9 51.1 50.6 503
200 66.3 59.2 56.0 54.3 53.1 51.7 50.9 50.4 50.0
The most efficient group sequential test in Table 3.4 has a maximum of 200 
groups and t = 1.6. For this test E(N\fi=S) is within 1% of the fixed sample size 
from that for the SPRT. Again the loss in efficiency from considering tests with 
10 groups or fewer is small. For example with ^ = 1 0  and t = 1.6 the optimal test 
is within 5% of the fixed sample size from the SPRT minimum.
An important difference between the optimal tests for F2 given in Tables 3.3 
and 3.4 and the optimal tests for F1 given in Tables 3.1 and 3.2 concerns the 
value of t at which the objective function is minimized for fixed K. For <* = 0.05 
and K > 10, F2 is minimized when t = 1.6. A similar pattern emerges for F2 when 
<*=0.01, with, for K > 20, minima occurring when * = 1.6. The corresponding 
minima for F1 tend to occur at lower values of t.
To demonstrate just how efficient our method is, we note that to obtain the 
optimal test with *=1.6 and K - 2  required just 2 seconds of CPU time on a 
Sun-4 computer. For K -  3 and t= 1.6, 4.9 seconds of CPU was required, while
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for A" = 10 and t -  1.6, 167.2 seconds of CPU time was needed. Compare tins 
with the original approach of Jennison (1987) which required something in the 
order of 10 hours of CPU time to compute this last test.
The minimization of F3: E(N\fi=2S) was first considered by Jennison 
(1987). Optimal tests for this objective function are designed to ensure that a trial 
is stopped early when treatment differences are large. These tests are not very 
robust, however, and, on average, may require more patients than the 
corresponding fixed sample size test when |/z| is small.
Table 3.5. Minima of F3: E(N\ji=2S) expressed as percentages of the fixed 
sample size, Np for a  = 0.01, t = 1.01, 1.05, 1.1, 1.15, 1.2, 1.3, 1.4, 1.5 and 1.6 
and K  = 2, 3, 4, 5, 10, 15, 20, 30, 50, 100 and 200.
K 1.01 1.05 1.1 1.15
t
1.2 1.3 1.4 1.5 1.6
2 52.2 53.1 55.3 57.7 60.1 65.0 70.0 75.0 80.0
3 41.4 38.8 39.0 40.0 41.2 44.1 47.1 50.3 53.5
4 38.2 33.9 33.0 33.0 33.4 34.8 36.7 38.7 40.9
5 36.6 31.8 30.3 29.8 29.8 30.3 31.4 32.6 34.1
10 33.2 28.4 26.5 25.5 25.0 24.4 24.3 24.3 24.5
15 32.0 27.2 25.3 24.3 23.7 23.1 22.8 22.6 22.6
20 31.5 26.6 24.7 23.7 23.1 22.4 22.0 21.9 21.8
30 30.9 26.1 24.1 23.1 22.5 21.7 21.3 21.1 21.0
50 30.5 25.7 23.7 22.6 22.0 21.2 20.7 20.5 203
100 30.3 25.4 23.4 22.3 21.6 20.8 20.3 20.0 19.9
200 30.1 25.2 23.2 22.2 21.5 20.6 20.1 19.8 19.6
There are no analytical results in the literature referring to the minimization 
of F 3. Tables 3.5 and 3.6, which give the minima of F3 for a  = 0.01 and 0.05 
and the same designs as in Tables 3.1-3.4, enable us to obtain good upper bounds 
on the overall minima of F3. For instance, from Table 3.5, the best test has a 
maximum of 200 groups and t -  1.6, and, on average, requires only 19.6% of the
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corresponding fixed sample size.
Tables 3.5 and 3.6 provide the most impressive justification for the adoption 
of group sequential tests. With K = 2,  *=1.01 and a  = 0.01 our optimal test leads 
to an average gain in efficiency of 47.8% Nf. For the same problem but with 
a  =0.05 the average gain in efficiency is 40.3% of the fixed sample size. As 
with objective functions and F2 gains in efficiency increase with K. However 
for K  greater than 10 the rate of gain in efficiency is small.
Table 3.6. Minima of F3: E(N\[i=2S) expressed as percentages of the fixed 
sample size, Np for cr=0.05, t = 1.01, 1.05, 1.1, 1.15, 1.2, 1.3, 1.4, 1.5 and 1.6 
and K  = 2, 3, 4, 5, 10, 15, 20, 30, 50, 100 and 200.
K 1.01 1.05 1.1 1.15
t
1.2 1.3 1.4 1.5 1.6
2 59.7 57.0 57.9 59.5 61.5 65.9 70.5 75.3 80.2
3 53.0 46.9 45.4 45.3 45.7 47.4 49.7 52.3 55.0
4 50.2 43.5 41.1 40.2 39.9 40.2 41.2 42.5 44.1
5 48.6 41.7 39.1 37.8 37.2 36.8 37.1 37.7 38.6
10 45.1 38.4 35.6 34.0 33.1 31.9 31.3 31.0 30.8
15 44.0 37.3 34.4 32.9 31.8 30.6 29.8 29.4 29.1
20 43.4 36.7 33.8 32.3 31.2 29.9 29.2 28.7 283
30 42.9 36.2 33.3 31.7 30.6 29.3 28.5 27.9 273
50 42.5 35.8 32.9 31.3 30.2 28.8 27.9 27.3 26.9
100 42.2 35.4 32.6 30.9 29.8 28.4 27.5 26.9 263
200 42.0 35.2 32.4 30.8 29.7 28.2 27.3 26.7 263
ables 3.7 and 3.8 give the minima of objective fu
F5: jE(N\ f i )S~1q>(fii/S)dfi for a  =0.01 and 0.05 respectively. The motivation 
for considering optimal tests for F5 lies in the desire to compute tests which are 
optimal or close to optimal over the entire parameter space for //. As we shall see 
in §3.11 these optimal tests are indeed very robust.
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Table 3.7. Minima of F5: J E ( N\ f i ) 8  1(p(fi/8) dfi expressed as percentages of the
fixed sample size, Np  for a  = 0.01, t = 1.01, 1.05, 1.1, 1.15, 1.2, 1.3, 1.4, 1.5 and
1.6 and K = 2 ,  3, 4, 5, 10, 15, 20, 30, 50, 100 and 200.
K 1.01 1.05 1.1 1.15
t
1.2 1.3 1.4 1.5 1.6
2 78.6 74.4 73.9 74.4 75.4 77.9 80.9 84.0 87.2
3 74.0 68.7 67.0 66.6 66.7 67.5 68.9 70.4 72.0
4 71.6 66.1 64.2 63.5 63.2 63.5 64.2 65.1 66.1
5 70.2 64.6 62.6 61.7 61.4 61.4 61.9 62.5 63.1
10 67.2 61.5 59.3 58.4 57.9 57.5 57.6 57.8 58.1
15 66.2 60.5 58.3 57.2 56.7 56.2 56.2 56.3 56.4
20 65.8 60.0 57.7 56.7 56.1 55.6 55.5 55.6 55.7
30 65.3 59.5 57.2 56.1 55.5 55.0 54.8 54.8 54.9
50 64.9 59.1 56.8 55.7 55.1 54.5 54.3 543 54.3
100 64.6 58.8 56.5 55.4 54.7 54.1 53.9 53.9 53.9
200 64.5 58.7 56.4 55.2 54.6 54.0 53.7 53.7 53.6
Many of the comments made concerning objective functions Fl , F2 and F3 
apply equally here. Again the largest gains in efficiency occur when going from a 
fixed sample size test to a 2 group sequential test. Also the average gain in 
efficiency is still substantial if we limit attention to designs with only 2 groups 
and a maximum sample size only 1% greater than the fixed sample size. With 
a  = 0.01 this gain is 21.4% of the fixed sample size, while with a - 0.05 the gain 
is 16.7% of Nf. Most of the gains in efficiency are obtained with tests with 10 
groups or less. As with objective function F3 there are no analytical results or 
approximations in the literature to the overall minima of Fs. Tables 3.7 and 3.8 
enable us to obtain fairly accurate approximations to these minima.
For instance with a  =0.01 it would appear that even with continuous 
monitoring of the data the overall minimum would be no less than 53% of the 
fixed sample size. With a =0.05 the overall minimum should be approximately 
56% of Np
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Table 3.8. Minima of F5: jF(N|//)<5 l <p{li/5) expressed as percentages of the
fixed sample size, Np  for a  = 0.05, t = 1.01, 1.05, 1.1, 1.15, 1.2, 1.3, 1.4, 1.5 and
1.6 and K  = 2, 3, 4, 5, 10, 15, 20, 30, 50, 100 and 200.
K 1.01 1.05 1.1 1.15
t
1.2 1.3 1.4 1.5 1.6
2 83.3 78.1 76.8 76.8 77.4 79.4 81.9 84.7 87.7
3 79.4 73.3 71.0 70.0 69.7 70.0 70.9 72.2 73.6
5 75.9 69.6 67.0 65.7 65.0 64.5 64.6 64.9 65.4
10 73.1 66.7 63.9 62.5 61.7 60.9 60.6 60.6 60.7
15 72.7 65.7 62.9 61.4 60.6 59.7 59.3 592 59.2
20 71.7 65.2 62.4 60.9 60.0 59.0 58.6 58.5 58.5
30 71.3 64.8 61.9 60.4 59.5 58.5 58.0 57.8 57.7
50 70.9 64.4 61.5 60.0 59.0 58.0 57.5 57.2 57.1
100 70.6 64.1 61.2 59.7 58.7 57.6 57.1 56.8 56.7
200 70.5 64.0 61.1 59.5 58.6 57.5 56.9 56.6 56.5
3.10 The Loss Functions for the Optimal Tests.
Tables 3.9 and 3.10 give values of d/{cNj}, where c is the cost of sampling 
an observation, for the optimal designs for objective function F2 with a  =0.01 
and 0.05 respectively. The entries in each table are given to one decimal place 
and are independent of 8 and a 1.
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Table 3.9. Values of d/ {cNj - }  corresponding to the minima of objective function
F2 with a  = 0.01, t = 1.01, 1.05, 1.1, 1.15, 1.2, 1.3, 1.4, 1.5 and 1.6 and K  = 2, 3,
4, 5, 10, 15, 20, 30, 50, 100 and 200.
K 1.01 1.05 1.1 1.15
t
1.2 1.3 1.4 1.5 1.6
2 151.2 33.4 17.5 12.1 9.3 6.5 5.0 4.1 3.4
3 153.4 41.1 24.0 17.9 14.7 11.3 9.4 8.2 7.2
4 146.7 41.0 25.0 19.2 16.2 13.0 11.3 10.2 9.4
5 144.2 40.3 24.8 19.3 16.4 13.5 12.0 11.1 10.4
10 142.9 39.5 24.2 18.8 16.1 13.4 12.1 11.4 10.9
15 142.4 39.4 24.1 18.8 16.0 13.3 12.0 11.3 10.8
20 142.1 39.4 24.1 18.8 16.0 13.3 12.0 11.3 10.8
30 142.0 39.3 24.1 18.7 16.0 13.3 12.0 11.3 10.8
50 141.8 39.3 24.1 18.7 16.0 13.3 12.0 11.3 10.8
100 141.8 39.3 24.1 18.7 16.0 13.3 12.0 11.3 10.8
200 141.8 39.3 24.1 18.8 16.0 13.3 12.0 11.3 10.8
The pattern in both tables is similar with little variation in d/[cNf] over K 
for fixed r, but entries increasing rapidly as t decreases towards 1.
Medical researchers are, understandably, reluctant to specify decision theory 
loss functions for clinical trials; however by considering tables such as Table 3.9 
and Table 3.10 ethically appropriate designs can be arrived at. For example 
consider a hypothesis testing problem with a  = 0.05 and fixed sample size, 
Nf = 100. If the researcher feels that the loss through making a wrong decision is 
1 000 times more expensive than the cost of admitting a further pair of patients on 
to the trial then he should choose a design with d/{cNj-} equal to 10. From Table
3.10 it can be seen that this corresponds to a group sequential experiment with t 
approximately equal to 1.1.
Alternatively the researcher might have arrived at values of K , t and a  and 
wish to simply check that the associated value of dl[cNf] is reasonable. He 
might find, especially with a  = 0.05 and t> 1.3, that the losses he is implicitly
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working with are unreasonable. To overcome this problem the experimenter 
should decrease a.
Table 3.10. Values of d/{cNf}  corresponding to the minima of objective function 
F2 with a= 0 .05 , t = 1.01, 1.05, 1.1, 1.15, 1.2, 1.3, 1.4, 1.5 and 1.6 and K = 2, 3, 
4, 5, 10, 15, 20, 30, 50, 100 and 200.
K 1.01 1.05 1.1 1.15
t
1.2 1.3 1.4 1.5 1.6
2 57.5 15.7 9.2 6.8 5.6 4.3 3.6 3.1 2.8
3 56.7 17.6 11.0 8.6 7.2 5.8 5.0 4.5 4.1
4 55.5 17.5 11.3 8.9 7.6 6.3 5.6 5.1 4.8
5 55.2 17.3 11.2 8.9 7.7 6.4 5.8 5.3 5.0
10 55.0 17.1 11.0 8.8 7.6 6.4 5.8 5.4 5.2
15 54.9 17.1 11.0 8.8 7.6 6.4 5.8 5.4 5.2
20 54.8 17.1 11.0 8.8 7.6 6.4 5.8 5.4 5.2
30 54.7 17.1 11.0 8.8 7.6 6.4 5.8 5.4 5.2
50 54.7 17.1 11.0 8.8 7.6 6.4 5.8 5.4 5.2
100 54.7 17.1 11.0 8.8 7.6 6.4 5.8 5.4 5.2
200 54.7 17.1 11.0 8.8 7.6 6.4 5.8 5.4 5.2
As can be seen from Table 3.9, values of dl{ cNj} for cr = 0.01 are universally 
higher than in Table 3.10.
3.11 Examples.
In this section we give four examples of optimal one-sided group sequential 
tests. All of the examples are based on the same hypothesis testing problem 
which we now describe.
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Suppose X j, X2,..  •, XKn are independent normal random variables with 
unknown mean fi and unit variance. A maximum of 5 groups of 10 observations 
are available for testing
H{~: n = - 0.25 vs Hx+: 0.25
with error rates
Pr ( V  | ii = -0.25) = P rC a r |j£  = ° -25) = 0.05.
The fixed sample size test for this problem requires 44 observations.
We shall consider the four optimal group sequential tests which minimize the 
objective functions F 1? F2, F3 and F5. To ease notation we shall denote these 
four tests by 7\, T2, T3 and T5 respectively. Table 3.11 gives the critical values 
and the attained values of F 1? F2, F3 and F5 for the four optimal tests.
Table 3.11. The critical values and the attained values of F ls F2, F3 and F5 for 
the four optimal group sequential tests T1, T2, T3 and T5.
Test Critical Values Objective Function
Cl C2 C3 c4 5^ F l f 2 f 3 Fs
6.243 5.141 4.010 2.727 0.0 34.2 26.7 18.1 28.6
t 2 5.274 5.050 4.623 3.697 0.0 34.6 26.2 16.9 28.4
t 3 4.586 5.496 6.021 5.663 0.0 36.5 27.1 16.3 29.5
t 5 5.431 5.121 4.441 3.276 0.0 34.4 26.3 17.1 28.4
As can be seen from the table, the stopping rules for T2 and T5 are very 
similar. As would be expected the stopping rule for Tx is conservative at the first 
analysis. Conversely the stopping rule for T3 is very liberal at the first analysis.
The similarity of the stopping rules for T2 and T5 is highlighted in the 
attained values of F lf F2, F3 and F5. Of course T2 is the best of the four tests in 
terms of minimizing F2, although T5 requires just 0.1 observations more on 
average. Indeed all of the optimal tests are, on average, within 1 observation of
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the overall minimum. Compare this with the fixed sample size test which require 
17.8 observations more than T2 on average.
In terms of minimizing F5 test T5 is optimal, although to 1 decimal place 
there is no difference between T5 and T2. Test Tx is close to optimal for this 
objective function, while T3 requires 1.1 more observations than T2 and Ts on 
average. All 4 group sequential tests can be seen to be substantial improvements 
on the fixed sample size test which requires 15.6 more observations than T5 on 
average.
For objective function F3 test T3 is optimal, although none of the group 
sequential tests requires more than 2 observations more than T3 on average. Test 
T2 is slightly better than T5 here, with test Tx the poorest of the 4 sequential tests. 
Savings over the fixed sample size test are at least 27.7 observations on average 
here.
In terms of minimizing Fx, test 7  ^ is optimal. Both T2 and T5 are close to 
optimal here, with T5 being the better of the two. Savings over the fixed sample 
size test are smaller here than in other cases. Even so the fixed sample size test 
requires 9.8 observations more than 7\ and 7.5 observations more than T3 on 
average.
Figure 3.1 shows E (N \n ) plotted against // for -1  < n < 1 (i.e. -48  < /z <48) 
for 7\, T2, T3 and T5. Also shown in Figure 3.1 is the curve giving the minimum 
of E(N\ii)  for each value of fx in the range [-1,1]. In line with the observations 
made concerning Table 3.11, tests T2 and T5 can be seen to be optimal or close to 
optimal over /z in this range. Test 7\ is optimal for /z = 0, close to optimal for 
| / /1 small and sub-optimal for |/z| large. In contrast with 7\, test T3 is sub- 
optimal for \fi\ small and optimal or near optimal for |/z| large.
It should be noted that the four optimal tests differ slightly in their operating 
characteristics, that is the probability of accepting H{~ as a function of jx (which, 
of course, is simply the mirror image of the probability of accepting 7/1+ as a 
function of /z). Symmetry and the error constraints ensure agreement at /z = 0 and 
/z = ±0.25, while numerical calculations show that the largest difference in 
operating characteristics between any two tests is less than 0.002. Hence it would 
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Figure 3.1. Expected sample size function, E(N\ju) for tests 7 \, T2, T3 and T5, 
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To conclude, unless there exist particularly strong a priori reasons for 
adopting tests such as 7\ or T3, we would recommend the use of either T2 or T5 
in practice. Clearly both T2 and T5 are optimal, or close to optimal over the 
entire parameter space for p. Note, however, that all four tests considered here 
have clear advantages over the corresponding fixed sample size test.
3.12 Optimization over Unequal Group Sizes.
In §§3.5-3.11 we have considered the computation of optimal group 
sequential tests for problems with equally sized groups of observations. By 
allowing unequal group sizes we introduce an extra level of complexity into the 
design stage of the experiment. On the other hand, allowing group sizes to vary 
may lead to substantial savings in the expected sample size. In this section we 
consider the minimization of F1: E(N\p=0), F2 : E (N\p=S\  F3: E(N\p=2S) and 
F5: J E(N\p)6~1<p(p/S) dp over group sizes as well as feasible stopping rules.
Before describing our approach in more detail we note that this topic has 
received scant attention in the literature. Colton & McPherson (1976) considered 
the minimization of 2 group one-sided sequential tests over group sizes. They 
concentrated on the unsymmetric problem of §3.3 with the restriction that early 
stopping with the acceptance of H0 was not permitted (i.e. cx = -oo). They 
pointed out that such a restriction will not normally amount to a serious ethical 
problem. (Indeed in our clinical trial example of §3.2 and §3.3 a case could be 
made out for continuing to sample when the standard treatment is no worse than 
the experimental in order to assess secondary issues.) The two remaining critical 
values, Ci and c2, are constrained by the Type I and Type II error rates. By 
considering percentage points of the bivariate normal distribution, tests were 
derived which minimize E(N\p=S) for both equally and unequally sized groups. 
Colton & McPherson pointed to the efficiency of these two stage designs with 
large savings in E(N\p=S)  over the single sample test.
For our approach to tests with unequal group sizes, consider again the 
problem described in §3.5, but this time with K  groups of sizes 
til, n2 ~rii, ..., nK — nK_i , where nx <n2 < . . . .<nK and, in general, group sizes 
are not equal. For fixed K, cr, S, /ilf n2,...,nK_i and nK, we can easily compute
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an optimal test for a given objective function, F, by simply generalizing the 
method of § § 3 .6 -3 .8.
We can minimize F  over group sizes as well as feasible stopping rules by 
searching over {lnnj, In (rt2 -M i),...,ln  (nK ~ n K_{)} e  R^. At each stage of the 
search we fix group sizes and compute the optimal feasible test in the way 
oudined above. We use the simplex algorithm of Nelder & Mead (1965) to search 
over group sizes. This algorithm requires the specification of (K+1) starting 
values when working in K  dimensions, but does not require the calculation of 
derivatives of the objective function. As we noted in §3.5 the Nelder & Mead 
algorithm is only really powerful in 7 or fewer dimensions. Fortunately, for this 
problem, the most interesting results occur with K  <5.
Table 3.12 gives the minima of Flt F2, Fs and F5 for tests with K -  2, 3, 4, 
and 5, a  = 0.05 and no constraints on the group sizes. Results are, again, 
expressed as a percentage of the corresponding fixed sample size, Nf, and are 
independent of 8 and a 2. The figures in parentheses are the corresponding 
minima for designs constrained to have equally sized groups.
Table 3.12. Minima of Fx, F2, F3 and F5 for tests with a -  0.05, K  = 2, 3, 4 and 
5 and no constraints on group size. Results are expressed as a percentage of the 
corresponding fixed sample size, Nf. The figures in parentheses are the 
corresponding minimum values for designs with equally sized groups.
K Fl Fs f 5
2 86.5 (87.0) 71.2 (72.7) 49.3 (57.0) 16 A (76.7)
3 81.7 (82.4) 63.9 (64.8) 38.2 (45.3) 69.4 (69.7)
4 79.2 (80.0) 60.0 (61.0) 33.6 (39.9) 66.0 (66.4)
5 77.7 (78.4) 57.7 (58.7) 31.2 (36.8) 64.2 (64.5)
Clearly, allowing unequally sized groups leads to only small percentage gains 
in efficiency for objective functions Flt F2 and F5. Such gains could well be
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outweighed by the additional complexities introduced into the design stage of the 
trial. Somewhat more substantial gains occur with objective function F3. We 
shall consider these tests in more detail.
Table 3.13 gives the cumulative group sizes, n2, ..., nK, expressed as 
proportions of the fixed sample size, for the optimal tests for F3 considered in 
Table 3.12. To ease notation we let n jN f  be denoted by (i= 1 ,2 ,.. . ,  K ).
Table 3.13. The cumulative group sizes for the optimal tests for F3 considered in 





3 0.24 0.6 1.79
4 0.17 0.38 0.77 2.2
5 0.15 0.29 0.51 0.95 2.65
The general pattern in Table 3.13 is for the first K— 1 analyses to occur 
relatively early compared with the Kth analysis. For instance with K= 2 the first 
analysis is conducted after only 29.3% of the maximum number of patients 
required by the test have responded. When K= 5 the 4th analysis is conducted 
after 35.8% of the maximum number of patients have responded.
For K > 3 the maximum sample size is large compared with the 
corresponding fixed sample size. Indeed when K = 4 and K = 5 the maximum 
sample size is more than twice as large as Nf. This would tend to suggest that 
while these tests may be very efficient for |//| large, they are likely to be sub- 
optimal when fi is small in absolute value. To confirm this we calculated 
: F(AT|//=0), E(N\fi=6/2), which, to ease notation, we shall denote by F SI2 > 
and F2 : E{N\fi-8)  for each of the 4 tests. The results, expressed as a percentage 
of Nf, are given in Table 3.14.
- 51 -
Table 3.14. Attained values of Fl9 E(N\fi=S/2) and F2 for the optimal tests for 




Fi 96.3 104.8 115.4 127.3
F812 90.8 95.1 101.7 108.9
f 2 77.1 73.1 72.7 72.6
For K> 2 and attained values of Fx our tests require more patients on 
average than does the corresponding fixed sample size test Moreover all 4 tests 
are substantially worse than the optimal tests for F1 given in Table 3.12. Even 
under fi = S /2 it would, on average, be preferable to adopt a single sample test 
than our optimal test with 5 groups. The attained values of F2 are at most 77.1% 
of the fixed sample size. However the tests are clearly sub-optimal when attained 
values of F2 are compared with the results for the optimal tests for this objective 
function given in Table 3.12.
To conclude, it should be said that for objective functions Fl , F2 and F5 
allowing unequal group sizes leads to only small gains in expected sample size. 
While more substantial gains are obtained for objective function F3 the resulting 
tests are rather sensitive to the actual treatment difference, fi. Indeed, if // = 0, 
these tests perform worse on average than does the fixed sample size test. We 
would recommend the employment of tests with equally sized groups unless there 
are strong reasons to the contrary.
3.13 Unpredictable Numbers of Groups and Group Sizes.
In practice group sizes and the maximum number of analyses may not be 
known at the design stage of a study. Typically a clinical trial monitoring 
committee will arrange to meet at equally spaced intervals in time (every 6 
months, say) over a fixed length of time. Clearly the number of patients
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responding between analyses is likely to be unpredictable. The maximum number 
of analyses might also be unpredictable. For example, if patient recruitment on to 
the study is slower than anticipated the length of the trial may well be extended 
and the maximum number of analyses increased.
Pocock (1977) was one of the first to consider the problem of unpredictable 
group sizes. He conducted a simulation study into the effect of unpredictable 
group sizes on the error rates of his two-sided group sequential tests (described in 
§4.4). Using a Poisson process to generate group sizes, Pocock showed that his 
tests were robust to such unpredictability.
Lan & DeMets (1983) proposed a procedure flexible enough to be used when 
both group sizes and the maximum number of groups are unpredictable. Their 
approach was based on the use of an error spending function (see the discussion 
of Jennison’s (1987) paper in §3.5). Suppose the planned maximum sample size 
of our test was «max. The function a*(r) specifies the error to be "spent" after a 
proportion r of nmax has been observed. The choice of cc*(r) is open to the 
experimenter, although the function is defined to satisfy a*(0) = 0 and a*(r) = a 
for r > 1.
Letting Sn. =X1 +X2 + ... +Xn.t the critical values of the Lan & DeMets test 
are computed numerically as the solutions of the following system of equations for 
i = 1,2....... K ,
Z Pr-idS*, |< C i  |Snj_, | < Cj_i ,S„. > cj) = cc*(njnmax). (3.13.1)
;'=  i
An important feature of these equations is that q  depends only on 
n i , n2y..., q  and q ,  c2, ..., q_ i. Hence it is not necessary to know future group 
sizes, critical values or the maximum number of analyses in order to compute the 
present critical value.
The experiment is terminated either before «max or at the first analysis such 
that the accumulated sample size is greater than «max. Therefore a* should be 
such that q  = 0  at the first analysis at which «t- > «max. In general a * can only 
satisfy this last condition if the sequence q  is known in advance.
However, in practice, it suffices to choose a* to satisfy this condition for an 
anticipated sequence of group sizes and then to set q  = 0 at the first analysis at 
which ni > rcmax; this will lead to only minor departures from the stated error
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probabilities a  dX fi = ±8.
Lan & DeMets considered three error spending functions, namely
(i) «!*(/•) = 2 (l-4 > (0 -1(l-a/2)/VT)) (O c rS l)
(ii) 02*(r) = alji {1 + ( e - l ) r )
(iii) «3*(r) = a r .
The function cq* has very similar properties to the two-sided test of 
O’Brien & Fleming (1979) (described in §4.4) with a rather conservative 
stopping rule at early analyses. In contrast a2 is similar to the test of Pocock 
(1977) with a liberal stopping rule at early analyses. The third error spending 
function, a 3*, can be seen to be a compromise between and a2*.
In order to compute a group sequential test which is both flexible and 
highly efficient with respect to some objective function, F, we propose to use 
Lan & DeMets’ method with the error spending function of an optimal test for 
F. Our only problem is that the Lan & DeMets approach requires a*(r) to be 
continuous in r (0 < r< l) . We propose to use the error spending function of 
an optimal group sequential test with a large number, 100 say, of equally sized 
groups, which clearly would be discrete in r, and then to use linear 
interpolation to obtain a continuous function.
As an example, suppose cr2 = 2  and <5 = 0.2, so that a fixed sample test 
with error probabilities 0.05 would require 136 observations, and it is desired to 
construct a group sequential test with a maximum sample size of 150 and with 
a low expected sample size at n  = ±<5. We first compute the boundary values 
?ioo) for the optimal group sequential test for this problem with 100 
groups of observations; there is no difficulty here in dealing with non-integer 
group sizes, we simply set nt = 1.5i and treat Sn. as having a normal 
distribution with mean 1.5i\i and variance 1.5/<x2. We then calculate
«*(//100) = i ;P r . ,{ |5 ni I < ? ! , I 11 < ?;_!, S > gj) j =  1 , 1 0 0  
;'= i
and define the remainder of a*(r) for 0< r < l  by linear interpolation between 
these values. Suppose the group sizes actually obtained are 20, 35, 40, 20, 25 
and 20. Solving (3.13.1) for j = l,...,5  and setting c6 = 0 gives q  = 17.0, 
c2 = 13.9, c3 = 11.2, c4 = 10.7 and c5 = 6.5. Note that this test has 
n6 = 160 > nmax; however, since c5 is so small, it is unlikely that the 6th group
of observations will be needed. This test has error probabilities 0.046 and 
expected sample size 88.2 at fi = ±S. The minimum possible E(N\{i=5) for a 
test with the same group sizes and error probabilities 0.046 at fi = ±8 is 87.0 , 
thus, the method has yielded a highly efficient test even though the actual 
group sizes were unknown.
In §3.5, we discussed the family of one-sided tests proposed by Emerson 
& Fleming (1989). The boundaries of these tests are indexed by a single 
parameter, A. For a pre-specified A the critical values of the Emerson & 
Fleming test are given by cx = (in)*z -  inS (i = 1 ,...,/sf), with z constrained to 
give a test of size a  and n chosen so that cK = 0. The family is easily 
generalized to the case of fixed but unequal group sizes, 
« i , »•••» nK~nK-i> ^  setting Ci = z -  (z = 1,...,AT) with nK
constrained so that cK = 0.
Emerson & Fleming went on to suggest the extension of their method to 
practical examples where both group sizes and the maximum number of 
analyses are unpredictable. At the design stage of the trial A and a  are fixed 
and K  is predicted. The relevant z, z', say, is calculated, and the group size n 
chosen so that cK = 0. Suppose the actual maximum number of analyses is K '  
and the group sizes are n \ t our critical values are
then given by
c'i = z ' - n ' i S  i= l , 2 , . . . , / r - l
and
c 'K' = 0.
Obviously K '  and may be less than, equal to or greater than K  and Kn 
respectively. Sampling is terminated at the first analysis after Kn observations 
have accrued.
Emerson & Fleming conducted a study of the attained significance levels 
of their method over a wide range of possible scenarios. For a  = 0.05, A=0 
and 0.5 and K  predicted to be 4, n and z' were calculated. Tests were then 
simulated with actual numbers of analyses K '  = 2, 3, 4, 5 and 6 and group
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where r = 0.8, 1.0 and 1.5, and n'K = 0.9, 1.0, 1.1. Obviously x 'K determines 
the attained maximum sample size. The parameter r  determines whether group 
sizes are equal ( r = 1.0), larger at early analyses (r = 0.8) or larger at later 
analyses ( r=  1.5).
The results of Emerson & Fleming are repeated here in Tables 3.15 
(A = 0) and 3.16 (A = 0.5). Also included is the ratio of E(N\n=S) to its 
corresponding minimum for each of the simulated designs - this ratio is known 
as an "efficiency ratio".
Table 3.15. Attained Type I errors and efficiency ratios for the simulated 
designs considered by Emerson & Fleming (1989) for r = 0.8, 1.0 and 1.5, tz'K’ 
= 0.9, 1.0 and 1.1 and K' = 2, 3, 4, 5 and 6. The design on which these 
simulated tests are based has A =0, AT = 4 and a =0.05.
r x 'K> 2 3
K '
4 5 6
.8 .9 .0546 1.0 .0556 .9771 .0563 .9679 .0569 .9641 .0573 .9618
1.0 .0472 1.0 .0492 .9625 .0508 .9426 .0520 .9328 .0530 .9271
1.1 .0421 1.0 .0457 .9486 .0484 .9164 .0504 .8997 .0518 .8909
1.0 .9 .0542 1.0 .0552 .9754 .0559 .9721 .0565 .9693 .0570 .9663
1.0 .0464 1.0 .0484 .9565 .0500 .9458 .0512 .9398 .0522 .9343
1.1 .0407 1.0 .0442 .9355 .0470 .9143 .0491 .9042 .0507 .8970
1.5 .9 .0535 1.0 .0545 .9949 .0552 .9820 .0558 .9770 .0562 .9735
1.0 .0450 1.0 .0469 .9859 .0484 .9664 .0496 .9551 .0506 .9480
1.1 .0383 1.0 .0415 .9705 .0441 .9462 .0462 .9279 .0480 .9165
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Table 3.16. Attained Type I errors and efficiency ratios for the simulated 
designs considered by Emerson & Fleming (1989) for r = 0.8, 1.0 and 1.5, n K' 
= 0.9, 1.0 and 1.1 and K'  = 2, 3, 4, 5 and 6. The design on which these 
simulated tests are based has A =0.5, K  = 4 and a  = 0.05.
r It'k ’ 2 3
r
4 5 6
.8 .9 .0375 1.0 .0445 .9973 .0502 .9958 .0550 .9951 .0590 .9948
1.0 .0328 1.0 .0405 .9951 .0465 .9921 .0514 .9907 .0555 .9901
1.1 .0294 1.0 .0376 .9931 .0437 .9887 .0487 .9866 .0528 .9858
1.0 .9 .0389 1.0 .0471 .9975 .0537 .9970 .0593 .9969 .0640 .9966
1.0 .0341 1.0 .0430 .9945 .0500 .9929 .0557 .9926 .0606 .9925
1.1 .0307 1.0 .0401 .9913 .0473 .9881 .0531 .9876 .0580 .9879
1.5 .9 .0416 1.0 .0520 1.0 .0607 .9952 .0680 .9888 .0743 .9824
1.0 .0366 1.0 .0478 .9994 .0569 .9958 .0644 .9902 .0709 .9842
1.1 .0330 1.0 .0447 .9971 .0541 .9943 .0618 .9895 .0683 .9842
The attained error rates are quite impressive, ranging from 0.0383 to 0.0573 
when A = 0 and from 0.0294 to 0.0743 when A =0.5. When the predicted 
maximum sample sizes are attained (i.e. n K = 1.0) these errors are even more 
impressive, with a range of 0.045 to 0.053 when A = 0 and 0.0328 to 0.0709 
when A = 0.5.
The efficiency ratios are also good. When K'  = 2 these ratios are always 
equal to one. With A=0 the tabulated tests are at worst 89.09% efficient. 
With A =0.5 the tests are never worse than 98.24% efficient.
Patently the Emerson & Fleming method performs well both in terms of 
attained significance levels and expected sample size under // = S. However we 
claim that our proposal for dealing with both problems of unpredictability is 
superior. Table 3.17 gives the attained sizes and efficiency ratios under for the
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simulated designs considered by Emerson & Fleming for our method based on 
the optimal test for F2 with t = 1.2, K  = 100 and a  = 0.05.
Table 3.17. Attained Type I errors and efficiency ratios for the simulated 
designs considered by Emerson & Fleming (1989) for r = 0.8, 1.0 and 1.5, k '
-  0.9, 1.0 and 1.1 and K' = 2, 3, 4, 5 and 6. The design on which these 
simulated tests are based is our optimal group sequential test for F2 with 
t= 1.2, £ = 1 0 0  and or = 0.05.
r k 'k ' 2 3
K'
4 5 6
.8 .9 .0507 1.0 .0522 .9998 .0528 .9991 .0532 .9984 .0534 .9980
1.0 .0452 1.0 .0471 .9990 .0479 .9982 .0483 .9978 .0486 .9977
1.1 .0414 1.0 .0437 .9975 .0448 .9952 .0455 .9934 .0460 .9916
1.0 .9 .0507 1.0 .0521 .9980 .0527 .9974 .0531 .9976 .0586 .9978
1.0 .0451 1.0 .0469 .9959 .0477 .9949 .0482 .9955 .0485 .9965
1.1 .0411 1.0 .0435 .9931 .0445 .9904 .0452 .9901 .0457 .9905
1.5 .9 .0492 1.0 .0513 .9937 .0523 .9979 .0528 1.0 .0531 .9991
1.0 .0432 1.0 .0459 .9887 .0471 .9946 .0478 .9970 .0482 .9978
1.1 .0388 1.0 .0421 .9826 .0436 .9894 .0445 .9929 .0450 .9939
Our method produces tests with Type I errors ranging from 0.0388 to 
0.0586. For k 'K'= \ . 0  this range reduces to 0.0432 to 0.0486. These 
impressive results are similar to those observed for the Emerson & Fleming test 
with A = 0 and superior to those in Table 3.16 when A = 0.5. The efficiency of 
our tests is no less than 98.26% for the designs tabulated in Table 3.17. In 
terms of efficiency, then, our method is a significant improvement on the 
Emerson & Fleming test with A = 0 and comparable with the results for
- 58 -
A = 0.5. Other examples follow a similar pattern.
3.14 Discussion and Conclusions.
In this chapter we have introduced a computationally efficient and 
numerically stable method for the derivation of optimal one-sided group 
sequential tests on the mean of a normal distribution with known variance. Up 
until comparatively recently the computation of optimal tests was impractical if 
not impossible. Instead tests were designed which required only a set of tables 
and a pocket calculator for their implementation. Some of these tests had the 
added bonus of being close to optimal for one or more objective functions.
The increase in both the power and availability of computers means that 
optimal tests may now be considered. Jennison (1987) was the first to derive 
fully optimal one-sided group sequential tests. Our approach can be seen to be 
an improvement on his. In particular we can obtain optimal tests for designs 
with a large number of groups and use them to compute flexible procedures for 
the sort of problem usually encountered in practice where both the group sizes 
and maximum number of groups are unpredictable. Simulations show that our 
method compares favourably with similar techniques suggested in the literature.
In Chapters 4 and 5 we extend our method to the problems of two-sided 
tests with or without the option to stop early and accept the null hypothesis 
respectively.
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Appendix. 
Appendix 3.1.
Consider again the symmetric one-sided group sequential hypothesis testing 
problem of §3.5. For any given stopping rule we can calculate the operating 
characteristic function (that is the probability of accepting Hx+ as a function of fi) 
and the expected sample size function, by multiple numerical integration.
For example, consider the calculation of E(N\fii). By analogy with equation
(3.3.3), we have 
E(N\fi) =
K  Cj , c,
n Z , J J J ••• J f M(.Xi)ffl(x2 - x 1) . . . f /1(xJ—Xj_l ) d x l . . .dXj_l dxj (3 .Al . l )
j =1 rj~Cj-1 ~C1
where rj = { (-°° ,-c /]u [c 7-,«>)} and /^ (x) is a normal density with mean rc/z and 
variance no 1.
Clearly E{N\n)  is the sum of an integral and K - 1 multiple integrals. The 
first integral in the sum is simply
which equals
1 -  $ Ci~nn
yln<72
+  d >
•Ci -nfi
yIna2
where O is the c.d.f. of the standard normal distribution. The NAG library 
contains subroutines, S15ABF and S15ACF, for calculating d>(.) and l-d>(.) 
respectively.
The second term in the sum is proportional to
ClJ j  f ^ x 2- x 1) f M(xl ) d x l dx2 . (3.A1.2)
r2 -Ci
The integral with respect to x l here can be evaluated using Simpson’s rule. A 
naive approach would be to choose the grid points of the rule to be equally spaced 
over the interval However, if the total number of grid points is fixed,
such an approach will lead to inaccurate calculations if the width of the interval,
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2Cj, is "large".
A more robust approach involves placing a grid of 6 N - 1  points 
{gt : 1 < i < 6 N - 1}, where N  is fixed, over x1 according to the rule:
For i = l , N
gi = n // -  Vn a  {3 + 41n(N/i')}
For i = N + l ,5 N - l
gi -  n n -  Vn a  {3 -6( i -N)/4N}
and, for i = 5N,6N-1,
gi = n fi + Vn a  {3 + 41n(//(6N-l))}.
This rule places a fixed number (4A0 of equally spaced points within 3 
standard deviations of the mean of the distribution we are integrating. In the tails 
of the distribution grid points are placed increasingly far apart. To obtain a set of 
grid points, { , , i : 1 < / l  <^1  to place over the interval we first find
gi and gi+1 such that
gi < - q  < gi+1
and gt and g/+1 such that
S i< c i <8 i+i-
We then set g1>x = -C j, g13 = 8 i+i* £1,5 = £,+2» —> £1, -^2 = 8j  ^  8 1 ,Ny = c i- 
(Note that if - c x <gx and/or cx >g6N-1 we set £1(1 =g: and/or g1 N 1  =g6N- 1.) 
The grid points with even subscripts {#! ,2i * 1 < (iVx —1)/2} are then positioned
halfway between the neighbouring grid points with odd subscripts, i.e.
£l,2i =  y  { £ l ,2 / - l  +  £l,2i+l }•
The weights {wlf il : 1 < i l  <Nt } for use in integral (3.A1.2) are given by
wi , i= y ( £ i ,2~ £ i,i)
wl,2i = j ( £ i , 2/ - £ i ,2j-i) i = l,2 ,....,(A /1- l) /2  
wl,2i+l = ^■(£l,2i+2“ £l,2/) 1 = 2, ..., (N1 -3)I2
w l , N l -  (8 1 ,Nt ~  8 1 ^ - 1 ) '
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Integral (3.A1.2) then becomes
Ni
|  X  ^ l .n  f ^ 8 i , i i ) f t,(x2 - g i in )dx 2
r2i 1=1
(3.A1.3)
We store the terms {wx ,/i): 1 ^ i l  ^ N i } in an array
{^ i(£ i,ii): for future use. The integral (3.A1.3) is equal to
Z  hl(8l,il)* 
/ 1=1
l - d >
c2 - 8 i , n - m
Vm Vrti
This sum is easily evaluated using the stored array {hi(gl<n): l < i l < N 1) and 
the NAG library subroutines S15ABF and S15ACF.
The third term in the sum (3.A1.1) is proportional to the multiple integral
c2 c,
J J J f M(x1) f fl(x2 - x 1) f^ (x 3 - x 2 )dxl dx2 dx3. (3.A1.4)
r3 —c2~C\
The first stage in evaluating the multiple integral (3.A 1.4) is to evaluate the 
integral with respect to x l . This is easily achieved by using the stored array 
( V S m ) :  1 -*1 - } •  The multiple integral (3.A 1.4) equals
C l Nx
r3 - c 2zl = l
(3.A1.5)
We can now use Simpson’s rule to evaluate the integral with respect to jc2. 
The relevant grid points and weights are obtained using the same rule as for the 
integral with respect to xx. We shall denote the grid points by 
{8 2 ,n : 1 ^ i 2 < N 2} and the weights by {w2> ,2: 1 - * 2 < N2}. Integral (3.A1.5) is 
then approximately equal to 
N2 Ni
j  X  X  (3.A1.6)
r3 z'2= 1/1=1
Ni
We store the terms { £  hi(8 i,11) ^ 2 ^ ( 8 2 ,12- 8 1 ,11)- 1 ^*2 ^ ^ 2} in an
fi=i
array {h2 {g2 ,n ) : 1 < /2 < } for future use. It follows that (3.A1.6) is equal to
n 2




+  0> C3 - 8 2 A2 - W
'fna
This sum is easily evaluated using the stored array { h 2 ( g 2 t i 2 : 1 ^ *2 <iV2} and the
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NAG library subroutines S15ABF and S15ACF.
All other terms in the sum (3.A 1.1) are calculated similarly. The Xth term 
equals
2  ^K-l(8K-l,i(K-l)y
i ( K - 1)=1
l - d >
V/Tcr
+cj>
where {hK_i(gK_i < i (K - l )  <Nk _ 1 } is a stored array with i (K -  l)st
element, /*a;-i (£a:-i ,/(*-!)) equal to
n k
2  ^K -2 ^S K -2 , i {K - 2 ) )w K - \ , i { K - \ ) f ^ S K - l , i { K - l ) ~ 8 K - 2 , i { K - 2 ) ) '
i{K-  2)=1
Using the same techniques as those explained above we can calculate the 
operating characteristic function of a given one-sided group sequential test:
0 .C .O O  = P r ( V |/0 .
Details are omitted.
Appendix 3.2.
Consider again the symmetric one-sided group sequential hypothesis testing 
problem introduced in §3.12, which has a maximum of K groups of sizes /q, 
n2 —nl , ..., nK - n K_ 1. (The problem of §3.5 is a special case of this problem 
with ni -  n2 ~ n l -  ... = nK -  nK_i = n.) Using the same notation as in §3.12, let 
Xj, X2, ..., XHk be independent identically distributed normal random variables 
with unknown mean (i and known variance a 1. We wish to test
H{~:p<  0 vs Hi+:fi> 0
with error rates
PrC9Ll+\n = S )  = Pr(j*r|/* = (3.A2.1)
Suppose the set of critical values {cx, c2, ..., cK) defines a feasible stopping 
rule for the above problem. By analogy with the results of §3.3, the expected 
sample size under n  for this problem, E(N\/i), is given by equation (3.A2.2)
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E(N\fi) =
jr Cj-1 C\X « / J  J ••• J fp(x1)fM(x2 - x 1). . . f /t(xj -Xj_l )dxl . ..dXj^dXj  (3.A2.2)
j=1 rj~cj-\ ~Ci
where r;- = {( —°°, — Cj ]u [c y >°°)} 0  = 1 , 2 , AT), fp(xx) is a normal density with 
mean n^ii and variance nxo 2 and (/ = 2 , 3 , K) are normal
densities with means («,•-«,•_!)// and variances ( r t i - n ^ ^ a 2.
Further, the operating characteristic function given fi for this problem,
OC(fi) = Pr(.fl1+|//), is given by equation (3.A2.3),
OC(fi) =
g 00 Cj-1 c\X j  J . . . l f fi( x l ) f fl(x2 - x 1) . . . f M(Xj -Xj_1) d x l . . . dxj _ l dxj . (3.A2.3)
j=lcj-Cj-l ~Cl
We now consider a new problem in which the variance of the original 
problem, cr2, is replaced by o 2, and the reference improvement, 8,  is replaced by 
(> 0). The Type I error rate of this new test, a , and the maximum number of 
analyses, K , remain the same as for the original problem.
Consider the following stopping rule for our new problem defined by the
g 28
rescaled set of critical values {ci*,c2 * , c K*}, where c* = — — c,-
a 2Sl
(1 = 1 ,2 ,. . . ,  AT), together with the rescaled cumulative group sizes
G 2 8 2
n*  = —-——rij (i = 1, 2 ,. . . ,  K). In this Appendix we prove the following 
g 2 8 2
Lemmas and Corollaries:
Lemma 3.1 : The operating characteristic function for our new problem, OC*(n), 
is such that
0C *(//) = OCiiiSIS)).
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Corollary 3.1 : From Lemma 3.1 it follows that
OC* (SO = OC(S)
and
O C *(-^ ) = OC(-S).
As OC(S)= 1 - a  and OC(-S) = a , it follows that the rescaled set of critical 
values { *  ,c2*, cK*} together with the rescaled cumulative group sizes, 
rii* ,n2 *, nK*, define a feasible stopping rule for our new problem.
Lemma 3.2 : Letting E(N*\f i) denote the expected sample size function for our 
new problem and Nf* denote the corresponding fixed sample size, we prove that
E (N * \ f i )  _  E (N \ ii£IS{) 
Nf ~ Nf
where E(N\fi) is the expected sample size function for the original problem and 
Nf is the corresponding fixed sample size.
Corollary 3.2 : From Lemma 3.2 it follows that
(f)  E { N * \ y = 0) = E (N \u = 0 )
Nf* Nf
(a ) g(Ar" | //=<;,) = E ( N \ ( i = s )
Nf* Nf
(iii) E(N*\fi=2Sl ) = £(iV|^=2<?)
Nf * Nf
(,•„) <p(n!8 )dn _ \ E ( N \ y ' ) 8 - 1 <p(fi IS)dfi
N /  “  Nf
where n  = fidlSy.
Proof of Lemma 3.1 :
The operating characteristic function for the new problem is given by 
OC*(n) =
o o  Cj - 1*  C \
S  J J ••• J f ^ x2 ~x\) — f M(Xj-Xj_i) dxx ... dXj_x dXj (3.A2.4)
j — \ C j  — C j _ ]  —  C j
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where r* = {(-c,* ,c,*)} for i = 1 , 2 , K - l ,  f^ix^)  is a normal density with 
mean n^* fi and variance n-^a2, and (i = 2, 3 , K)  are normal
densities with means and variances (n*
g 28\
Consider the substitutions z\ -  — —  xt for i = 1,2, in equation
g 28
(3.A2.4). We obtain 
0C*(/z) =
j r  « »  Cj - \  C 1
X j  J — { g/i'(z1)gM'(z2- z 1) . . . g M'(zj-Zj-1)dz1 dz2 :-dzj-idzP-A2.5)
j = l c j - C j - 1 - C j
where /z =/i£/£lt g^'(zi) is a normal density with mean n^ii and variance ni<r2,
8M'(Zi~Zi_i) (i = 2v3  AT) are normal densities with means («/-«/_i)/z and
variances and {q , c2, ..., is a feasible set of critical values for
our original problem.
Comparing the RHS of equation (3.A2.5) with equation (3.A2.3), we see that
0C*(/z) = OC(ii') = O C C /z ^ ). (3.A2.6)
Q.E.D.
Proof of Corollary 3.1 :
Substituting /z = Si in to equation (3.A2.6) gives
OC*(80 = OC(8),
and from equation (3.A2.1) we have OC{8) = 1 -a .  Therefore O C*(^) = 1 -a .  
Substituting /z = - S 1 in to equation (3.A2.6) gives
OC'i-SO = OC(-8)  
and from equation (3.A2.1) we have OC{-8 ) = a. Therefore OC*(-8i) = a.
Hence the set of rescaled critical values {ci* ,c2*,.. . ,  cK*} together with the 
rescaled group sizes, *, •••» n K * ~ n K - 1*» define a feasible stopping rule
for our new problem.
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Proof of Lemma 3.2 :
The expected sample size function for our new problem is given by 
E(jV*||0 =
K 0-1 ‘ Cl*
X nj* J J ... J Xj_l )d x 1...dXj_1dxj (3.A2J)
j= 1 Tj*  C j - j  * - C l  *
where ry* = {(-°°,-Cy*),(cy*,«>)} for 7 = 1,2, . . .» K, / ^ ( x ^  is a normal density
with mean nx*p and variance and (i = 2 , K )  are normal
densities with means {n{*-n^*)f i  and variances (n * -/i,-_i*)<72.
tr2^
Consider the substitutions z,- = — — jc/5 for /=  1, 2 , in equation
g 28
(3.A2.7). We obtain 
£ ( A T | / / )  =
^  o-i o
| > 7*J J . . . J fy 'U i)  (3.A2.8)
7=1 O'-O-i -ci
where ry- = {(-oo,-cy)u(cy,<»)} for 7 = 1, 2 , . . . , ^ ,  g^{z\)  is a normal density
with mean riifi and variance tiiG2, gM’(Zi-Zj-1) (t = 2 ,3 ,  ,AT) are normal
densities with means (n1- n i_1)(T2 and variances (W j-n^^cr2, and 
{c j, . . . ,  , cK) is a feasible set of critical values for our original problem.
Comparing the RHS of equation (3.A2.8) with equation (3.A2.2), we have
E(N*\u)  = -^ -E iN l f i ' )  (3.A2.9)
n
where E(N\fi ) is the expected sample size function of our original problem under 
a treatment difference of / / .
From earlier we have
- 2 c 2  * G\ d n = —-—-  n.
<7 Si
Substituting for n* in equation (3.A2.9) and rearranging, we obtain
E(N*\u) _ E(N\m ) (3.A2.10)
l O U CJja , 2S2 o 252
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and dividing both sides of equation (3.A2.10) by {0 1 (1 —or) }2 and rearranging 
gives
E(N*\m ) = E{N\m ) 3A211)
N f  Nf
where, by analogy with equation (3.5.3),
( j f
N/  = - \ W ~ \ l - a ) } 2.
Q.E.D.
Proof of Corollary 3.2 :
(i) Substituting /z = 0 in to equation (3.A2.11) gives
E(iY*ln=0) = E(N\ti=0) 
Nf Nf
(ii) Substituting fi = 8X in to equation (3.A2.11) gives
E(N*\ft=8j) _ E(N\h =8) 
N /  Nf
(iii) Substituting n = 28l in to equation (3.A2.11) gives
E{N*\n=28{) _ E(N\m=2S) 
1V/ Nf
(iv) Consider substituting fi' = 8{i/Si in the expression




From Lemma 3.2, it follows that,
f E(N'\n '8 i!5)  ,
J  —  s  tp(n /S)dfi
1 <p(n!8{) dfi ^ E ( N \ n ) S  1 <p(n IS)dfi 
N /  ~ Nf
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4. Optimal Two-Sided Group Sequential Tests. 
4.1 Introduction.
In §3 we introduced a numerically stable and computationally efficient 
method for deriving optimal one-sided group sequential tests on the mean of a 
normal distribution with known variance. In both §4 and §5 we generalize our 
method to the problem of two-sided group sequential tests.
In §4 we consider tests which allow an experiment to be stopped early with 
the rejection of the null hypothesis, H0, but acceptance of H0 is only permitted at 
the final analysis. In §5 we go on to consider tests which allow early stopping for 
both the acceptance and rejection of H0.
As in §3 the motivation for this work comes from a clinical trials problem. 
However both the designs and the results of §4 have much wider applications.
4.2 The Fixed Sample Size Test.
Consider a clinical trial with 2N  patients available for testing the relative 
efficacies of two experimental treatments which we shall denote by A and B. On 
entry to the trial each patient is randomly assigned to one of the two treatments. 
An allocation method such as the randomized permuted block design is used in 
order to ensure that exactly N  patients are entered on to each treatment arm. Let 
the random variable Xt (j = l,...,iV ) represent the difference in response between 
the ith patient on treatment A and the ith patient on treatment B. Suppose that the 
Xf’s are independent and normally distributed with unknown mean /z and known 
variance cr2. The parameter // is, then, a measure of treatment difference about 
which we would like to make inferences. For example consider the following 
single sample two-sided hypothesis test on 
We wish to test
H j - : {i<0 vs H0: // = 0 vs : n>  0
with Type I error rate
Pr(J*r u  V U  = 0) = a  (4.2.1)
where A{~ and denote the acceptance of H{~ and respectively.
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The uniformly most powerful unbiased test for this problem accepts H0 if
|s* | = i f  X,\ < V ^ O - ‘(l-a /2 )
1 = 1
it rejects H0 in favour of if
SN > ^ N a 2 <D_1 (l-« /2 ) 
and it rejects H0 in favour of H{~ if
SN < - ' I nct2 Q - ' i l - M ) .
The Type II error rates of the above test depend on the sample size. Letting 
%  denote the acceptance of H0, the test satisfies the Type II error constraints
P r C ^ u V I  H = S )  = P (4.2.2)
and
Pr ( .a r  u  IH = S) = P (4.2.3)
if N  is chosen equal to Nf where
2
Nf = {0>-1(l-/3 ) + <I>_1(l-a/2)}2. (4.2.4)
S2
The above fixed sample size test is widely used in clinical trials. However, 
as was mentioned in §3.2, there often exist strong economic and ethical 
arguments for the adoption of group sequential rather than the fixed sample size 
tests. In §4.3 we outline a two-sided group sequential test on the mean of a 
normal distribution with known variance.
4.3 Two-Sided Group Sequential Tests.
Consider again the two-sided hypothesis testing problem outlined at the start 
of §4.2. This time, however, a maximum of K  groups of 2n patients are available 
for entry on to the trial with n patients in each group being randomly assigned to 
treatment A and the remaining n to treatment B. At the ith analysis 
( /=  1,...,AT-1) we can either stop the trial and reject H0 in favour of H{~ or 
H x+, or we can admit the next group of 2n patients on to the experiment. If the
trial continues to the Kth analysis, it is terminated with either the acceptance or
the rejection of H0.
- 7 0 -
As was mentioned in §4.1, this test does not permit a trial to be stopped 
early with the acceptance of H0. This does not necessarily constitute a serious
ethical problem as early evidence in favour of H0 would suggest that the
treatments are equally effective. Indeed continuing the trial could be advantageous 
as it would allow the experimenter to assess secondary issues such as the side 
effects of the treatments.
So we shall consider symmetric stopping rules of the general form :-
At analysis i (1 < i < A '-l),
if Sin > ct stop entering patients on to the trial and accept H]+\ 
if Sin < -  ci stop entering patients on to the trial and accept
if | Sin | < Ci enter the next group of 2n patients on to the trial.
At analysis K,
if SKn > cK stop entering patients on to the trial and accept H ^ ;  
if SKn < -  cK stop entering patients on to the trial and accept H{~ \ 
if IS^J < cK stop entering patients on to the trial and accept H0.
Given n and K, we can use numerical methods to compute a set of critical 
values satisfying the error constraints (4.2.1)-(4.2.3). We term such a set feasible, 
and a test with a feasible stopping rule a feasible test. From equations (4.2.1)-
(4.2.3) we require cl , c2, ... ,cK to satisfy
£  P r ( |S j < q ,  •••, \SU- i )n\ < ^ - i .  \S jn \^cj \ t i  = 0 ) = a  (4.3.1)
y=i
X  P r ( |5 j < Cl, ..., Sj n e r f » \ n  = S) = P (4.3.2)
j= i
where ry(1) = (-°°,-Cj) for j  < K  and = (-© o,^), and
X  Pr (|5n| < Ci, ..., Sj n e r / 2)\ju = - S )  = p  (4.3.3)
j= i
where = ( c y- ,o o )  for j < K  and rK^  = (-%,©©).
These joint probabilities may be expressed in terms of multiple integrals and
evaluated by multiple numerical integration based on Simpson’s rule (see
Appendix 5.1 for further details).
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Our group sequential test may also be considered in terms of its nominal 
significance levels a Y, a2, ..., aK. The ith nominal significance level, ait is 
simply the Type I error of the fixed sample size test with in observations and 
critical values ±c,-, i.e.
l-a >
>line2
So in the earlier discussion the critical value ct may be replaced by
Clearly the sample size of our two-sided group sequential test is not fixed 
a priori, but is a random variable. The expected number of patients on each 
treatment arm under a given treatment difference //, E(N\p), is given by equation
(4.3.4)
E(N\p) = n j ^ j  Pr(\Sn\< c l  |Sn0-_i)| < C/_i, |Snj\ e r / 3>| p ) (4.3.4)
where ry(3) = {(-°°,-cy)u (cy-,«x>)} for j < K  and rK^  -  R.
Two-sided group sequential tests with the same error rates may be compared 
in terms of their expected and maximum sample sizes. Clearly the maximum 
sample size of the above sequential test is 2nK, while the maximum number of 
patients on each treatment arm is nK. A comparison of two-sided group 
sequential tests in terms of their maximum and expected sample sizes is given in 
§4.9.
4.4 A Review of the Literature on Two-Sided Sequential Tests.
There is a substantial body of literature relating to two-sided sequential tests. 
As with the one-sided sequential tests discussed in §3.4, the earliest two-sided 
tests were fully sequential (i.e. n = 1).
Fully Sequential Two-Sided Tests.
Armitage (1957) suggested setting ct = a + bi (/ = 1, 2, ..., K ) where a 
and b are chosen to satisfy the error constraints (4.2.1)-(4.2.3). To obtain good 
approximations for a and b Armitage considered an analogous problem in
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continuous time. The feasible stopping rule for the continuous time problem is 
readily obtained and this can be used to give an approximately feasible stopping 
rule for the original discrete problem. We note that with a modem computer the 
relevant values of a and b could be obtained directly.
Armitage, McPherson & Rowe (1969) and McPherson (1974) considered
tests with constant nominal significance levels (i.e. cq = a2 =... = aK = a \  say).
/
They showed that for given a  the overall Type I error of a test, a, increases with 
K  and that, even for moderately large K, can be much greater than the nominal 
level, a'. For example with K - 10 and a ' = 0.05 the probability of wrongly 
rejecting H0 is 0.19. Indeed, as was pointed out by Robbins (1952), a ->  1 as 
K  —» ©o by the law of the iterated logarithm.
In order to preserve the overall size of the test, Armitage et al. (1969) 
suggested conducting interim tests at a very stringent nominal significance level. 
For given a  and K  the relevant a ’ was computed by numerical methods. Table 
4.1 gives a'  for a  = 0.05 and K = 1, 5, 10, 20, 50, 100 and 200.
Table 4.1. The nominal significance level a ' leading to a test with overall 
significance level a  = 0.05 for the Armitage, McPherson & Rowe (1969) test with 
K  = 1, 5, 10, 20, 50, 100 and 200.
K 1 5 10 20 50 100 200
a f 0.05 0.015 0.01 0.007 0.005 0.004 0.003
It is important to realize that the results given in Table 4.1 are independent of 
<72 and S. Clearly the effect of increasing K  is to decrease a ' which in turn 
increases the critical values of the test given by ct = Vm<72 d>-1(l-a7 2 ).
Group Sequential Two-Sided Tests.
Pocock (1977) pointed out that fully sequential methods are likely to be 
impractical in the context of a clinical trial. He proposed a two-sided group 
sequential test (i.e. n > 1) with constant nominal significance levels. For a given 
problem with K  and a  fixed, the relevant nominal level is independent of group
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size. Hence for a  = 0.05 and K  = 1, 5, 10, 20, 50, 100 and 200 the nominal 
significance levels for Pocock’s test are given in Table 4.1. For tests with other 
values of a  and K, nominal levels can be computed using the same techniques as 
Armitage et al.. The group size, n, is then chosen to satisfy the Type II error 
constraints (4.2.2) and (4.2.3).
Pocock’s test is relatively simple to implement and quite insensitive to small 
changes in group sizes. The test has the added advantage of being close to 
optimal in terms of minimizing E(N\fii=S) and E(N\fii=-S) over the set of 
feasible tests for /? "small". Furthermore, for reasonably large group sizes, the test 
is robust to departures from normality (by the Central Limit Theorem) and to the 
assumption that the population variance, cr2, is known.
There are, however, strong arguments for considering tests with increasing 
nominal significance levels (i.e. cq < < ... < ocK). For instance Pocock’s test is
often criticized for being too liberal at early analyses when the accumulated 
sample size tends to be small. Many people have argued that a rather extreme test 
statistic would be required at, say, the first interim analysis for the trial’s 
monitoring committee to want to stop the experiment and reject H0. One possible 
reason for this could be the desire to continue the trial in order to assess 
secondary issues such as treatment side-effects.
Both Pocock (1982) and DeMets (1987) have argued for group sequential 
tests which resemble the corresponding fixed sample size test at the final analysis. 
The problem with the constant nominal significance level approach is that it 
requires a relatively conservative test at the final analysis. For example with 
K -  5 and a  =0.05, Pocock’s test would only reject H0 at the 5th analysis if 
1751 = \S5nri5ncr2 1 > 2.42. The corresponding single sample test would reject 
H0 if \S5nri5ncr2\ > 1.96. So, for instance, an observed test statistic of 
T5 = 2.35 would lead to radically different conclusions depending on how many 
times the data had been analysed and how much Type I error was left to be spent 
at the 5th analysis. This contradiction leads to confusion and lends weight to the 
criticisms by non-frequentist statisticians.
Several tests have been proposed in the literature which avoid the problems 
associated with the constant nominal significance level approach. Haybittle (1971) 
and Peto et al. (1976) suggested adopting very conservative critical values at the 
first K— 1 analyses. The stopping rule for these tests set
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q  = 3 Vmcr2 (or or,' =0.001) for i = 1 , 2 , ^ - 1 .  At the K\h analysis we can 
either set cK = 0 _1(l-a /2 ) VKna2 and obtain a test with Type I error marginally 
greater than a , or we can compute the critical value cK giving a test of size a  
exactly. As DeMets (1987) pointed out, the Haybittle/Peto test is extremely 
flexible; for instance, it is not necessary to specify the maximum number of 
analyses, K, at the design stage of the trial, although, as has been noted by Lan & 
DeMets (1989), it is only legitimate to alter K for reasons unrelated to the inferred 
treatment difference. The main disadvantage of the Haybittle/Peto test is that the 
probability of stopping early is, not surprisingly, relatively small.
O’Brien & Fleming (1979) proposed a test with critical values given by 
q  = z (i = 1 ,2 ,..., K)  where z is a constant chosen so that the overall size of the 
test equals a. Again an appropriate choice of group size leads to the Type II error 
constraints being satisfied. The test is rather conservative at early analyses 
(sometimes more conservative than even the Haybittle/Peto test!) but becomes 
increasingly more liberal at each stage. At the ATth analysis the O’Brien & 
Fleming test is similar to the fixed sample size test of size a  based on the same 
number of observations. For example with K - 5 and or = 0.05 the nominal 
significance levels of the O’Brien & Fleming test are given by: ax = 10~5, 
a2 = 0.0013, a3 = 0.0084, a4 = 0.0025 and a5 = 0.041. The O’Brien & Fleming 
test avoids many of the problems associated with the Pocock test while, in 
general, it offers a higher probability of stopping the trial early for \fi\ large than 
does the Haybittle/Peto test. DeMets (1987) concluded that the O’Brien & 
Fleming test provides a good compromise between the earlier two approaches.
Fleming, Harrington and O’Brien (1984) defined a family of two-sided group 
sequential tests in terms of the Type I error spent at each analysis. Let denote 
the Type I error spent at analysis i, then
*<• = P r ( |S „ |< c 1, |S(/_I)II|< c f_1, |S j > c , - |^  = 0) i = 1 K.
For a test of size a  we require that = a . Fleming et al. suggested
choosing k x -  n2 -  ... -  nK_x -  k, say, with kk  = a -  ( K- I ) t u .  For a given 
choice of 7C, K  and a  numerical methods give the resulting set of critical values.
In choosing k, Fleming et al. recommended considering the parameter 
7 = ( K - \ ) n l  a  which is the ratio of the Type I error spent at the first K- 1 
analyses to a. Choosing /  small (large) gives a test which is conservative (liberal)
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at early analyses. Fleming et al. considered y  = 0.1, 0.2, ..., 0.5. A suitable 
choice of y  gives rise to a test which provides a compromise between the extreme 
conservatism typical of the early analyses of the O’Brien & Fleming and 
Haybittle/Peto tests and the controversial liberalism at the early analyses of the 
Pocock test.
Like the Haybittle/Peto test, the Fleming et al. test is very flexible. For 
instance it allows us to consider tests with unequal group sizes. For the problem
outlined at the start of §4.3, but with K  groups of sizes nlf n2 - n 1, ..., nK- n K_lt
this is achieved by computing from the equation
= Pr (l5n, I < Cl I V ,  I < c,_!, |S„, I > Ci  I n  = 0) i =
and then proceeding as for the case of equally sized groups
The Fleming et al. test also allows for the maximum number of analyses, AT, 
to be altered during the course of a trial. This is a major advantage if, for 
example, originally a maximum of K  analyses are planned at fixed points in time 
(e.g. every six months) but patient response turns out to be slower than 
anticipated. It should be noted however that, as with the Haybittle/Peto test, K 
can only be changed for reasons unrelated to the inferred treatment difference at 
interim analyses.
4.5 Optimal Two-Sided Group Sequential Tests.
The definition of an optimal two-sided group sequential test is similar to that 
for a one-sided group sequential test given in §3.5. For the problem outlined in 
§4.3 with a maximum of K  groups of n observations and some given objective 
function, F, the optimal test minimizes F subject to the error constraints (4.2.1)-
(4.2.3).




Fs = jE (N \ f i )S - 1p(M/S)dfi.
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There is a substantial body of literature concerning the computation of 
optimal two-sided tests. For instance Pocock (1982) considered the minimization 
of F2: E{N\h=8 ). For fixed K  and a  he searched over sets of nominal 
significance levels for the required minimum. At each stage of the search the 
group size, n, was constrained to give a test with Type II error p  at // = ± 8 . 
Pocock demonstrated that his constant nominal significance level test is near 
optimal when p  is small (i.e. when the power of detecting the treatment difference 
l i - 8  is large). He also showed that when p  is large (>0.5, for example) the 
O’Brien & Fleming (1979) test is near optimal.
Of course Pocock’s observations only apply to objective function F2. For 
other objective functions Pocock’s test is sub-optimal when p  is small.
Elashoff & Reedy (1984) considered two-group sequential tests with both 
equal and unequal group sizes. They were particularly interested in the effect of 
varying the first nominal significance level, aq. For the tests of Pocock (1977) 
and O’Brien & Fleming (1979), oq equals 0.0294 and 0.005 respectively when 
K = 2. Elashoff & Reedy considered the performance of these two tests in terms 
of E(N\/ i  )/Nf for both p  = 0 A  and p  =  0.5. In both cases the O’Brien & Fleming 
test is superior when \fi\ is either particularly small or particularly large. For 
intermediate values of | /z| the Pocock test is superior. Elashoff & Reedy 
suggested setting aq = 0.015 for a test which performs fairly well for all //.
Wang & Tsiatis (1987) considered minimizing F2 over a family of stopping 
rules indexed by a single parameter A. The critical values of these stopping rules 
are given by: ct -  iA z {i = where z is constrained to give a test of size
a . Two special cases of the Wang & Tsiatis family of tests are the Pocock test 
(A = 0.5) and the O’Brien & Fleming test (A = 0). For fixed K  and a, Wang & 
Tsiatis searched over A for the "minimum" of F2. At each stage of the search the 
group size was fixed to give a test with Type II error p  at = ± 8 . By comparing 
their results with those of Pocock (1982), Wang & Tsiatis demonstrated that their 
tests are very close to being optimal. In agreement with Pocock’s results they 
showed that the constant nominal significance level test is indeed near optimal for 
P<0.1,  while the O’Brien & Fleming test is near optimal for p > 0 A .  For 
intermediate values of p  the Wang & Tsiatis boundaries with A somewhere 
between 0 and 0.5 are approximately optimal.
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Although Wang & Tsiatis only considered the single objective function, F2, 
their approach could be easily extended to compute near optimal tests for other 
objective functions.
Clearly the problem outlined in §4.3 is more complicated than either of those 
considered by Pocock (1982) or Wang & Tsiatis (1987). Given n and K  our 
problem is one of determining a set of critical values {cx, c2 , c K) which 
minimizes an objective function, F, subject to the error constraints (4.2.1)-(4.2.3). 
An obvious way of proceeding is to use a method similar to that of Jennison 
(1987) for one-sided tests. As the constraints (4.2.2) and (4.2.3) are effectively 
the same our problem has K— 2 degrees of freedom and so we could search over 
c1, c2 , c K _ 2 for the minimum of F  while, at each stage of the search, 
constraining cK_i and cK to give a feasible test. The pair cK_x and cK are 
obtained by using the method of Powell (1970) for solving two non-linear 
simultaneous equations in two unknowns. (Powell’s algorithm is available as a 
subroutine of the NAG library.) When no such pair exists the objective function 
would be assigned a high positive value to move the search away from infeasible 
regions.
With only two analyses (K= 2) our problem is simply to obtain the unique 
pair {Cj ,c2} giving rise to a feasible test. When K=3 we are faced with a one­
dimensional minimization problem and we use the Golden Section Search 
algorithm. When K  is greater than 3 we have a multi-dimensional minimization 
problem and we use the simplex algorithm of Nelder & Mead (1965).
It is not difficult to see that the above approach suffers from the same 
inadequacies as Jennison’s method. Slow convergence, no guarantee of 
convergence to the global minimum and unreliability in more than about 7 
dimensions force us to consider an alternative approach.
In §4.6 we propose an improved method for the computation of optimal 
two-sided group sequential tests. Our improved method has the important 
advantages of being computationally efficient and numerically stable.
The approach is a generalization of the method for computing optimal one­
sided group sequential tests described in §3.6. Initially we consider a family of 
problems in Bayesian decision theory with a common prior distribution and cost 
of sampling function. The forms of the prior and cost function are determined by 
the objective function we are interested in minimizing. Individual problems within
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the family differ in terms of their loss functions. These loss functions are indexed 
by a pair of loss parameters, d0 and dx. We show that by searching over d0 and 
di we obtain a loss function which gives rise to a Bayes decision problem with a 
Bayes decision rule which has Type I error a  and Type II error /? at fi = ±S, and 
which minimizes our chosen objective function over the set of all decision rules. 
This Bayes decision rule can equally be viewed as an optimal stopping rule for 
our original frequentist problem.
In §4.6 we describe our improved method for objective function 
F2: E(N\/i =5), while in §4.7 we indicate how to adapt our approach when 
minimizing other objective functions.
4.6 An Improved Method for the Computation of Optimal Two-Sided
Group Sequential Tests.
Consider again the clinical trials problem outlined in §4.3 with a maximum 
of K  equally sized groups of 2n patients. The random variable Xt 
(/ = 1, 2, . . . ,  Kn) denotes the difference in response between the ith pair of 
patients and is normally distributed with unknown mean // and known variance
<T2.
Here we wish to make a choice between the three decisions :
Dx~: / /< 0 , D0: ju = 0 and D2+: f i> 0 .
Decisions D{~ and Dx+ can be made at any one of the K  analyses, but we can 
only make decision D0 at the Fth analysis.
We shall consider a family of Bayes decision theory problems with a 
common prior distribution for ji given by 7t{-S) = ;r(0) = 7u(S) = 1/3 with 
/r(//) = 0 otherwise, and a common cost of sampling function given by 
c(-S )  = c(S) = 1 with c{(i) = 0 otherwise. Individual problems within the 
family differ in their loss functions, L(D,fi), which are indexed by a pair of 
parameters, d0 (> 0) and dx (> 0). The general form of L(D,[i) is given by
L{D0 , - S )  = U D f . S )  = dx 
L ( D r ,0) = /.(D j+ ,0) = d0  
= L(D0 ,S) = dt
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with L (D ,//) = 0 otherwise.
Suppose for the moment that d0 and dx are fixed. Consider a general 
decision rule for the above problem which we shall denote by tB. Because our 
family of Bayes decision problems is symmetric about //=  0 we shall only 
consider decision rules which are symmetric about zero. So ® is of the general 
form :
At analysis i (1 </ < ^ -1 ) ,
if Sin > ci stop entering patients on to the trial and make decision
Di+>
if Sin < -  ci stop entering patients on to the trial and make decision
o r .
if | Sin \ < Ci enter the next group of 2n patients on to the trial.
At analysis K,
if SKn > cK stop entering patients on to the trial and make decision
A +;
if SKn < - c K stop entering patients on to the trial and make decision
J>r;
if I $Kn I < ck st0P entering patients on to the trial and make decision
A)-
The risk associated with which we shall denote by is defined
as the sum of the total expected sampling cost of the trial plus the total expected 
loss through making a wrong decision. That is
r ( $ ,4 )^ i )  = c ( -S ) E ( N \ f i i= S )x ( - 5 )  + c{8 ) E{N\n=8 ) n(S)
+ dx Pr(D0u D 1+1//= -£ ) k ( - 8 )
+ d0 Pr(D1- uZ>1+|//=0) ;r(0)
+ dx Pr(D1_u D 0|//= ^ )^ (5 )
where Pr(D,- kjDj | //)  denotes the probability of making either decision Dt or 
decision Dj under a treatment difference fi.
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As F2 = E(N\fii=8 ) = E(N\/i=-S)  for symmetric decision rules, it follows
that
r { < B , d = y  {2F2 +di PrtDoUZVI//=-<?)
+ d0 Pr(D1_ u D 1+|//=0) + d1 P rtD ^ u D o l//=£)}.
The Bayes decision rule for our problem, minimizes this risk over
the set of all decision rules, S , i.e.
r(© (4 , ^ ) ,4 ,J i)  = min
*BeS
We can compute *B*(d0 ,di) by dynamic programming (the necessary computations 
are described in §4.8). Using numerical integration we can calculate the Type I 
and Type II errors of $*(^0,^ ) .  Suppose these errors are given by
Pr(D1_ u D 1+|//=0) = Qt
and
Pr(D0uZ)1+1//= -£ )  = P rC D ^ u D o l/^ )  = fi,
then clearly
rOB*(<Z0,d i) ,4 )^ i)  = y  {2F2 + 2 dx f i+  d0 a}.
It follows from the definition of the Bayes rule that there can be no other decision 
rule with errors and f i  which attains a lower value of F2.
Using the algorithm of Powell (1970), we search over (dQ,d{) for a pir of 
loss parameters { d ^  , d ^ )  giving rise to a Bayes decision theory problem with 
a Bayes rule, lB*(fi?0(a),J 1(^ )), which has errors a  and fi. Clearly
r C S ' ^ K d ^ J o ^ K d ^ )  = ' j  {2 F2 + 2 rfjW p  + 4 , (o) «)•
Again, from the definition of the Bayes rule, there can be no other decision 
rule for this problem with a smaller risk, i.e.
Moreover there can be no other decision rule with errors a  and fi which attains a 
lower value of F2. By equating decisions Dx~, D0 and D1+ with the acceptance 
of hypotheses Hx~, H0 and respectively we have computed the optimal two­
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sided group sequential test for our original frequentist problem.
4.7 Applying our Improved Method to Other Objective Functions.
Our improved method for the computation of optimal two-sided group 
sequential tests for F1 is easily adapted for use with other objective functions. 
Here we provide details of the necessary adaptations for objective functions 
f 3: E(N\fi=2S) and F5: J E(N\n) S ' 1 q>(n!5) dfi.
Consider the minimization of F3. A suitable family of Bayes decision theory 
problems has the common prior distribution for // given by 
7t {-28) -  t t{- 8 ) = x(0) = tt{8 ) = tt{28) = 1/5 with k{^l ) = 0 otherwise, and a 
common cost of sampling function given by c{-28)  = c(2 S ) = 1 with c(//) = 0 
otherwise. The general form of the loss function, L(D,/x), is identical to that 
given in §4.6, with, in particular, L{D,28) = L(D,-28)  = 0 for any decision, D.
For fixed loss parameters, d0 and dy, the risk of a given decision rule, (B, is 
denoted by r(®,^0»^i) and equals
c(-28) E(N\{i=-2S) tc{-28)  + c{28) E(N\n=28) x{28)
+ dl Pr(£>0 u / V | //=-<?)/r(-S)
+ d0 Pr(D1- u£>1+|//=0) ;r(0)
+ di Pr(D1_u D 0|//=^) jt{8 )
That is,
= y  {2F3 + dl Pr(D0u D 1+|/z=-<5)
-I- d0 Pr(D1_u D 1+|//=0) + di Pr(Z)1_u D 0|^=^)}.
The Bayes decision rule for this problem, ^ ( d o ,^ ) ,  minimizes this risk over the 
set of all decision rules, 5, i.e.
r { <B * { d Q , d i ) , d Q , d i )  =  m jn { r (® ,< /g » d i ) }
Suppose V^do 'd i)  ^as errors given by
Pr(D1“ u D 1+|//=0) = Ct
and
Pr(D0 u D !+ | /*=-£) = P rC D ^ u D o l//^ )  = 0,
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then clearly
r{!B*(dQ4\),do4\)  -  y  (2F3 + 2 d x 0  + d0 a ) ,
and, from the definition of the Bayes rule, there can be no other decision rule with 
errors a  and 0  which attains a lower value of F3.
By searching over (do>^i) we obtain a pair of loss parameters, dQ^  and 
giving a Bayes decision theory problem with an associated Bayes rule, 
which has errors a and p. Clearly,
<*,<*>)) = J  {2F3 + 2 d x p +  do a ) .
By the definition of the Bayes decision rule there can be no other decision rule for 
this problem with a smaller risk, i.e.
r(B*(do<“) .d iW)).d0(“) .rflW>) = min , d ^ a\ d ^ ) ) .
<BeS
Moreover there can be no other decision rule with errors a  and P which attains a 
lower value of F3. By equating decisions DQ and D1+ with the acceptance 
of the hypotheses Z^- , Hq and H - 0  we obtain the optimal two-sided group 
sequential test for our original frequentist problem.
For the minimization of F5: J E(N\n) 8 ~l <p(fil8 ) dfi we consider the family 
of Bayes decision theory problems with the common prior distribution:
tzr(/z) = "
1/4 if /z = -<S, 0 or 8
(1/4)S~l<p(n/8 ) otherwise
and the common cost of sampling function
fl if fi 4=-£,0 or +5 
c(F) -  |q  otherwise.
The general form of the loss function is identical to that given in §4.6, with, in 
particular, L(D,/z) = 0 for n =|=0, ± 8 .
For fixed d0 and the risk of a general decision rule, (B, is denoted by 
r($,do»^i)> and is equal to
J c(fi) E(N\fi) 7c(/i) d/i +di Pr(D0u D 1+|/z= -J) x ( - 8 )
+ d0 Pr(D1_u D 1+|//=0) 7i(0 ) + d\ Pr(D1" u D 0|^= 5) x ( 8 ).
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That is,
rO M o ,^ )  = (p(n/S)d}i +
di Pr(£)0u D 1+|/z= -^) + d0 Pr(Di“ u D i+1//=0) + Pr(D1“ u D 0|//= 5)|‘
= j { F 5 +dx Pr(D0 u  D j+ j/i=-S)+d0 Pr(D1~ u  \ //=0)+<i1Pr(D1_ u D 01 H=8 )}.
The rest of the logic is analogous to that for objective functions F2 and F3 
described earlier. In particular, we search over (dQ,di) for a pair of loss 
parameters dQ^  and d ^ \  giving rise to a Bayes decision theory problem with 
an associated Bayes rule, (B*(dQ^  , d ^ ^ ) ,  which has errors a  and p. By the 
definition of the Bayes rule there can be no other decision rule for this problem 
with a smaller risk, i.e.
r i ^ i d o ^ K d ^ h d o ^ K d ^ )  = min { r C M o ^ ) ,^ ) )} .
!B e S
Moreover there can be no other decision rule with errors a  and p  which attains a 
lower value of Fs. By equating decisions Dx~, D0 and Dr+ with the acceptance 
of the hypotheses H{~, H0 and Hx+ we obtain the optimal two-sided group 
sequential test for our original frequentist problem.
Clearly our improved method for computing optimal two-sided group 
sequential tests is easily extended to other objective functions.
4.8 The Dynamic Programming Algorithm.
As has already been mentioned, for any given Bayes decision theory problem 
the Bayes rule is computed using dynamic programming. In this section we 
describe the dynamic programming algorithm for a general problem. Throughout 
we shall assume that the Bayes rule is monotone. That is at stage i 
(/ = 1 ,2 ,. . . ,  K - 1) it is optimal to make decision Z>1+ if Sin > ct and decision D{~ 
if Sin<-Ci, while for - c t <Sin <ct it is optimal to sample the next group of n 
observations. Further, at stage K  it is optimal to make decision if ^Kn -  cKy 
decision D0 if - c K  < SKn < c K  and decision D{~ if SKn < - c K . Numerical checks
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siipport our assumption that is monotone.
Consider again the problem described in §4.6 with a maximum of K  groups 
of n observations available for choosing between the decisions
D{~:p<  0, D0:p  = 0 and Dl+:p>  0.
This time we have a general prior distribution, n(p),  defined over some parameter 
space M, and a general cost of sampling function, c(ji ), also defined over M. 
Finally we have a loss function, L(D,p),  which is of the same general form as 
that given in §4.6.
Suppose that the loss parameters d0 and dx are fixed. Letting p^l\ p \ x )  
denote the current posterior distribution of p  at analysis i (1 <i <K)> given that 
Sin = x, the loss from making decision D1+ equals
dl p il)(-S\x) + dop(l\ 0 \x)
and the loss from making decision D{~ equals
dop {l)(0\x) + d1 p ('l\S \x ) .
At analysis K  the loss from making decision D0 equals
di {p^K)( S \ x )  + p(K\S\x)} .
If We let y^l\ x )  denote the minimum loss from stopping at stage i 
( /=  1, 2 ,.. . ,  K) and making a definite decision, it follows that
y(K\ x )  = min[{d0 p iK)(0\x) + di p (K)(S\x)}, dx {p(K\ - S \ x )  + p {K)(S\x)},
{di p iK\ - 8 \x) + doPiK\ 0 \x)}]
while, for i < K - 1,
y (l\ x )  = m in[{dop {l\ 0 \x) + dx p {l)(S\x)} , [dx p {l)( - 8 \x) + d0 p^l){0 \x)}].
Further, let f r l\ x )  denote the minimum additional risk from sampling the 
(/+ l)st group (i = 1 ,2 ,..., K-X) and then proceeding optimally. Denoting the 
c.d.f. of given that Sin = x b y  F (,+1)(*S'(,+1)n|x), we have
p ^ - ' H x )  = n X c{p)p^K- l\ p \ x )  + J y^K\ S Kn) d F & \S Kn\x)
/ / e  M  S Kn
- 85 -
and, for i < K - 1,
P{l)(x) = n j  c(p)p^ l)(p\x)
f i e  M
+ J min{y3(i+1)(5(i+1)n) >r (i+1)(S(i+i)„)} ^ ' +1)(S(i+1)„|x)
S(i+l)n
where the summation signs in the above equations are replaced by a mixture of 
sums and integrals for objective functions such as F5.
We compute the critical values of by starting at the £th analysis
and working back.
At analysis K  it is optimal to make decision Z>1+ for all x  (> 0) such that 
dx p ^ H - S l x )  + dop<K\0 \x )  < dx {p(j:)(-5|jc) + p (A:)(<S|*)} (4.8.1)
and to make decision D0 for all x  (> 0) such that
di {p{K\ - S \ x )  + p iK)(S\x)} < di p {K){-S\x ) + do p {K)(0\x). (4.8.2)
Using the bisection method we obtain the £th critical value, cK, as the 
solution, for x > 0, of the equation
di {p {K\ - S \ x ) + = dx p (Ar)(-<S|;c) + do p<K)(0\x). (4.8.3)
Clearly it is possible that equation (4.8.3) does not possess a solution for x > 0. 
To avoid our algorithm getting in to computational difficulties we can build a 
simple check in to our program. The check tests whether inequality (4.8.2) holds 
for x = 0. If this is not the case we set cK -  0 and go back to the (AT-l)st 
analysis. Similar checks can be built in at other analyses.
The symmetry inherent in our problem makes it optimal to choose decision 
L>i~ if SKn < - cK, and decision D0 if - c K < SKn < 0.
At analysis K- 1 it is optimal to make decision D1+ for all =x (>0)
such that
di p ^ ~ ^ ( —8\x) +  J 0 P (^-1 ) (0 |jc) <  p^K~l\x )
and to decide to sample the Kih group of observations and then to proceed 
optimally for all x  (> 0) such that
p^K~l ^{x) < d i  p ( K~l ^( -8 \x )  + /?(^-1)(0|jt).
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Here J3^ K 1J(jc) is given by
n E c { p )p iK~l\ p \ x )
/ i €  M
+ dy Pr-« (SKn > cK I x ) p {K- l)( - 8 \x) + d0 Pr0 (SKn 2: cK | x )p (i:_1)(0|.x)
+ dy {Pr_*(ISjo.1 ^ c K \x)p^K- l\ - 8 \x) + P r,( |S & | ScjrljO p**-1^ * ) )
+ d0 Pr0 (SKn <. - c K | jc)P ^-«(0 |jc) + dy Pig (So, < - c K | x)p<~K- lHS\x).
Again we use the bisection method to obtain the (AT—l)st critical value, cK_x 
as the solution, for x  > 0, of equation (4.8.4)
dy p (K~})(-S\x)  + dop (Ar_1)(0|x) = (4.8.4)
The symmetry inherent in our problem makes it optimal to choose D{~ if 
S(K-i)n -  ~CK-1 to continue sampling if < S ^ - i ) n -0-
At analysis K - 2 it is optimal to make decision Dx+ for all S^K_2)n ~ x  (^0) 
such that
dy p {K~2)(,-S\x) + d0 p (K~2)(Q\x) < p {K~2)(x)
and to decide to enter the (AT— l)st group of patients on to the trial and then to 
proceed optimally for all x  (> 0) such that
J3(K~2\ x )  < dx p {K~2\ - 8 \x) + d0 p (K~2\0 \x ) .
Here p^K~2\ x )  is given by
n E c ( p ) p iK~2)(p\x)
M
+ dy Pr_4 (% _!)„ >cK_y I x ) p (K~2\ - 8 \x) + do Pr0 (S(x-i)» >Ck-i I x )p (Ar_2)(0|x) 
+ do Pr0 (S(Ar-i)n - - c a:-i I x ) p ^ - 2k0|*) + dy Prs (S^-y)n -  ~ck~i I x ) p IK~2\S \x )
Cx-l
+  j  ^ X - ' H S y K - y y J d F V - ' H S y K . y ^ X )
-Ck- i
Again the bisection method gives the (K-2)n& critical value, cK_2, as the 
solution, for x > 0, of equation (4.8.5)
dy p {K~2K - 8 \x) + d0 p iK~2\ 0|jc) = p iK- 2\ x ) .  (4.8.5)
The symmetrical nature of our problem makes it optimal to choose D{~ if
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Sn(K- 2) -  ~ck - 2 ^  t0 continue sampling if - c K _ 2 < Sn(K- 2) -0*
We work back to the first analysis in a similar fashion. The error 
probabilities of the resulting decision rule are then computed and a test for 
convergence conducted. If convergence has not been achieved the error 
probabilities are fed into Powell’s method and a new pair (dQ , dx) obtained.
4.9 Results and Discussion.
Tables 4.2-4.7 give the minima of F2: E(N\n=S), F3: E(N\n=2$) and 
F5: J E(N \n) 6 ~1(p(fi/S) d/i expressed as percentages of the fixed sample size, Np 
for a= 0 .05 , /? = 0.05 and 0.1, K  = 2, 3, 4, 5 and 10 and t, the ratio of the 
maximum sample size of the sequential test to Np equal to 1.01, 1.05, 1.1, 1.15,
1.2, 1.3, 1.4, 1.5 and 1.6. The minima are independent of a 2 and 8  (for 
verification of this fact see Appendix 5.2).
In each table the entry for K -  10 and t -  1.6 is missing. So, although it is 
possible to compute feasible tests for each of these problems, there does not exist 
a Bayes decision theory problem giving rise to a Bayes rule with the required 
errors. The reason for this is almost certainly linked to the fact that decision D0 
is only open to the experimenter at the K\h analysis. For the inner wedge 
problems considered in §5, where any of the decisions D{~, D0 and Dx+ can be 
made at each analysis, optimal feasible tests were always obtained.
Tables 4.2 and 4.3 refer to the minimization of F2: E(N\fi=8 ) for a  =0.05 
and p  = 0.05 and 0.1 respectively.
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Table 4.2. Minima of F2 : E ( N \ n = 8 )  expressed as percentages of the fixed sample
size, Nf , for a=0.05, £=0.05, t = 1.01, 1.05, 1.1, 1.15, 1.2, 1.3, 1.4, 1.5 and 1.6,
and K  -  2, 3, 4, 5 and 10.
K 1.01 1.05 1.1 1.15
t
1.2 1.3 1.4 1.5 1.6
2 78.6 72.6 71.8 72.4 73.6 76.8 80.4 84.3 88.3
3 74.0 67.2 65.2 64.8 65.0 66.3 68.1 70.1 72.3
4 71.6 64.8 62.6 61.9 61.8 62.5 63.7 65.1 66.6
5 70.1 63.3 61.0 60.3 60.1 60.6 61.6 62.7 63.8
10 67.1 60.3 57.9 57.1 56.8 57.0 57.6 58.4
In considering Table 4.2 we begin by looking at group sequential tests with 
K  = 2. Each of these tests leads to large savings in F2 compared with the fixed 
sample size test. The largest saving occurs with t= 1.1 and equals 28.2% of the 
fixed sample size. Even if logistical considerations limit us to a test with K = 2 
and / = 1.01 the expected saving is 21.4% of the fixed sample size.
For fixed t gains in efficiency increase with K, however the rate of gain in 
efficiency decreases with K. For example with f = 1.2 the expected gain in 
efficiency in doubling the maximum number of groups from 5 to 10 is only 3.3% 
of the fixed sample size.
For fixed K, the minimum of F2 over tabulated values of t is shown in bold 
type. We see that even with AT = 10 there would appear to be no point in 
designing experiments with t much greater than 1.2. Note that, as with the one­
sided optimal tests of §3.9, the minima of F2 are a U-shaped function of t for K  
fixed.
Many of the comments made concerning Table 4.2 apply equally to Table
4.3. Again the largest gains in efficiency occur when going from a fixed sample 
size test to a group sequential test with a maximum of 2 groups. For instance 
with t = 1.1 and K = 2 the expected saving over the fixed sample size test is
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22.4% of Nf. Even with f = 1.01 and K = 2 this expected saving is 16.1% of Np 
Most of the gains in efficiency occur with K  < 5. As can be seen doubling K  from 
5 to 10 results in only moderate gains in efficiency.
As with Table 4.2 the minimum of F2 over tabulated values of t for K fixed 
is shown in bold type. Here, there would appear to be no point in considering 
tests with t> 1.15.
Table 4.3. Minima of F2 : E{N\fi=8 ) expressed as percentages of the fixed sample 
size, Np  for a=0.05, >5=0.1, t = 1.01, 1.05, 1.1, 1.15, 1.2, 1.3, 1.4, 1.5 and 1.6, 
and K  = 2, 3, 4, 5 and 10.
K 1.01 1.05 1.1 1.15
t
1.2 1.3 1.4 1.5 1.6
2 83.9 78.4 77.6 78.2 79.4 82.6 86.2 90.0 94.0
3 79.9 73.9 72.3 72.1 72.5 74.2 76.3 78.6 80.9
4 77.7 71.7 70.0 69.6 69.8 71.0 72.7 74.4 76.2
5 76.3 70.4 68.6 68.1 68.3 69.3 70.8 72.3 73.9
10 73.6 67.6 65.7 65.1 65.2 65.9 67.1 68.4
Tables 4.4 and 4.5 give the minima of F3: E(N\ju=2S) for cr = 0.05 and 
>5 = 0.05 and 0.1 respectively. Obviously it is when treatment differences are 
large that the ethical argument for stopping a trial early is strongest. Both tables 
illustrate the advantage of an optimal group sequential test when treatment 
differences are large.
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Table 4.4. Minima of F3 : E(N\ f i=2S)  expressed as percentages of the fixed
sample size, Nf , for cr=0.05, £=0.05, t = 1.01, 1.05, 1.1, 1.15, 1.2, 1.3, 1.4, 1.5
and 1.6, and K  = 2, 3, 4, 5 and 10.
K 1.01 1.05 1.1 1.15
t
1.2 1.3 1.4 1.5 1.6
2 50.9 52.6 55.0 57.5 60.0 65.0 70.0 75.0 80.0
3 36.8 36.2 37.3 38.7 40.3 43.5 46.7 50.0 53.4
4 32.0 29.4 29.5 30.2 31.1 33.2 35.4 37.8 40.2
5 30.0 26.3 25.6 25.8 26.2 27.5 29.1 30.8 32.6
10 26.7 22.1 20.5 19.7 19.4 19.2 19.4 19.8
As can be seen gains in efficiency are extremely impressive. For example 
with K = 2 it is almost certain that the trial will stop at the first analysis under 
li = ±28. While with AT= 10 the expected sample size is only about 20% of the 
fixed sample size for each value of p  and K.
In both tables the largest gains in efficiency occur when going from a fixed 
sample size test to a group sequential test with K =2 There is a stronger case for 
considering tests with a "large" maximum number of groups here than was the 
case with optimal tests for objective function F2. For fixed t there are quite 
substantial gains to be made in going from a 5 to a 10 group design. This is 
because, under fi = ± 2 S, there is a high probability that the test will stop at the 
first analysis and, for fixed t, the first analysis occurs after twice as many 
observations when K = 5 compared with when K = 10.
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Table 4.5. Minima of F3 : E(N\fii=2S) expressed as percentages of the fixed
sample size, Nf, for a=0.05, 0 =0 . 1 ,  t = 1.01, 1.05, 1.1, 1.15, 1.2, 1.3, 1.4, 1.5
and 1.6, and number of groups, K -  2, 3, 4, 5 and 10.
K 1.01 1.05 1.1 1.15
t
1.2 1.3 1.4 1.5 1.6
2 52.0 53.0 55.2 57.6 60.1 65.0 70.0 75.0 80.0
3 40.3 38.0 38.5 39.6 41.0 43.9 47.0 50.2 53.5
4 36.7 32.5 31.8 32.1 32.7 34.4 36.3 38.5 40.7
5 35.0 30.0 28.7 28.4 28.6 29.4 30.7 32.1 33.7
10 31.7 26.5 24.5 23.5 23.0 22.6 22.6 22.8
Tables 4.6 and 4.7 refer to the minimization of objective function 
Fs : J E(N\ (p(fil8 ) dfi for a -  0.05 and 0  = 0.05 and 0.1 respectively.
Table 4.6. Minima of F5: j  E(N\fi)S~1q>(fi/S) dfi expressed as percentages of the 
fixed sample size, Nf,  for a=0.05, /?=0.05, t = 1.01, 1.05, 1.1, 1.15, 1.2, 1.3, 1.4, 
1.5 and 1.6, and K  = 2, 3, 4, 5 and 10.
K 1.01 1.05 1.1 1.15
t
1.2 1.3 1.4 1.5 1.6
2 84.5 83.6 85.3 84.5 90.5 96.4 102.6 108.8 115.1
3 81.1 79.2 80.1 81.9 84.1 89.0 94.1 99.4 104.7
4 79.6 77.4 78.0 79.6 81.6 86.0 90.7 95.6 100.4
5 78.7 76.4 77.0 78.4 80.3 84.5 89.0 93.7 98.3
10 76.9 74.6 76.9 76.4 78.1 82.0 86.3 90.6
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Gains in efficiency here are less impressive than was the case with objective 
functions F2 and F3. Indeed for certain tests in each table the expected sample 
size exceeds the fixed sample size for this problem. The reason for this is linked 
with the prior distribution for p, which places a large proportion of its total 
density at or around p  = 0, where the probability of stopping early is small.
The most impressive gains in efficiency occur when t is small. For example 
with K = 2, /? = 0.05 and r = 1.05 the expected saving over the fixed sample size 
test is 16.4% of Nj. With K -  5, fi = 0.05 and 1 = 1.05 this saving has increased 
to 23.6% of Nf. Expected gains in efficiency from doubling K  from 5 to 10 are 
small here. For instance with /? = 0.1 and 1= 1.05 the expected gain in efficiency 
in going from a design with K = 5 to one with /T = 10 is just 1.7% of the fixed 
sample size.
In practice there would appear to be little point in employing an optimal test 
for F5 with t > 1.05 or K  > 5.
Table 4.7. Minima of F5: J E (N \p ) 8 ~l <p(p/S) dp expressed as percentages of the 
fixed sample size, for a=0.05, /?=0.1, t = 1.01, 1.05, 1.1, 1.15, 1.2, 1.3, 1.4, 
1.5 and 1.6, and number of groups, K = 2, 3, 4, 5 and 10.
K 1.01 1.05 1.1 1.15
t
1.2 1.3 1.4 1.5 1.6
2 86.9 86.1 87.8 90.3 93.1 99.2 105.4 111.8 118.2
3 84.0 82.3 83.4 85.3 87.6 92.6 98.0 103.5 108.9
4 82.7 80.8 81.6 83.4 85.4 90.1 95.1 100.2 105.3
5 81.9 79.9 80.7 82.3 84.3 88.8 93.6 98.5 103.4
10 80.2 78.2 79.0 80.5 82.4 86.6 91.2 95.8
We have not considered the minimization of F1 = E(N\p=0) so far in this 
chapter. Under p  = 0 the probability of stopping early is at most a  (from equation
(4.2.1)). Hence a lower bound on Fj is na + n K ( l -a ) t which, even for fairly
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small maximum sample sizes, will exceed the fixed sample size. For example 
with a  = 0.05, 0  = 0.1, t= 1.01 and K -  2, 3, 4, 5 and 10 the minima of Fx 
expressed as percentages of the relevant fixed sample size are given in Table 4.8. 
The results are independent of 8  and a 2.
Table 4.8. Minima of Fl expressed as percentages of the fixed sample size, Np for 
tests with a=  0.05, 0  = 0.1, t= 1.01 and K = 2, 3, 4, 5 and 10. Results given are 
independent of 8  and a 2.
K 2 3 4 5 10
100 Ft/Nf 100.67 100.61 100.57 100.55 100.48
For each of the 5 tests considered in Table 4.8 the expected sample size 
under // = 0 is greater than the fixed sample size. Indeed, at best, E(N\fi=0) is 
only 0.5% of Nf less than the maximum sample size. If minimizing the expected 
number of patients entering a trial under /z = 0 is important we would recommend 
the use of one of the inner wedge tests described in §5.
The results for designs with more than 10 groups, for other objective 
functions and for other values of a  and 0  are not given here. It suffices to say 
that our method for the computation of optimal two-sided group sequential tests is 
easily extended to deal with such problems.
4.10 Examples.
In this section we give three examples of optimal two-sided group sequential 
tests. All of the examples are based on the same hypothesis testing problem 
which we now describe.
Suppose X l , X2,..., XKn are independent normal random variables with 
unknown mean n and unit variance, and that we wish to test
Hx~: /z< 0 vs H0: /z = 0 vs H ^ :  /z>0
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with error rates
P r U r  u  V | / /  = 0) = 0.05 (4.10.1)
Pr (j?o u  ^ +|// = -0 .5 ) = 0.1 (4.10.2)
and
P r ( * r  u  = 0.5) = 0.1. (4.10.3)
The fixed sample size test for this problem would require 42.03 patients on 
each treatment arm. In practice, of course, we would assign 42 patients to each 
treatment with the result that the power of detecting the treatment differences 
fi =±0.5  would be slightly less than 0.9.
For our first example we consider the group sequential test with a maximum
of 5 groups of 20 patients which minimizes F2 subject to the error constraints
(4.10.1)-(4.10.3). The standardized critical values for this test, c{  (=ci!'(]n), are 
given by: c1' = 2.537, c2' = 2.350, c3' = 2.369, c4' = 2.426 and c5' = 2.381. The 
corresponding nominal significance levels are: a?} =0.011, a2 = 0.019,
a3 =0.018, a4 = 0.015 and a5 = 0.017. As can be seen the a^s  are not 
monotonically increasing as one might expect. This point was also taken up by 
Pocock (1982) who noted the ‘curious’ tendency for a4 to be smaller than a3 
and/or a2 in optimal 5 group designs. We note however that there is no 
theoretical reason for expecting increasing nominal levels.
For our first example we have 2s(A/|//= 0.5) = 28.7 (remember this 
represents the expected number of patients on each treatment) which is 68.2% of 
the corresponding fixed sample size. Clearly this is a substantial saving in terms 
of both financial and human resources. The maximum of the expected sample 
size function (at // = 0) is very close to 50. Indeed \fi\ must exceed 0.2 before we 
can expect our optimal test to require fewer than the 42 patients needed by the 
fixed sample size test. (If minimizing expected sample size for \n\ small is a 
priority we would strongly recommend the use of one of the inner wedge designs 
of §5).
As a second example of an optimal group sequential test we consider the 
minimization of F3 : E(N\{i=2S) for the same problem as in our first example. 
The standardized critical values for this test are: c1/ = 2.203, c2 =2.626, 
c3' = 2.949, c4' = 3.095 and c5 '  = 2.309. The corresponding nominal significance
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levels are given by: 0^=0.028, a2 = 0.009, a3 = 0.003, a4 = 0.002 and 
a5 = 0.021. It is interesting to note that more than half of the total Type I error is 
spent at the first analysis while almost all the remaining Type I error is spent at 
the final analysis. This is in marked contrast to the first example.
Differences between E(N\ju) here compared with our first example are small, 
although the optimal test for F2 is better for |/z| close to 0. Under // = ± 1 the 
second test is optimal, of course, with E(N\pi=l) = 12.0 or 28.5% of the 
corresponding fixed sample size.
For our third example we consider the group sequential test which minimizes 
F5 for the same problem as in our earlier two examples. The standardized critical 
values for this test are given by: q ' = 2.463, c2 =2.386, c3 =2.403, c4 = 2.440 
and c5' = 2.374. The corresponding nominal significance levels are: cq =0.014, 
a2 = 0.017, a3 = 0.016, a4 = 0.015 and a5 = 0.018.
The operating characteristic function and Pr(^1+|//)  are almost identical for 
all three examples. This demonstrates that the frequentist, while only specifying 
errors at three points of the parameter space, effectively defines error functions 
over the entire parameter space.
4.11 A Comparison of Two-Sided Group Sequential Tests.
In this section we compare a selection of our optimal two-sided group 
sequential tests with 5 of the tests proposed in the literature and described in 
§§4.4 and 4.5. Comparisons are made in terms of the expected sample size 
under ju = S and the maximum sample size for each test.
For designs with K  = 2, 3, 4, 5 and 10, ar=0.05 and y? = 0.05, Table 4.9 
gives F2: E(N\ji=S) and the maximum sample size, nK, both expressed as 
percentages of the relevant fixed sample size, Nf, for the tests of O’Brien and 
Fleming (OBF); Wang & Tsiatis (WT) with A = 0.25; Pocock; Fleming, 
Harrington & O’Brien (FHOB) with 7 = 0.25; Haybittle/Peto and the optimal test 
(F2*), which minimizes E(N\fi=S) over both feasible stopping rules and group 
sizes. The results of Table 4.9 are independent of both 8 and <r2.
In terms of minimizing F2, F2* is, of course, optimal for each value of K. 
However Pocock’s test is very close to optimal, never being more than 0.8% of
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the fixed sample size above the overall minimum. The other 4 tests, in decreasing 
order of efficiency, are: WT, FHOB, OBF and Haybittle/Peto. Even the 
Haybittle/Peto tests, however, with their extremely simple stopping rule, show 
reasonable gains in efficiency over the fixed sample size test.
Table 4.9. E(N\fi =5) expressed as a percentage of the fixed sample size, Np and, 
in parentheses, t, the maximum sample size expressed as a proportion of Nf for the 
optimal test, F2*, OBF, WT (A =0.25), Pocock, FHOB (7 = 0.25) and the 
Haybittle/Peto test with a  = 0.05, /? = 0.05 and K  = 2, 3, 4, 5 and 10.
K
F2* OBF WT 
A = 0.25
Pocock FHOB 
y  = 0.25
Haybittle / 
Peto
2 71.8 80.2 74.0 71.8 75.1 83.9
(1.10) (1.01) (1.03) (1.09) (1.02) (1.00)
3 64.8 74.8 68.2 64.9 71.3 77.8
(1.15) (1.01) (1.04) (1.14) (1.02) (1.01)
4 61.8 71.3 65.5 61.9 69.8 74.4
(1.18) (1.02) (1.05) (1.17) (1.02) (1.01)
5 60.1 69.4 63.8 60.2 68.9 72.2
(1.20) (1.02) (1.06) (1.19) (1.02) (1.01)
10 56.7 65.7 60.1 57.5 67.4 67.1
(1.22) (1.03) (1.07) (1.25) (1.02) (1.03)
In terms of having a low maximum sample size the Haybittle/Peto tests can 
be seen to be the best. Even with 10 analyses it only requires at most 3% more 
observations than the single sample test. The OBF test is almost as good with 
f < 1.03 for K < 10. The optimal test and the Pocock test require the largest
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maximum sample sizes. However it should be noted that optimal tests could be 
designed with the same values of t as Haybittle/Peto and with substantial savings 
in E(N\ii =8).
Table 4.10 is identical to Table 4.9 except that 0  = 0.1. Most of the 
comments made concerning Table 4.9 are equally applicable here. It is interesting 
to note that the optimality of the Pocock test has declined slightly at K = 5 and 10 
with the increase in the Type II error. Conversely the OBF, Wang & Tsiatis, 
FHOB and Haybittle tests are closer to being optimal.
Table 4.10. E(N\fi = 8) expressed as a percentage of the fixed sample size, Np 
and, in parentheses, t the maximum sample size expressed as a proportion of Np 
for the optimal test, F2*, OBF, WT (A = 0.25), Pocock, FHOB (7 = 0.25) and the 
Haybittle/Peto test with a  = 0.05, 0  = 0.1 and K = 2, 3, 4, 5 and 10.
K
Fi* OBF WT 
A = 0.25
Pocock FHOB 
y  = 0.25
Haybittle /  
Peto
2 77.6 85.0 78.9 77.6 80.5 88.2
(1.10) (1.01) (1.03) (1.10) (1.03) (1.00)
3 72.1 79.5 74.1 72.1 77.5 83.4
(1.14) (1.01) (1.04) (1.15) (1.02) (1.01)
4 69.6 76.4 71.6 69.7 76.3 80.6
(1.15) (1.02) (1.06) (1.18) (1.02) (1.01)
5 68.1 74.7 70.1 68.5 75.6 78.8
(1.16) (1.02) (1.06) (1.21) (1.02) (1.01)
10 65.1 71.3 66.8 66.6 74.4 74.5
(1.17) (1.03) (1.08) (1.27) (1.02) (1.03)
4.12 The Repeated Confidence Interval Approach.
In this section we describe how the optimal group sequential tests of §§ 3 
and 4 may be combined with the repeated confidence interval method of Jennison 
& Turnbull (1984), (1989) to give a flexible and optimal procedure for use in 
clinical trials.
Throughout §§3 and 4 it has been assumed that a study will only be stopped 
when a pre-defined stopping boundary is crossed. Of course in practice the 
decision to stop a trial is far more complex than this as it will often depend on 
such issues as the side-effects of the treatments and the quality of life for patients 
on the experiment. To quote Jennison & Turnbull (1984) ’...As a result there is 
no guarantee that a particular stopping rule will be adhered to, nor is this 
desirable’.
Unfortunately frequentist properties, such as the probability of making a 
correct decision, depend on a strict adherence to a pre-defined stopping rule. As 
an alternative, more flexible, frequentist analysis of interim results Jennison & 
Turnbull (1984), (1989) have suggested constructing repeated confidence intervals 
(RCIs) for the parameter of interest. A suitable choice of these RCIs ensures that 
the probability that they all contain the true parameter value is acceptably high. 
At any analysis a decision to stop the study can be made on the basis of the 
current interval. However, if the study is stopped for any other reason, such as 
those cited earlier, the RCIs remain valid.
As an example of the RCI approach consider the clinical trial outlined in 
§4.3 with two treatments, A and B, and a maximum of K  groups of 2n patients 
available for entry on to the study. Again let Xi denote the difference in response 
between the ith patients on treatments A and B respectively. We assume that 
Xj ~ 72) where a 1 is known.
Suppose that the critical values cq, c2, ..., cK define a feasible stopping rule 
for the hypothesis testing problem of §4.3, and that c1 \ c 2' , c K' are the 
corresponding standardized critical values (i.e. c /  =ci/ylin(j2, i = 1, 2 ,.. . ,  K). For 
i = 1, 2 ,. . . ,  K, let X(i)  denote the mean of the first i groups of observations (i.e. 
X(i) = Sin/iri), and, to ease notation, let
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and
Mi = X ( i ) +  -7= - c / ,  
yin
it follows that
Pr(^,- < //< /! ,-  for all 1 < i< K )  = (1 -a ) .  (4.12.1)
We term i = 1, 2 ,.. . ,  K } (1 - a )  RCIs for the parameter p. As has
already been mentioned these RCIs are valid no matter how a decision to stop a 
study is made. We can, however, recover our original group sequential hypothesis 
test from the RCIs. This is achieved by adopting the following stopping rule
At analysis i (1 <i< K - 1),
if yj > 0 stop entering patients on to the trial and accept H ^ ;  
if //,- < 0 stop entering patients on to the trial and accept Hi~; 
if Mi < 0 < Mi enter the next group of 2n patients on to the trial.
At analysis K,
if Mk  > 0 st0P entering patients on to the trial and accept HY+\ 
if /fx: < 0 stop entering patients on to the trial and accept H ^ ;  
if Mk < 0 < Mk st0P entering patients on to the trial and accept H0.
Jennison & Turnbull (1984), (1989) based their RCIs on the critical values 
for the tests of Pocock (1977) and O’Brien & Fleming (1979). Clearly by basing 
RCIs on the critical values of one of our optimal group sequential tests we obtain 
a procedure which is both flexible and highly efficient We do not consider any 
results here, as the expected sample sizes of these RCIs are identical to the 
expected sample sizes of our optimal tests
The RCI approach can also be used when testing an experimental treatment 
against a standard as was the case in §3. We shall describe the method for the 
symmetric problem considered in §3.5. The generalization of this symmetric 
problem to the asymmetric problem, considered by Freedman & Spiegelhalter
(1983) and Freedman, Lowe & Macaskill (1984), is quite straightforward.
Consider the hypothesis testing problem described in §3.4 with a maximum 
of K  groups of n pairs of patients for testing Hx~: n = - 8  vs : n  = 8 (S > 0).
-  1 0 0  -
Suppose that the set of standardized critical values c \ , c '2, c'K defines a
feasible stopping rule for this problem. Using the same notation as before, it
follows that
Pr(^- < }i< Hi for all 1 < i < K)  = (1-2a).
The intervals {& ,//,); i = 1 , 2 , }  are then 1-2a  RCIs for the parameter //. 
We can recover our one-sided test by adopting the following stopping rule:-
At analysis i (1 <i< K— 1),
if & >  - 8  stop entering patients on to the trial and accept / / 1+; 
if jli < 8 stop entering patients on to the trial and accept 
if & < - 8  and Hi > 8 enter next group of n pairs of patients on 
to the trial.
At analysis K,
if yjc > - S  stop entering patients on to the trial and accept 
if jiK < S stop entering patients on to the trial and accept H±~.
Choosing the width of the Kth RCI less than 25 ensures that the trial is
terminated at the £th analysis. This is equivalent to choosing
2 'C7Z CK
n > —  ----- .
5 K
Again, by basing these RCIs on a stopping rule for one of the optimal tests 
of §3 we obtain a procedure which is both flexible and highly efficient. Results 
for the expected sample sizes of these RCIs are not included here for the same 
reasons as cited earlier.
4.13 Discussion and Conclusions.
In §4 we have considered an improved method for the computation of 
optimal two-sided group sequential tests on the mean of a normal distribution with 
known variance. Our improved method is a generalization of that used for 
computing optimal one-sided tests (described in §3). The improved method is 
both computationally efficient and numerically stable.
-  1 0 1  -
The resulting tests are highly efficient and a substantial improvement on the 
fixed sample size test. They are also improvements (in some cases substantial 
improvements) on the two-sided group sequential tests proposed in the literature.
By basing the repeated confidence interval approach of Jennison & Turnbull
(1984), (1989) on the stopping rule of one of our optimal two-sided tests, we 
obtain a procedure which is both flexible and optimal.
We have not extended our method to problems with unequal group sizes. 
Such an extension would be quite simple however. Likewise we could easily 
consider the minimization of objective functions over group sizes.
-  1 0 2  -
5. Optimal Inner Wedge Tests. 
5.1 Introduction.
In §4 we considered two-sided sequential tests which allowed for the early 
rejection of the null hypothesis. Acceptance of H0 was only permitted at the final 
analysis. Gould & Pecore (1982), Gould (1983), Whitehead & Stratton (1983) and 
Emerson & Fleming (1989) have all proposed two-sided tests which permit the 
early acceptance of H0. We shall term such tests inner wedge tests or, simply, 
wedge tests.
As an example of where a wedge test might be appropriate, consider testing 
two experimental treatments, A and B, say. If A and B are therapeutically 
equivalent we would obviously like to stop our clinical trial as soon as possible in 
order to save money and to release valuable resources for use on other studies. 
Wedge tests are particularly appropriate for clinical trials designed to test for the 
bioequivalence of two drugs. We shall consider using optimal wedge tests on 
bioequivalence studies later on in this Chapter.
We shall give a formal description of a wedge test in §5.2 and review the 
literature on this topic in §5.3. In §5.4 we introduce optimal wedge tests. By 
generalizing our method for computing optimal two-sided tests (described in 
§§4.6, 4.7 and 4.8) we obtain an efficient and stable method for computing 
optimal wedge tests. In §§5.5, 5.6 and 5.7 we describe our method before 
giving some results in §§5.8 and 5.9. A comparison of our optimal wedge tests 
with some of the optimal two-sided tests of §4 and other wedge tests proposed in 
the literature is given in §5.10. In §5.11 we consider the use of optimal wedge 
tests in the bioequivalence problem.
5.2 Inner Wedge Tests.
Consider a clinical trial with a maximum of K groups of n pairs of patients 
available for testing the relative efficacies of two experimental treatments, A and 
B, say. Let X,- be the random variable representing the difference in response 
between the ith patient on treatment A and the ith patient on treatment B.
- 103 -
Suppose the X,’s are independent and normally distributed with unknown mean // 
and known variance <72, and we wish to test
Hx~ : / /< 0  vs H0: fi = 0 vs / / 1+: // > 0
with error rates
Pr ( A f  v  A1+ \fi = 0) = a  (5.2.1)
Pr (^o U V 1 H = ~8)  = p  (5.2.2)
P r(^ j-  u  S^\ii = S) = 0. (5.2.3)
Here, as in §4, and denote the acceptance of H{~, H0 and
respectively.
Also as in §4, the fixed sample size test for this problem requires Nj patients
on each treatment arm, where Nj is given by equation (5.2.4)
Iff = 4-{<D_1( 1-/?) + <t>~l ( l - a / 2 ) } 2. (5.2.4)
J s 2
For the group sequential wedge test we shall consider stopping rules of the 
general form:-
At analysis i (1 < / < X -l) ,
if Sin > Ci stop entering patients on to the trial and accept / / 1+; 
if Sin < -  c,- stop entering patients on to the trial and accept HY~\ 
if |Sin| < lt stop entering patients on to the trial and accept H0;
if /,- < | Sin | < ct enter the next group of n pairs of patients on to
the trial.
At analysis K,
if SKn > cK stop entering patients on to the trial and accept Hl+\ 
if SKn < -  cK stop entering patients on to the trial and accept Hx~\ 
if | SKn | < cK stop entering patients on to the trial and accept H0 .
Here we require /f < Ci (1 < i < K - 1).
We term a set of critical values { ( / i ,^ ) , . . .  AIk- i *ck- i ) ' ck } feasible if it 
defines a test satisfying the error constraints (5.2.1) - (5.2.3). Any test with a
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feasible stopping rule is termed a feasible test. Clearly, for a given, sensibly 
formulated, problem there will exist infinitely many feasible tests.
As with the sequential tests of §§3 and 4 the sample size of a sequential 
wedge test is a random variable. The expected sample size under a given 
treatment difference pi, E(N\pi), is given by equation (5.2.5)
KE(N\fi) = n ^ j  J J ...J f fl(x2 - x l ) . . . fM(xj -Xj_1) dxl ...dxj _ l dxj (5.2.5)
7=1 sjrj-i rx
where f M(x) is a normal density with mean npi and variance ncr2, 
n = {(-cJ- ,- /I)u ( / I-,q)} for / = 1,2, — ,AT— 1 and s,- = { ( -~ ,- c J u [ - /y-,/Ju[c;-,oo)} 
for 7 = 1,2, . . . ,£ . We can calculate E(N\pi) numerically (details are given in 
Appendix 5.1).
The maximum sample size for our problem is nK observations (or 2riK 
patients). Wedge tests are compared in terms of their expected and maximum 
sample sizes in §5.10.
5.3 A Review of the Literature on Sequential Wedge Tests.
Sobel & Wald (1949) were the first to propose an inner wedge test. They 
suggested using two one-sided sequential probability ratio tests (see §3.4 for a 
description of the SPRT): one for testing ji -  - 8  vs H0: pi -  0 and the 
other for testing H0: pi = 0 vs Hx+: pi = 8. The test is fully sequential (i.e. n -  
1) and open (i.e. there is no upper bound on the maximum sample size of the 
test). The critical values of the first test are given by
iS a 2 .= -----+ ------In
2 8 1 - a
A l '  iS a  1and li = + —  in l - P
a
while the critical values of the second test are given by
.2
In p , i8 a 2 . and Ci = — H------ In
*  ^
i - p
1 - a 1 2 8 a
Sampling stops when both tests have terminated, with the acceptance of Zf1+ if St 
( = Xx + ... + Xt) > ci and the acceptance of H{~ if St < c /.
The continuation regions of the two tests overlap for i < i , where
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In order to preserve the overall error rates of the test H0 is accepted if both lt and 
/,• are crossed before i=i . For i>i H0 is accepted if I- <St </,-.
Unfortunately the open nature of this test together with the requirement that 
data monitoring is fully sequential make it unsuitable for use in clinical trials.
In order to place an upper bound on the maximum sample size, 
Schneiderman & Armitage (1962) and Armitage (1975, Ch. 5) proposed a closed 
or restricted sequential wedge test with a maximum of K observations. They 
pointed out that for the two-sided restricted sequential test of Armitage (1957) 
(described in § 4.4) the probability of rejecting H0 is small when the number of 
observations, i, is close to K  and Si ~ 0. Hence it would seem reasonable to 
generalize this test to allow for the early acceptance of H0. Obviously there are 
infinitely many ways of defining an inner wedge for this test. Schneiderman & 
Armitage suggested using the locus of points £ where the null probability of 
crossing either of the outer boundaries from any point on £ equals some small 
constant, e \  In order to preserve the overall size of the test Schneiderman & 
Armitage recommended increasing K  to K \  (Alternatively we could fix K and 
widen the boundaries of the continuation region). The Type II error of the test, /?, 
will, in general, change but, typically, not by any substantial amount. The 
resulting procedure leads to large savings in E(N\fi)  compared with the original 
two-sided restricted test when |//| is small.
Gould & Pecore (1982) and Gould (1983) suggested modifying the two-sided 
group sequential test of Pocock (1977) (described in §4.4) to allow for the early 
acceptance of H0. They set q  = (/ = 1,2, . . . ,  K)  and /x- = / VT
(i = 1 ,2 ,. . . ,  K - 1). The experimenter is free to choose / while c is constrained to 
give a test of size a. Clearly c and I are related; for K= 2 and a  = 0.05 Gould & 
Pecore (1982) claimed that a good polynomial approximation to this relationship is 
given by
c = 2.173 -  0.0124/ + 0.0005Z2 -  0.27Z3 .
Although neither paper talks explicitly about controlling the Type II error rate 
it is clear that a suitable choice of group size gives a test with errors p  at = ±S.
Pocock’s test is a special case of the Gould & Pecore test with / = 0. For n 
and K  fixed, the Pocock test maximizes the power of detecting the treatment
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difference fi = ±S  over the family of Gould & Pecore tests. Unfortunately it also 
maximizes the expected sample size under // = 0 over the same family. Increasing 
I (with n and K  still fixed) reduces both the power of detecting fi = ±S  and
Gould & Pecore pointed to the robustness of their tests to departures from 
normality. With K=  2, (=2d>(-/)) equal to 0.5 and 1.0, a= 0 .0 5  and p  = 0.1
and 0.2, Monte Carlo simulations were conducted on data from the binomial and 
Student t distributions. The observed error rates were impressively close to a  and 
p. Further simulations were conducted on the Student t distribution, this time with 
unpredictable group sizes. Again the error rates of the tests were close to a  and
A major criticism of the Gould & Pecore test concerns the form of its inner 
wedge at the first few analyses when accrued sample sizes tend to be small. 
Clearly it is dubious, to say the least, to interpret a small test statistic at, say, the 
first analysis, as strong evidence in favour of treatment equivalence. One possible
7+1 < / < K - 1. The choice of 7 being made at the design stage of the experiment.
Whitehead (1983, Ch. 4) and Whitehead & Stratton (1983) suggested using 
two one-sided triangular tests for the wedge problem: one for testing 
H{~: fi< 0 vs H0: /* = 0 and the other for testing 770: // = 0 vs H ^ :  p>  0. 
As was mentioned in §3.3 the triangular test assumes continuous data monitoring 
and it is necessary to adjust the boundaries to take into account the effect of 
discrete monitoring. Therefore the critical values for the first test are given by
E(N  |//=0).
way of overcoming this problem would be to set /,• = 0 for i < I  and /; = / V7 for
and
h = — log — -  0.583 V/T -  — ni, 
1 S 6 a+p  4
while the critical values for the second test are given by
+ 0.583 Vn + H -n i4
and
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Ci =  7 108 a+p
-  0.583 V/T + — ni 4
where the constant 0.583 is a correction factor for discreteness due to Siegmund 
(1979) and Cuzick (1981). As with the test of Sobel & Wald (1949) sampling 
continues until both tests have terminated, with the acceptance of / / 1+ if Sin > ch 
and the acceptance of H{~ if Sin < c - . The continuation regions of the tests 
overlap for
* ^
0.583x4 V/Tni < _ 8_ 
3 S:
log 1a+p 3 S = t
To preserve the overall error rates of the test we accept H0 if both lt and /,• are 
crossed before ni = t*. For ni> t*, H0 is accepted if / /  <Sin < /,-.
Whitehead & Stratton compared their test with that of Pocock (1977), by 
considering an example and some simulations. In particular they pointed to the 
large savings in E(N\p=0) made possible by their test.
Emerson & Fleming (1989) proposed a family of symmetric wedge tests 
where p  = a/2. The critical values of these tests are given by ci -  (n iYz  and 
lt = max(0,mJ-C/), where p  is a design parameter, z is chosen to give a test of 
size a  and the group size, n, is constrained so that lK = cK, i.e.
l
n = 1
KP- l 2 z
p-1
The above choice of group size means that, in general, the Type II error constraint 
will not be satisfied exactly. Emerson & Fleming stated that ’... The power under 
the alternative hypothesis for a level .05 two-sided symmetric test is typically .976 
when p = 0 and .98 when p  = .5.’
For AT < 10 and a  =0.01 and 0.05, Emerson & Fleming compared their tests 
for p = 0 and p = 0.5 with the two-sided tests of Pocock (1977) and O’Brien & 
Fleming (1979), and the wedge test of Whitehead & Stratton (1983), in terms of 
both F1: E(N\p=0) and F2:E(N\p=S).  For objective function Fx the three 
wedge tests exhibit large gains in efficiency compared with the two-sided tests. 
Under p  = 8 the Pocock test leads to the smallest expected sample sizes with the 
Emerson & Fleming test with p  = 0.5 almost as efficient.
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5.4 Optima] Group Sequential Wedge Tests.
For a given problem, with n, K, a , p  and S fixed, the optimal wedge test 
minimizes some chosen objective function, F, over the set of feasible wedge tests.





Fs : jE(N\M)S~l q>(fl/d)dft.
Of particular interest is the minimization of F1 now that the early acceptance of 
Ho is permitted. In §5.8 we give results for the minimization of Fx, while in 
§5.10 we compare the optimal wedge tests for Fx with some of the other tests 
proposed in the literature.
The computation of optimal wedge tests by a direct numerical search over 
feasible stopping rules is, in general, impractical because of the large number of 
unconstrained critical values. For instance with K as small as 5 there are 7 free 
boundary points to optimize over, and the simplex algorithm of Nelder & Mead 
(1965) would begin to experience problems (see §3.5 for a more detailed 
discussion of the inadequacies of the Nelder & Mead algorithm). Instead we 
choose to extend our improved method for the computation of optimal two-sided 
tests to wedge tests. Again, unlike the direct numerical search method, our 
improved approach is computationally efficient and numerically stable. In §5.5 
we describe our improved method for objective function FX:E{N |/z=0), while in 
§5.6 we indicate how to adapt our approach when considering other objective 
functions.
5.5 An Improved Method for the Computation of Optimal Wedge Tests.
Consider again the clinical trials problem described in §5.2 with a maximum 
of K equally sized groups of n pairs of patients. The random variable Xt 
(/ = 1 ,2 ,.. . ,  nK) denotes the difference in response between the ith pair of 
patients and is normally distributed with unknown mean // and known variance
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Here we wish to make a choice between the three decisions :
Dx~: fii< 0, D0: fi = 0 andD1+: / /> 0 .
We shall consider a family of Bayes decision theory problems with a 
common prior distribution for fi given by tc( -6 )  = ;r(0) = 7t(S) = 1/3 with 
/r(/z) = 0 otherwise, and a common cost of sampling function given by c(0) = 1 
with c{fi) = 0 otherwise. Individual problems within the family differ in their 
loss functions, L(Z),//), which are indexed by a pair of parameters, d0 (> 0) and 
dx (> 0). The general form of L(D,{i) is given by:
L(D0 - S )  = L(D1+ - S )  = dl 
L(ZV,0) = L(ZV,0) = 4)
L(D1~,S) = L(D0,S) = d1
with L(D,fi)  = 0 otherwise.
Suppose for the moment that d0 and dx are fixed. Consider a general 
decision rule for the above problem which we shall denote by tB. Because our 
family of Bayes decision problems is symmetric about fi= 0 we shall only 
consider decision rules which are symmetric about zero. So #  is of the general 
form :
At analysis i (1 </ <K-1),
if Sin > ct stop entering patients on to the trial and make decision D1+; 
if Sin < -  ct stop entering patients on to the trial and make decision Dx“ ; 
if | Sin | < stop entering patients on to the trial and make decision D0; 
if h < I Sin I < ci enter the next group of n pairs of patients on to the trial. 
At analysis K,
if SKn > cK stop entering patients on to the trial and make decision D1+; 
if SKn<-cK stop entering patients on to the trial and make decision D{~\ 
if \SKn\<cK stop entering patients on to the trial and make decision D0 .
Here we require Z{- < ct (1 < i < K - 1).
-  1 1 0  -
The risk associated with $, which we shall denote by r(®,d0» i^)> is defined 
as the sum of the total expected sampling cost of the trial plus the total expected 
loss through making a wrong decision. That is
r(^B9dQ,di) = c(0) E(N\fi=Q) x(0) + d1 Pr(D0u D 1+|//= -^ )  ^ (-5 )
+ d0 Pr(£)1_ u D 1+|//=0) ;r(0) + dx Pr(D1“ u D 0|//=5) x{8)
where Pr(Dt-kjDj \(i ) denotes the probability of making either decision Dt or 
decision Dj under a treatment difference fi.
It follows that
r('B,d0ld1) = y  {Fi + dx P f i D o V D ^ l n ^ S )  + d0 P rC Z V uiV I/^O )
+ dl Pr(£)j “ uZ)0| //=<S)}.
The Bayes decision rule for our problem, (B*(dQ,di), minimizes this risk over 
the set of all decision rules, 5, i.e.
r($ (do,di),dQ,di) = min {r(©,^/o>^i)}*
'BeS
We can compute by dynamic programming (the necessary computations
are described in §5.7). Using numerical integration we can calculate the Type I 
and Type II errors of $*(^0,^ ) .  Suppose these errors are given by
Pr(D1~ u D 1+| ia=0) = Ct
and
PrU>0u D 1+1 ;*=-£) = P rC D ^ u D o l//^ )  = fi,
then clearly
r(&(d0,dl),d0,d{) =  +  2 d j  0 +  d0 a}.
It follows from the definition of the Bayes rule that there can be no other decision 
rule with errors Ct and f i  which attains a lower value of Fl .
Using the algorithm of Powell (1970) we search over {dQ,d{) for a pair of 
loss parameters (do ^K d f i^ )  giving rise to a Bayes decision theory problem with 
an associated Bayes rule, (d0 a^\ d f i ^ ) ,  which has Type I error a  and Type II 
error f i  Clearly
r(‘B*(d^a\ d i ^ ) , d 0<~a\d ^ '> )  = j  {Fj + 2d ^ f i  + d o ^ a ] .
- I l l  -
Again, from the definition of the Bayes rule, there can be no other decision 
rule for this problem with a smaller risk, i.e.
Moreover there can be no other decision rule with errors a  and p  which attains a 
lower value of F j. By equating decisions D j", Dq and D j+ with the acceptance 
of the hypotheses Hi~t H0 and H±+ respectively we have computed the optimal 
two-sided group sequential test for our original frequentist problem.
5.6 Applying our Improved Method to Other Objective Functions.
Our improved method for the computation of optimal wedge tests described 
in §5.5 is easily adapted for use with other objective functions. The logic of the 
method has been described a number of times already and will be omitted here. 
We will, however, describe suitable families of Bayes decision theory problems 
for the minimization of objective functions F2: E{N\jj.-8) and 
F5: \E { N \ h )8~x <p({i/S) dfj..
Consider the minimization of F2. A suitable family of Bayes decision theory 
problems has the common prior distribution for }i given by : 
n{-8)  = ;r(0) = n{8) = l/3  with n(fi) = 0 otherwise, and a common cost of 
sampling function given by : c{-8)  = c(8) = 1 with c(f i) = 0 otherwise. The 
general form of the loss function, L(D,/z), is identical to that given in §5.5, with, 
in particular, L(D,/z) = 0 for /z + 0, ±5. The rest of the logic is identical to that 
given in §4.6.
For the minimization of F5, a suitable family of Bayes decision theory 
problems has the common prior distribution for ji given by :
J l /4  if /z = - 8 ,0 or 8
otherwise,
and the common cost of sampling function :
c(F) = '
The general form of the loss function is identical to that given in §5.5, with, in
1 if /z ^  - 8,0 or +8 
0 otherwise.
-  1 1 2  -
particular, L ( D , p )  = 0 for p  4 - 8 , 0, <5.
The rest of the logic is identical to that given in §4.7 when considering the 
minimization of F5 over feasible two-sided group sequential tests.
5.7 The Dynamic Programming Algorithm.
As in §§3 and 4, for any given Bayes decision theory problem the Bayes 
rule is computed using dynamic programming. Here we shall describe the 
dynamic programming algorithm for a general wedge problem. Throughout we 
shall assume that the Bayes rule is monotone. That is, at analysis i
(i = 1 ,2 ,..., K)  it is optimal to make decision Dx+ if Sin > c,- and decision D{~ if
Sin < -Ci and decision D0 if -/,• < Sin < lh while for /,• < \Sin \ < ct it is optimal to
sample the next group of n observations. Numerical checks support our 
assumption that <B*(d0,di) is monotone.
Consider again the Bayes decision theory problems of §5.5 with a maximum 
of K  groups of n pairs of patients available for choosing between the three 
decisions
0, D0:p  = 0 and D1+:p>  0.
This time suppose that we have a prior distribution which is denoted by n(p)  and 
is defined over some parameter space M, and that our cost of sampling function is 
denoted by c{p)  and is also defined over M. Finally we shall suppose that our 
loss function is denoted by L(D,{i) and that it is of the same general form as that 
given in §5.5.
Suppose the loss parameters d0 and dx are fixed. Letting p^Hfi\x)  denote 
the current posterior distribution of // at analysis i (1 <i<K),  given that Sin =x, 
then the loss from making decision D^+ equals
dl p {l)(-S\x) + d0 p (l\  0|x), 
the loss from making decision D0 equals
d\ {pil)( S \ x )  +/>(0(<5|*)} 
and the loss from making decision D{~ equals
dop {l)(0\x) + d iP ^ iS l x ) .
- 113 -
If we let y ^ { x )  denote the minimum loss from stopping at analysis / 
(i = 1, 2 , K)  and making a definite decision, it follows that
y (l\ x )  = m m [{d op (l\0 \x )  + d1p (l)(S\x)},d1 {p(l)( -6 \x )+ p (l\S \x)} ,
{dl p ( l)(-S\x) + d0 p (O(0|x)}]
Further, let fi^l\ x )  denote the minimum additional risk from sampling the
(/+ l)st group (f = l , 2 ,   isT— 1) and then proceeding optimally. Denoting the
c.d.f. of given that Sin =x  by F(l+l\ S ( i+1)n\x), it follows that
P {K~l)(x) = n 2  c{p)p^K~l){p\x) + J y (K\ S Kn) dF^K){SKn\x)
/ / e M  S u n
and, for i < K - 1,
j9<0(*) = n 2  cOOp<'>(p|*)
//eM
+ J min {^ (i+1)(5(j+i)„) , / <i+1)(S(i+1)n)} <iF<i+1>(S(i+1)„|*)
S ( i + \ ) n
where the summation signs in the above equations are replaced by a mixture of 
summations and integrals for objective functions such as F5.
We compute the critical values of ®*(d0>^i) by starting at the Kth analysis 
and working back.
At analysis K  it is optimal to make decision D1+ for all x  (> 0) such that 
dl p (K\ - S \ x )  + d0 p^CO lx) < dx (5.7.1)
and to make decision D0 for all x  (> 0) such that
di [p{KH-S\x) + p iK)(S\x)} < dl p {K){-S\x ) + d0 p {K){$\x). (5.7.2)
Using the bisection method we obtain the ATth critical value, cK, as the 
solution, for x  > 0, of the equation
d\ {p{K)( S \ x )  + p {K)(S\x)} = dl p (K\ - S \ x ) + dop {K\0 \x ) .  (5.7.3)
Clearly it is possible that equation (5.7.3) does not possess a solution for x > 0. 
To avoid our algorithm running in to computational difficulties we can build a 
simple check in to our program. The test checks whether inequality (5.7.2) holds 
for x  = 0. If this is not the case we set cK = 0 and go back to the (AT-l)st 
analysis. A similar check can be built in at other analyses.
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The symmetry inherent in our problem makes it optimal to choose decision 
Dx if Sjrn — — and decision Dq if —Cj^  < $Kn ^ 0*
At analysis K— 1 it is optimal to make decision Dx+ for all S^K_XXn =x (>0) 
such that
d\ p^K~l\ - S \ x )  + d o p ^ ' V ^ x )  < P^K~l\ x )
and not to make decision D x+ for all x (> 0) such that
p(K~i)(x) < ^  p(K~l)(-S\x) + do/?(*_1)(0U)>
where the function p^K~l\ x )  is given by
p K-V{x) = n £  c{p)p^K~l\ p \ x )  
f i e  M
+ dx Pr_d (SKn > cK | x ) p {K~l\ - S \ x )  + d0 Pr0 (SKn > cK | x ) p (K~1\ 0|x)
+ dx {Pr_£ {-lK < SKn < lK | x )p (K~l\ - 8 \ x )  + Prs (- /*  < SKn < lK | x ) p ^ ~ 1\6\x)}
+ d0 Pr0 (SKn < -c K | a:)/7(A:_1)(0|^) + dx Prs {SKn< -c K | x) p {K~l) (8\x).
Again we use the bisection method to obtain cK_x as the solution, for jc > 0, of 
equation (5.7.4)
dx + dQ p(K~l\0 \x )  = (5.7.4)
The symmetry inherent in our problem makes it optimal to choose D{~ if 
*S(tf-i)n -  ~ ck - l not to choose D{~ if - c K_x < Sn K^_^  <0.
Also at analysis K— 1 it is optimal to make decision D0 for S^ K_ ^ n =x (>0) 
such that
d i  { p (* - 1 ) ( - s | * )  +  p (* - 1 ) ( « l* ) }  <  y?(JC_1)W  
and not to make decision D0 for all jc (> 0) such that
p(K~l\ x )  < dx {/>(*- 1)(-£|jc) + /7(^ _1)(J|jc)}.
We obtain lK_x as the solution, for jc > 0, of the equation
di {p(Ar-1)(-£|*) + p(Ar_1)(<5|*)} = P{K~l\x ) .
The symmetry inherent in our problem makes it optimal to choose D0 if 
- Ik - i  ^ Sn(K-i) and not to choose D0 if <Sn(jr-i) < - l K_x.
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Clearly it is possible that Ik- i > ck-\- ^  this is the case, sampling is 
terminated at the (AT-l)st analysis with a decision in favour of D1+ if Sin > c* 
and a decision in favour of D0 if 0 < Sin < c*,  where c* is the solution, for x  >0, 
of the equation
d\ {p (^ -1)(_ £ |*) + p^K~l^{81jc)} = di p^K~l\ - S \ x )  + d op^ '^ iO lx ) .
At analysis K - 2  it is optimal to make decision D ^  for all S^K_2)n =x (>0) 
such that
di p(K~2\ - S \ x )  + dQ p^K~2^  (Q\x) < p^K~2\ x )  
and not to make decision for all x  (> 0) such that
P^k- 2\ x ) < di p^K~2^ {-S\x) + d0 p^K~2\ 0 \ x ) , 
where the function P^K~2\ x )  is given by
p(K~2)(x ) = n £  c ( p ) p {K~2){p\x)
/ / e  M
+d1Pr_s(SiK_1)n>cK_1\x)p^K- 2)(-S\x) + d0PT0(SiK_l)n>cK_l \x)p^K- 2)(0\x) 
+d1 { P r _ ^ ( | | | x)p^K 2)(-<?|*) +Pr5( |5(^_i)n|</jf_i \x)p^K 2)(£|*)} 
+^oPro(^(A'-i)/i-- c A'-i IX)P^K 2H0|*) + d{Pts{S^K_l n^<-cK_l |x)p^K 2H<5|*)}
+ J )n)dF^ K 1)(‘S,(A:_1)n|^)+ J p^K 1)(5(^_i)n)^F(Ar_1)(5(A-_1)/I|j:).
h-\ ~Ck-\
Again the bisection method gives the (Ar-2)nd critical value, cK_2, as the solution, 
for x  > 0, of equation (5.7.5)
di p^K~2\ - S \ x )  + d0p(K~2\ 0|jc) = p^K~1){jc). (5.7.5)
The symmetry inherent in our problem makes it optimal to choose D{~ if
S(K-2)n — —^ K-2 n ot tO Choose D { if —^ K—2 ^ (^AT—2)/i
Also at analysis K -2  it is optimal to make decision D0 for S^K_2^ n =x (>0) 
such that
^  {p (K~2\ - S \ x )  + />(* -2)(<5|;c)} < PiK~2)(,x) 
and not to make decision D0 for all x  (> 0) such that
p(K~2\ x )  < di {p^K~2\ - S \ x )  + p(K~2\S \x ) } .
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We obtain lK_2 as the solution, for x > 0 ,  of the equation
dx l p iK~2\ - 8 \ x )  + p (K~2)(8\x) ) = p ^ - ^ i x ) .
The symmetrical nature of our problem makes it optimal to choose decision D0 if 
~Ik- 2 -  S(K-i)n and not to choose D0 if S^K_2)n < - Ik-2 •
We work back to the first analysis in a similar fashion. The error 
probabilities of the resulting decision rule are then computed and a test for 
convergence conducted. If convergence has not been achieved the error 
probabilities are fed into Powell’s method and a new pair (d0 , d{) obtained. The 
method is computationally very fast and efficient.
5.8 Results and Discussion.
Tables 5.1, 5.2 and 5.3 give the minima of F1: E(N\fi=0), F2: E(N\fi=S) 
and F5: $E(N\f i )S~1 <p(ii/S)dti respectively expressed as percentages of the 
fixed sample size, Np for a  = 0.05, p  = 0.1, K  = 2, 3, 4, 5, 10, 15, 20, 30, 50, 100 
and 200, and f, the ratio of the maximum sample size of the sequential test (nK) 
to Np equal to 1.01, 1.05, 1.1, 1.15, 1.2, 1.3, 1.4, 1.5 and 1.6. The minima are 
independent of S and a 1 (for verification of this fact see Appendix 5.2).
It is important to realize that the results given here are generally much better, 
and never any worse, than the results of §4.9. The reason for this is that, for any 
given problem, the set of feasible two-sided tests is a subset of the set of feasible 
wedge tests.
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Table 5.1. Minima of Fx : E(N\fii=0)  expressed as percentages of the fixed sample
size, Nf , for <*=0.05, 0=0.1, t = 1.01, 1.05, 1.1, 1.15, 1.2, 1.3, 1.4, 1.5 and 1.6
and K  = 2, 3, 4, 5, 10, 15, 20, 30, 50, 100 and 200.
K 1.01 1.05 1.1 1.15
t
1.2 1.3 1.4 1.5 1.6
2 92.1 79.9 76.2 75.4 75.6 77.3 79.6 82.4 85.5
3 82.7 77.9 75.0 73.0 71.9 71.1 71.1 71.6 72.4
4 82.2 73.5 71.3 70.9 70.6 70.1 69.9 69.8 69.8
5 79.6 73.0 69.5 68.2 67.8 68.1 68.6 68.9 69.1
10 77.2 70.0 66.8 65.6 64.9 64.0 64.0 64.2 64.3
15 76.3 69.0 66.0 64.6 63.8 63.1 62.8 62.7 62.8
20 75.8 68.5 65.5 64.0 63.3 62.5 62.1 62.1 62.2
30 75.4 68.1 65.1 63.6 62.8 62.0 61.6 61.5 61.4
50 75.0 67.7 64.7 63.2 62.4 61.6 61.2 61.0 60.8
100 74.7 67.4 64.4 62.9 62.1 61.2 60.8 60.6 60.5
200 74.6 67.3 64.3 62.8 62.0 61.1 60.6 60.4 603
Many of the comments made concerning the results of §§3 and 4 apply 
equally here. Again the largest gains in efficiency come from going from a single 
sample test to a sequential test with 2 groups. For fixed t, gains in efficiency 
decrease as K  increases. Indeed an expected gain of no more than 4% of the fixed 
sample size is obtained in going from a 10 to a 200 group design. Even if 
economic considerations limit us to designs with r = 1.01, Table 5.1 shows that 
substantial savings in £ (A |//=0) are possible.
If we compare the results of Table 5.1 for tests with / = 1.01 and £< 10 , 
with the corresponding results for two-sided tests given in Table 4.8, we see the 
very substantial gains which can be made from employing optimal wedge tests. 
Indeed, for any two-sided test with a  = 0.05, Fx must be at least 95% of the 
maximum sample size. The optimal wedge tests show substantial improvements 
on this lower bound for all the designs considered in Table 5.1.
- 118 -
One unique feature of Table 5.1, which is worth commenting on, is that the 
minimum values of F1 for K= 3  and K = 4 occur at higher values of t than do the 
same minima for K  = 5 and K  = 10. The reasons for this are not clear, however 
they must be linked in some way with the introduction of the inner wedge.
Table 5.2. Minima of F2: E(N\fii=S) expressed as percentages of the fixed 
sample size, Np for or=0.05, >3=0.1, t = 1.01, 1.05, 1.1, 1.15, 1.2, 1.3, 1.4, 1.5 
and 1.6 and K  = 2, 3, 4, 5, 10, 15, 20, 30, 50, 100 and 200.
K 1.01 1.05 1.1 1.15
t
1.2 1.3 1.4 1.5 1.6
2 83.9 78.4 77.2 77.3 77.8 79.6 81.9 84.5 87.3
3 79.2 73.7 71.8 71.2 71.1 71.3 71.9 72.9 74.1
4 77.6 71.4 69.4 68.5 68.2 68.1 68.4 68.8 69.3
5 76.2 70.0 67.8 67.0 66.5 66.2 66.4 66.7 67.0
10 73.4 67.1 64.8 63.7 63.1 62.6 62.4 62.4 62.5
15 72.4 66.1 63.7 62.6 62.0 61.3 61.0 60.9 60.9
20 72.0 65.6 63.2 62.1 61.4 60.7 60.4 60.2 60.2
30 71.5 65.2 62.7 61.6 60.9 60.1 59.8 59.5 59.4
50 71.1 64.8 62.3 61.2 60.5 59.7 59.3 59.0 58.9
100 70.9 64.5 62.0 60.9 60.1 59.3 58.9 58.6 58.4
200 70.8 64.3 61.9 60.8 60.0 59.1 58.7 58.4 58.2
Table 5.2 exhibits many similar features to Table 5.1, with large gains in 
efficiency resulting from employing a 2 group design and only small gains 
resulting from using more than 10 groups. For K > 4 the minima of Table 5.1 are 
uniformly larger than the minima given here.
It is of interest to compare the results of Table 5.2 with those for designs 
without an inner wedge given in Table 4.2. For K large and/or t small the gains 
in efficiency for the wedge tests are quite small. With K = 2 and t -  1.6 a 
further saving of 6.7% of fixed sample size is possible on adding the inner wedge,
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while for K = 5 and r = 1.6 this further saving is 6.9%. For K  fixed the 
minimum of F2 over t tends to occur at a higher maximum sample size for the 
wedge designs.
Table 5.3. Minima of Fs : jE (N \ f i )  S~* (p(ii/S)dn expressed as percentages of 
the fixed sample size, Np for or=0.05, p=0.l,  t = 1.01, 1.05, 1.1, 1.15, 1.2, 1.3, 
1.4, 1.5 and 1.6 and K = 2,3,  4, 5, 10, 15, 20, 30, 50, 100 and 200.
K 1.01 1.05 1.1 1.15
t
1.2 1.3 1.4 1.5 1.6
2 86.3 80.0 77.9 77.5 77.8 79.4 81.8 84.5 87.5
3 79.9 74.8 73.3 72.4 71.8 71.5 71.9 72.8 74.0
4 78.1 72.2 69.7 68.8 68.7 68.6 68.8 69.1 69.6
5 76.7 70.9 68.5 67.1 66.4 66.1 66.5 67.0 67.5
10 73.9 68.0 65.4 64.0 63.3 62.5 62.1 62.1 62.4
15 72.9 67.0 64.4 63.0 62.2 61.3 60.9 60.8 60.7
20 72.5 66.5 63.9 62.5 61.6 60.7 60.3 60.1 60.0
30 72.1 66.1 63.4 62.0 61.1 60.1 59.6 59.4 593
50 71.7 65.7 63.0 61.6 60.7 59.6 59.1 58.9 583
100 71.4 65.4 62.7 61.3 60.4 59.3 58.8 58.5 58.4
200 71.3 65.3 62.6 61.2 60.3 59.1 58.6 58.3 583
The main reason for computing optimal designs for objective function F5 is 
to obtain tests which are optimal, or close to optimal, over the entire parameter 
space for //. As can be seen from Table 5.3 the resulting tests are highly efficient. 
The table shares many of the characteristics of Tables 5.1 and 5.2.
As with objective functions F1 and F2 it is interesting to compare the results 
of Table 5.3 with the analogous ones for the two-sided test given in Table 4.6. 
The gains in efficiency from adopting a wedge design can be seen to be highly 
impressive. For example with K = 3 and t -  1.6 a further saving of 34.9% of the 
fixed sample size is achieved, while with K  = 10 and r = 1.5 this further saving
-  1 2 0  -
is 33.7%. For t small and/or K large these savings are less impressive but still 
significant.
The minimization of objective function F3 : E(N\n=2S)  has not been 
considered in this Chapter. The expected gains in efficiency from considering a 
wedge test rather than a two-sided test are small and often non-existent here.
Clearly our improved method for computing optimal wedge tests could be 
extended to consider other objective functions and/or other values of a  and /?.
5.9 Examples.
Consider again the hypothesis testing problem of §4.9. Using the same 
notation as before, let , X2, . . . ,  XKn be independent normal random variables 
with unknown mean n  and unit variance. We wish to test
Hx~: n<  0 vs H0: n = 0 v,s H ^ :  fi> 0
with error rates
Pr u  ^ ! + | ^  =  -0 .5 ) = 0.1
P rt# !-  u  .fl1+|/z = 0) = 0.05
Pr(.%-  u  Jfy|/z = 0.5) = 0.1.
A maximum of 5 groups of 10 pairs of patients are available for entry on to the 
trial.
As a first example we consider the optimal wedge test for objective function 
F1: E(N | /z=0). The standardized critical values for this test, c / = c j^ ln  and 
//  = /,/V ^, are given by: / /  =0.0, c {  =4.001, l2 =0.665, c2' =3.122, l3' =1.03, 
c3 -2 .1 2 0 ,  lA' =1.351, c4' =2.404 and c5' =1.848. It is interesting that the 
optimal wedge test does not permit the acceptance of H0 at the first analysis. 
Under // = 0 the expected sample size is 28.4, which compares very favourably 
with the relevant fixed sample size for this problem of 42.03 pairs of patients, and 
the optimal two-sided test for which E(N\fi=0) = 48.7.
The optimal wedge test for F2 : £(AT|//=0.5) has standardized critical values: 
/ /  =0.0, ci =2.613, l2 =0.266, c2 =2.920, l3 =0.838, c3 =2.385, / /  =1.425,
-  1 2 1  -
c4 =2.404 and c5' =2.243. As with the first example it is optimal not to accept 
H0 at the first analysis. As one would expect, both I- and ct are smaller here 
than in the first example when i <4. Under // =±0.5 the expected sample size of 
the test is 28.13 which is a slight improvement on the optimal two-sided test for 
this problem where Zs(N|//=0.5) = 28.7.
The optimal wedge test for objective function 
/ ^ J e c a ^ x o . s ) - 1 (p((i/Q.5)d[i has standardized critical values: / j = 0 .0 ,  
Ci =2.691, /2' =0.508, C2 =3.016, /3' =0.977, c3' =2.463, /4' =  1.413,
c4 =2.388 and c5 =2.070. Here F5 =33.3 which compares favourably with the 
optimal two-sided test where Fs =35.3. As would be expected the stopping rule 
for this wedge test lies somewhere between the stopping rules for the first two 
examples.
It is interesting to note that the optimal wedge test for objective function 
F3: E(N\fi=28) is identical to the optimal two-sided test given in §4.10. This is 
a result of the fact that under = 28> the gains in efficiency from being able to 
stop early and accept H0 are small relative to the gains from accepting t f1+.
5.10 A Comparison of Group Sequential Wedge Tests.
In this section we compare our optimal wedge tests with some of the wedge 
tests introduced in the literature and described in §5.3, and some of the two-sided 
tests of § 4.
To simplify notation we let 7^* denote the optimal wedge test for objective 
function F1: E(N |/*=0) over t with K  fixed. Further we let 7\+ denote the 
optimal two-sided test for Fx with f = 1.01 and K  fixed.
Table 5.4 gives F{ expressed as a percentage of the fixed sample size, Np 
and, in parentheses, t, the ratio of the maximum sample size to Np for the tests of 
Gould & Pecore (1982) with tu1 = 1.0, 0.5 and 0.15, and the optimal tests, Tx* 
and 7 \+. Results are given for a -  0.05, /? = 0.1 and K = 2, 3, 4, 5 and 10, and, 
as before, they are independent of a 2 and 8. The fixed sample size test for this 
problem has K=  1, t= 1.0 and E(N\fi=0) = cr2x l0 .6 /52.
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Table 5.4. F1: E{N\fi = 0) expressed as a percentage of fixed sample size, Np and, 
in parentheses, f, the maximum sample size expressed as a proportion of the fixed, 
for the tests of Gould & Pecore (1982) with n l -  1.0, 0.5 and 0.15, the optimal 
wedge test for 7\*, and the optimal two-sided test for Fx with f = 1.01, 7 \+, 
for a - 0.05, j5 = 0.1 and K  = 2, 3, 4, 5 and 10.
K
— 1.0 -  0.5 nx = 0.15 V Ti+
2 108.3 84.2 81.3 75.4 100.7
(1.10) (1.15) (1.46) (1.16) (1.01)
3 112.8 78.8 81.4 71.1 100.6
(1.15) (1.35) (2.13) (1.34) (1.01)
4 115.6 78.2 82.3 69.8 100.6
(1.18) (1.61) (2.83) (1.52) (1.01)
5 117.7 80.0 82.7 67.8 100.5
(1.21) (1.91) (3.54) (1.21) (1.01)
10 123.4 94.4 83.2 64.0 100.5
(1.27) (3.71) (7.08) (1.37) (1.01)
By design the optimal wedge tests give the lowest value of Fl for each K. 
The largest maximum sample size for an optimal wedge test occurs when K = 4 
and equals 152% of the corresponding fixed sample size.
The Gould & Pecore test with ^  = 1.0 is, as was mentioned in §5.3, 
identical to the two-sided test of Pocock (1977) (described in §4.4), and so does 
not permit the early acceptance of H0. As one would expect, these tests have the 
largest values of and, with the exception of 7T1+, the lowest maximum sample 
sizes.
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The other test without an inner wedge, Tx+, also leads to large values of 
£(N |//=0). For the examples given in the table it is always worse than the fixed
sample size test. If we compare 7 \+ with the corresponding optimal wedge tests,
the advantage of allowing the early acceptance of H0 becomes clear.
Of the other two Gould & Pecore tests the one with = 0.15 is closest to
optimal. It is never more than 20% of Nf from the overall minimum.
Both tests require very large maximum sample sizes (especially when 
K  = 10) to meet the power requirements at //=±£. For example, the test with 
Ki = 0 .15  and K -  10 has a maximum sample size more than 7 times greater 
than Nf. In fact with kx reasonably small and K > 3 large maximum sample sizes 
would arguably render the Gould & Pecore tests impractical.
We have also compared wedge tests in terms of the objective function 
F2: E(N\(i=8 ). Again to simplify notation we let T2* denote the optimal wedge 
test for F2 over t with K  fixed. Further we let T2+ denote the optimal two-sided 
test for F2 over t with K  fixed. Table 5.5 gives F2 expressed as a percentage of 
the fixed sample size, Nf, and, in parentheses, t, for the tests of Gould & Pecore 
(1982) with -  1.0, 0.5, and 0.15, T2* and T2+. Again results are given for 
a  = 0.05, p  = 0.1 and K  = 2, 3, 4, 5 and 10, and they are independent of a 2 
and 8 .
- 124-
Table 5.5. F2: E(N\fi = 5) expressed as a percentage of fixed sample size, Np 
and, in parentheses, t, the maximum sample size expressed as a proportion of the 
fixed, for the tests of Gould & Pecore (1982) with x 1 = 1.0, 0.5 and 0.15, the 
optimal wedge test for F2, T2*, and the optimal two-sided test for F2, T2+, for 
a - 0.05, p = 0 . 1 and K  = 2, 3, 4, 5 and 10.
K
oII ffi = 0.5 KX = 0.15 T-1 T + 1 2
2 77.6 77.3 84.3 1 1 2 77.6
(1.10) (1.15) (1.46) (1.12) (1.10)
3 72.1 72.1 83.9 71.1 72.1
(1.15) (1.35) (2.13) (1.22) (1.14)
4 69.7 70.4 84.2 68.1 69.6
(1.18) (1.61) (2.83) (1.24) (1.15)
5 68.5 70.1 84.3 66.2 68.1
(1.21) (1.91) (3.54) (1.30) (1.16)
10 66.6 72.0 84.5 62.4 65.1
(1.27) (3.71) (7.08) (1.44) (1.17)
Again, by design, the wedge tests give the lowest values of F2. Both the 
Pocock test (#! = 1.0) and the optimal two-sided test are close to the optimal 
wedge test when K  is small. They also require somewhat smaller maximum 
sample sizes than T2*. However with K = 10 the wedge test is substantially 
better than the other five designs.
Of the other two Gould & Pecore tests the one with = 0.5 is clearly the 
best in terms of giving low values of F2. As kx decreases the critical values of 
the inner wedge, Zf, increase which, in turn, forces the outer critical values, cv to 
increase. This leads to a smaller probability of stopping early under fi = S and
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explains the inefficiency of the tests with 7Ul = 0.15.
The maximum sample sizes for the Gould & Pecore tests are, of course, the 
same as in Table 5.4. Hence the earlier criticisms remain concerning the need for 
large maximum sample sizes when is small and K  is large.
The tests of Emerson & Fleming (1989) cannot be compared directly with the 
tests of Tables 5.4 and 5.5 as, in general, they do not satisfy the Type II error 
constraints exactly. We can, however, compare any given Emerson & Fleming 
test with an optimal test with the same errors.
To ease notation, let r^ be the ratio of E(N\p)  for the optimal test to 
E(N\fi) for the Emerson & Fleming test, expressed as a percentage. Clearly 
rM < 100%, with = 100% if the Emerson & Fleming test is optimal. Table 5.6 
gives r0 and rs for the Emerson & Fleming tests with p = 0 and p  = 0.5, K  =2 , 
3, 4, 5 and 10 and a  = 0.05. Also given, in parentheses, are the attained Type II 
errors under p=S.  The results given are independent of <r2 and S.
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Table 5.6. The efficiency ratios r0 and rs, and, in parentheses, the Type II errors 
under p = 8 , for the tests of Emerson & Fleming (1989) with p = 0 and p = 0.5, 














































The Emerson & Fleming tests with p = 0 are between 77.5% and 92.5% 
efficient under p  = 0, and between 80.4% and 87.8% efficient under p  = 8 . The 
observed Type II errors range from 0.0237 up to 0.0249.
The tests with p = 0.5 can be seen to be uniformly closer to optimal than 
those with p  = 0. Under p = 8  the tests are between 90.2% and 95.6% efficient, 
while under p -  0 efficiency ratios are particularly impressive, ranging from 
89.3% up to 97.5%. Observed Type II errors are between 0.017 and 0.025.
For any given problem, with K  and a  fixed, we can minimize a chosen 
objective function over the family of Emerson & Fleming tests, by searching over 
the parameter p. This has been done for objective functions Fl : E(N\p=0) and 
F2: E(N\p=S), a - 0.05 and K  = 2, 3, 4, 5 and 10. Table 5.7 gives r0 and rs for
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the "optimal" Emerson & Fleming test for each problem. Also given, in 
parentheses, are the attained Type II errors under fi = S.
Table 5.7. The efficiency ratios r0 and r5, and, in parentheses, the Type II errors 
under // = <5, for the "optimal" tests of Emerson & Fleming (1989) for K  = 2, 3, 4, 






















The results are rather impressive, with not one of the "optimal" Emerson & 
Fleming tests being less than 90% efficient. We note however that the computer 
time necessary to compute an "optimal" Emerson & Fleming test is not 
substantially less than that required to compute an overall optimal test using our 
improved method.
-  128 -
5.11 The Bioequivalence Problem.
As has already been mentioned, one of the most important applications of 
wedge tests is in the area of bioequivalence tests, in this section we describe the 
bioequivalence problem and the reasons why optimal wedge tests are particularly 
suitable here.
Suppose that all patients suffering from a particular disease are given a 
standard drug, S. A new drug, N, has been developed which it is thought will 
result in patients experiencing fewer side-effects than is the case with S. The two 
drugs are chemical equivalents; that is, as defined by Metzler (1974), they are 
drugs ’... of the same dosage form which contain equal amounts of the same 
active ingredient as indicated by official standards’. Chemical equivalence on its 
own does not guarantee that the two drugs will be equally effective in the 
treatment of patients. To try to establish whether S and N are equally effective 
we could conduct a clinical trial similar to those described in §4.2 and §5.2. 
However such trials are complicated and expensive to run. Metzler (1974) 
suggested that logistical considerations often lead us to investigate the biological 
equivalence of S and N. He stated that biological equivalents are ’... those 
chemical equivalents which deliver the same amount of active ingredient into the 
circulating blood’. Drugs which are biological equivalents are assumed to be 
equally effective.
There are a number of possible patient responses one might record when 
testing for bioequivalence. Racine-Poon et al. (1986) and (1987) suggested that 
one might record the logarithm of the ratio of the areas under the blood level 
concentration curves for S and N, which they denoted by 4/. Most of the 
literature on bioequivalence assumes that a two-period crossover design is 
employed by the experimenter. Here patients are randomly assigned to one of the 
two treatments on entry to the trial. Their blood level concentration is then 
monitored over time. A wash-out period follows to remove the effects of the 
drug, and then the patients are given the treatment they did not receive in the first 
period.
Racine-Poon et al. (1986) and (1987) considered a Bayesian approach to the 
bioequivalence problem. The parameters *P and a 1 (the variance of the patient 
responses which is assumed unknown) are assigned a vague prior distribution.
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After the experiment has finished the posterior distribution for 'F is formed and 
the bioequivalence of the two drugs accepted if
Pr(0.8 < ¥  < 1.2 | y) > 0.95
where y  represents the data.
Racine-Poon et al. noted that typical bioequivalence trials are conducted with 
as few as 6 patients. For most vague priors such a small sample is unlikely to 
lead to the acceptance of bioequivalence even when = 1. To deal with this 
problem they suggested a two-stage sequential approach. In the first stage 
patients (where r%i is typically around 6) are admitted on to the trial. On the basis 
of their responses the probability of accepting bioequivalence is predicted. If this 
probability is suitably high (low) the trial is stopped and bioequivalence is 
accepted (rejected). Otherwise the second group of n2 patients is entered on to 
the trial and after they have responded the trial is terminated with the acceptance 
or rejection of bioequivalence.
This two-stage procedure has a markedly higher probability of accepting 
bioequivalence when 'P is close to one than does the single sample approach. We 
note that it is also a Bayesian "inner wedge" design in so far as it allows the 
acceptance or rejection of bioequivalence at the first stage.
We now consider a frequentist two-stage approach to bioequivalence. 
Suppose Yx, Y2 , ... are independent normal random variables with mean XF and 
known variance t 2 and we wish to test
4/ < 1 v.s ^ 1^=1 vj # 1+: ¥ >  1
with error rates
Pr(^o u | =  0 . 8 )  =  p
Pr(^1" u ^ 1+ |'F  = 1) = a  
Pr(^1" u ^ ) |'F = 1 .2 )  = p.
To tie this problem in with the symmetric one posed in §5.2 we consider the 
following transformation:
Let
Xi = ( Y ‘ ~ 1 ) ' 0 2
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then X,~Af(/z,<72), where
fi = 0 F - 1) — and a 2 = -7—^ —.^  0.2 0.04
and we wish to test
Hx~ :n<  0 vs H0:fi = 0 vs H 1+:^i> 0
with error rates given by equations (5.2.1)-(5.2.3). Optimal stopping rules for this 
problem are easily transformed for use with the first problem (see Appendix 5.2 
for details).
Before continuing it is worth pausing to comment on some unusual features 
of this hypothesis testing problem. Jennison (1986) in the discussion of Racine- 
Poon et al. (1986) questioned the use of a two-sided test for this problem. He felt 
that as we are testing a new formulation against a standard, a one-sided test would 
be more appropriate. Racine-Poon et al. countered by pointing out that if the null 
hypothesis is false then either too little of the active ingredient of the drug is 
released into the blood stream and the new drug may be relatively ineffective, or 
too much of the active ingredient is released which may produce a toxic effect. 
Rejection of H0 in either direction should clearly lead to the termination of the 
development of the new drug.
In all the previous examples we have considered, acceptance of H0 has 
resulted in a passive action - the continuing use of the standard treatment. In the 
bioequivalence problem, however, the roles of the null and alternative hypotheses 
have swapped. Now acceptance of H0 would lead to the possibility of a change 
in treatment regimens with the new treatment replacing the standard. The roles of 
our Type I and Type II errors have also swapped. To reject the null hypothesis 
when it is true (a Type I error) would cost the drug company in needlessly lost 
profits and effect patients in the sense that they do not receive the new drug with 
the less harmful side-effects. To accept H0 when it is false (a Type n  error) is 
clearly unethical. This change in roles of the error rates has to be borne in mind 
when designing trials.
Bioequivalence testing is an area where a Bayesian approach is attractive 
because of the large amount of prior information which is likely to be available to 
the experimenter. Jennison (1986) has suggested that this prior information might 
be used in the design of optimal ffequentist tests. His idea was to produce an
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optimal test which minimizes expected sample size integrated over the 
experimenter’s prior. The optimal tests for F5 are examples of such designs.
We now proceed to consider the optimal frequentist designs for the following 
priors:
(i) iTiifi) ~ N(0,4S2)
(ii) x2 ({i) -  N(0,9S2).
We shall denote the optimal tests which minimize expected sample size integrated 
over nii f i )  and n2 { p ) by F6 and F7 respectively. We note that the optimal tests 
for jF6 correspond to the case where the experimenter’s a priori beliefs are vaguer 
than was the case with F5. Objective function F7 corresponds to a still vaguer set 
of prior beliefs.
Table 5.8 gives the minima of F6 and F7 for K = 2, t = 1.01, 1.05, 1.1 and 
1.15, a  -  0.05 and 0.1 and p  = 0.01, 0.025 and 0.05. The results given are 
independent of 8  and cr2.
Table 5.8. Minima of F6 and Fn expressed as percentages of the fixed sample 









p  = 0.01 67.4 66.2 66.5 67.6 62.1 61.8 62.8 64.4
a  = 0.05 p  = 0.025 68.9 67.1 67.2 68.2 63.2 62.5 63.3 64.8
p  = 0.05 70.5 68.0 67.9 68.7 64.3 63.2 63.9 65.2
i—HooII 67.0 66.5 67.1 68.2 61.8 62.0 63.2 64.7
i—HoIIS P = 0.025 68.6 67.7 67.9 68.9 62.9 62.9 63.8 65.2
P = 0.05 70.2 68.9 68.8 69.6 64.1 63.8 64.5 65.8
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Even though we have confined ourselves to two-stage procedures, Table 5.8 
shows that very efficient designs may be obtained. About 33% of the fixed 
sample size is saved in each problem. Even when t and p  are very small the 
gains in efficiency are large.
Our results show that it is possible to obtain an optimal frequentist group 
sequential design for the bioequivalence problem which makes use of the 
experimenter’s a priori beliefs when choosing a suitable objective function. The 
opportunity to stop sampling after the first stage with the acceptance or rejection 
of bioequivalence make our designs particularly attractive.
5.12 Discussion and Conclusions.
In §5 we have considered the generalization of the two-sided group 
sequential designs of §4 to allow for the early acceptance of H0. Results show 
that such a generalization can lead to large gains in efficiency particularly when 
looking at optimal tests for objective function Fx: E(N |//=0).
An important application of wedge designs is in the area of bioequivalence 
testing. In §5.11 we considered optimal wedge designs for this problem and 
showed that, even when logistical considerations limit us to two-stage procedures 




This Appendix is similar to Appendix 3.1 where we gave details of how to 
calculate numerically the power function and the expected sample size function for 
a one-sided group sequential test. Here we give similar details for wedge tests. 
As a two-sided group sequential test is just a special case of a wedge test, the 
work of this Appendix applies to the tests of §4 as well.
As an example consider calculating the operating characteristic function, 
OC{fi) = Pr(j^ol^), given by equation (5.A1.1)
K  ^
OC(m) = X  J J . . • j f M(x1) f /l(x2 - x 1 ) . . . f /i(xJ—Xj_1)dxl ...dXj_1 dXj (5.A1.1)
7= 1-/;!}-! r,
where rt = for i = 1 ,2 ,.. . ,  K - l ,  and f^{x) is a normal
density with mean nfi and variance no2.
Clearly OC(fi) is the sum of an integral and K - l  multiple integrals. The 






- l x -nji
yIno2
where <J> is the c.d.f. of the standard normal distribution. The NAG library 
contains a subroutine, S15ABF, for calculating d>(.).
The second term in the sum is
h
J \ ff i{x l ) f^{x2 - x l )dxl dx2 (5.A1.2)
~hr\
The integral with respect to x 1 here can be evaluated using Simpson’s rule. One 
approach would be to use a fixed number of equally spaced grid points. However, 
as was pointed out in Appendix 3.1, for a multi-use algorithm such an approach 
might lead to inaccurate calculations.
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An improved approach involves placing a grid of 6 N - 1  points 
{gt : 1 < j < 6 N - 1}, where N  is fixed, over jtx according to the rule:
For i = l , N
gt = n jj, -  'fn a  {3 + 41n(N/i)}
For j = N+1, 5 N - 1
gi = n /i -  f^n a  {3 - 6 ( i -N ) /4 N }
and, for / -  5N, 6 N - 1,
gi = n fi + yin a  {3 + 41n(//(6N-l))}.
This rule places a fixed number (4N ) of equally spaced points within 3 
standard deviations of the mean of the distribution we are integrating. In the tails 
of the distribution grid points are placed increasingly far apart. To obtain a set of 
grid points, {#! n : 1 < i l  } to place over the interval rx we first find gt and 
gi+l such that
<gi+1,
we next find g( and g f +1 such that
Si' <~h ^ S i \  1
and then gj and gj+1 such that
S j ^ h  < Sj+i ■
and finally gf  and gj +1 such that
g y < c l £ g f + 1-
We then set gx>1 = - c lf g 13 = g i+1, g15 = g,+2, —, £i,mi-2 = £ /'-1» £i,mi “ ~h> 
g\,Mi+i  = i^» 8i ,M i+3= 8j+i* —» g\,Nx- 2 = gj' ^  «i,jvk = ci- (Note that if 
- c x < g x and/or we set g u l  = g 1 and/or g l>N1 = g6N-i-) The Srid
points with even subscripts {g\t2i : 1 -  * -  ( — 1 )/2} are then positioned halfway 
between the neighbouring grid points with odd subscripts, i.e.
#1,2/ =  y  { £ l ,2 i - l  +  £l,2/+l }•
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The weights {wx a  : 1 < i l  < } for use in integral (5.A1.2) are given by
wl,2i ~ ^ ( 8 l,2i+l~ 8 l,2i- 0  / -  1, 2, ( M l - l)/2
w i,2/+i ~  'g‘ (£i,2*+3_ £ i )2 / - i )  / - 1 , 2 , . . . ,  ( M l - 3 ) / 2
Wl.Ml+l -  ■^■(^l,Ml+3_ <?l,A/l+2) 
wl,2i+l = 'g '(£l,2i+2" '£ l>2i) * = (Ml + l)/2, ..., ( A l -2)/2
Wi,2i =  ^ ( « i . 2 i +2 - « i , 2 i - 2) i =  (A / l+ 3 ) /2  . . . ,  (ATl-2)/2
Then the multiple integral (5.A1.2) is approximately equal to
ll N 1J X witiifti(8i,n)fp(x2-8itii)dx2
-l2i 1=1
(5.A1.3)
at this stage in the computations we store the terms { w j tn): 1 £ i l  <Nl)  
in an array {^i(gi,ii): 1 < / l  <iVl} for future use.
The integral (5.A1.3) is equal to
N1 
il = l
h ~ 8 i , i i - W
VnCT
- h - 8 \ , n - m
V/ii
This sum is easily evaluated using the stored array {hi (g1 n ): 1 < / l  <7V1} and 
the NAG library subroutine S15ABF.
The third term in the sum (5.A 1.1) is the multiple integral
J j  j f M(x1 ) f /l{x2 - x 1) f /t(x3 - x 2 )dx1 dx2 dx3.
- h  r 2 T\
(5.A1.4)
Clearly the first stage in evaluating (5.A1.4) is to evaluate the integral with respect 
to x1. This is easily achieved by using the stored array {h^igi n ): 1 < t l  <iVl}.
- 136 -
So the multiple integral (5.A1.4) is approximately equal to
NlJ J l l h 1<.Si,n)fM(.x2- g i , n ) f fl^ 3- x 2)d x 2 dx3
- l 3r2il = l
(5.A1.5)
We can now use Simpson’s rule to evaluate the integral with respect to x2. 
The relevant grid points and weights are obtained by using the same rule as for 
the integral with respect to x i . We shall denote the grid points by 
{8 2 ,1 2 : 1 ^ *'2 < N2} and the weights by {w2 ,-2 • 1 ^ i2<N2}. Integral (5.A1.5) is 
then approximately equal to
N2 Nl
i X  X  fll(8l,il)w2,i2fM(82,i2-8l,il)fM(^-g2,i2)dx3- (5.A1.6)
-l-i i2=1 i 1 = 1
ah
We store the terms { X  w2 ,n f ^ 8 2 ,i2 ~8 i , n ) : 1 ^ i2 < N 2 }  in an
*i=i
array {h2 (g2 ,*2) : 1 -  *2 ^ ^ 2 }  for future use. It follows that (5.A1.6) is equal to
N2




- l3 S 2 , i 2 ~ n V
VaT<7
This sum is easily evaluated using the stored array {^2(£2,/2) : * -  i2 < N 2 } and 
the NAG library subroutine S15ABF.
All other terms in the sum (5.A1.1) are calculated similarly. The Kth term 
equals
N(K -l )
2  h K - i ( g K - l ti ( K - l ) y  
i (K-l )=l
Ir  ~ 8 k ~ 1, i (K-l )
Vn o
~ I k ~ 8 k - 1 , i(K- l)  ~ nM
where {hK_i(gK_i ^ K^ ) :  1 < i ( K - l )  < N(K -\ )}  is a stored array with i ( K - l)st 
element
^ K - 1 ( S k ~ 1, i(K— 1)) =
N(K-  2)
X  ^ K - 2 ^ 8 K - 2 , i (K-2 ) ) WK -  l,i(AT-1 ) / / / ( # £ - 1, i (K - l ) ~ 8 K - 2 , i ( K -2 ) ) • 
i(K-2)=l
Using the same techniques as those explained above we can calculate the 
expected sample size function and the power function of a given group sequential 
wedge test. Details are omitted.
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Calculations for the expected sample size function, power function and 
operating characteristic function of a given two-sided group sequential test are 
similar to those described here, with lt = 0 of course.
Appendix 5.2.
Consider again the group sequential inner wedge problem introduced in §5.2, 
which has a maximum of K  groups of n pairs of patients. Using the same 
notation as before, let , X2, ..., XKn be independent normal random variables 
with unknown mean // and known variance a 1. We wish to test
0 vs H0:fii = 0 vs Hl+:fi> 0
with error rates given by equations (5.2.1)-(5.2.3).
Suppose the set of critical values {(/i,c1),(/2,c2),...,(/a'_i,cA^_1),c^} 
defines a feasible stopping rule for the above problem. The expected sample size 
function for this test is given by equation (5.2.5). Further, the operating 
characteristic function for this problem, OC(ji) = Pr(J3o | f i ), is given by equation 
(5.A2.1)
K ^
0C (//) = £ j  J ••• j f fl(x2 - x 1) . . . f M(xj -Xj_1 )dx l ...dxj _ 1 dXj (5.A2.1)
7=1—(/O'-1 ri
where rt = { ( - C j , - l j ) v ( l j , C j ) }  for i = 1, 2 , . . . ; K - l ,  lK = cK, and f M(x) is a 
normal density with mean tin and variance ncr2.
Finally the power function, ^ ( /z )  = Pr(^1+|//), is given by equation 
(5.A2.2)
K °°
( V ) =  Z  J J • ♦ • J f n ( * i ) f f i ( x 2 ~ x l ) • ■•'• f M(X j -X j - 1 )dxx...dxj_! dxj(5.A2.2)
j= \C j r j_x rx
We now consider a new problem in which the variance of the original 
problem, cr2, is replaced by a 2, and 5 is replaced by Si (>0). The maximum 
number of analyses for this new test, K, and a  and p  remain the same as for the 
original problem.
Consider the following stopping rule for our new problem defined by the 
rescaled set of critical values (/2*,c2* ),..., (Ik- i *>ck- i *)’ck*}’ where
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g 2 8  o 2S
li = — — li (*'= 1, 2 ,.. . ,  JT-1) and c* = — — ct (i = 1, 2 , K), together^  Wl  \  r  *  ,  —  ,  f  * /  w  # A
<7 <?! (7 S\
2 S2
with the rescaled group sizes w* = — ——n.
>i
a f 8 *
In this Appendix we prove the following Lemmas and Corollaries:
Lemma 5.1 : The operating characteristic function for our new problem, OC*(fi), 
is such that
OC*(fi) = OC(nS/8 i ).
Corollary 5.1 : From Lemma 5.1 it follows that
OC*( 0) = OC( 0) = 1-cr.
Lemma 5.2 : The power function for our new problem, x 1 *(//), is such that
= KiinSISi).




As 7Ui(S) = l~P  and z \ (-S ) = p, it follows from Corollaries 5.1 and 5.2 
that the rescaled set of critical values {(li*,q * ) , ..., (Ik-i* >ck- i* ) ’ck*} together 
with the rescaled group sizes, n*, define a feasible stopping rule for our new 
problem.
Lemma 5.3 : Letting E(N*\{i) denote the expected sample size function for our 
new problem and N f  denote the corresponding fixed sample size, we prove that
E(N*\fi) _ £(AflM/<?i)
n;  ~ Nf
where E(N\}i) is the expected sample size function for the original problem and
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N f is the corresponding fixed sample size.
Corollary 5.3 : From Lemma 5.3 it follows that
(,') E ( N * \ u = 0 )  = E(N\ f i=0)
N f Nf
£(W *U = ^i) = E(N\ f t=S)
N f  Nf
N f  "
where fi =n8 /8 1#
Proof of Lemma 5.1 :
The operating characteristic function for the new problem is given by 
O C \ n )  =
k  l>*
£  J J . . . \ f M(xl ) f M(x2 - x l ) . . . f M(Xj-Xj_1)dxl ...dXj_l dXj (5.A2.3) 
j=\-i;rj^  rr
where r* = { ( - c , * , c , * ) }  for i = 1 ,2 ,    AT— 1, and f^(x)  is a normal
density with mean n* fi and variance n*<Ji2.
a 2 S1
Consider the substitutions zf = — —  x{ for i= 1 , 2 , K,  in equation
g 2 8
(5.A2.3). We obtain 
OC*(/0 =
K  ^
X  J I  — i g M'(zi)gM'(z2 -Z i ) . . .g M'(Zj-Zj- i)dzi . . .dzj -idzj  (5.A2.4)
j=l~ljrj-i rx
where rt = { (-C ;,-//)^ /,-,^ )}  for i = 1, 2 , K - l ,  fi =n8 / 8 l9 g^(z)  is a 
normal density with mean nfi and variance na2, and 
{(/j ,cx) , ick - 0 > ck)  is a feasible set of critical values for our original 
problem.
Comparing the RHS of equation (5.A2.4) with equation (5.A2.1), we see that 
OC*(n) = OC(ii') = OC(fi8 l8 i). (5.A2.5)
Q.E.D.
- 140 -
Proof of Corollary 5.1 :
Substituting /z = 0 in to equation (5.A2.5) gives
OC*( 0) = 0C(O),
and from equation (5.2.1) we have OC{0) = 1 -a .  Therefore OC*(0) = 1 -a.
Proof of Lemma 5.2 :
The power function for the new problem is given by 
* 1*00 =
K °°S j  J — j f M(xl ) f fl(x2 - x l ) . . . f fl(Xj-Xj_l )dx1 ...dXj_l dXj (5.A2.6)
;=ic/r;_r rr
where, as in Lemma 5.1, r* = {(-c*  ,c*)} for / = 1 ,2 ,..., A '-l, and
f M(x) is a normal density with mean n*n  and variance n * ^ 2.
G2 Sl
Again, we consider the substitutions z,- = — —  xt for i = 1, 2, . . . ,£ , this
a 2 8
time in equation (5.A2.6). We obtain
K 00s j  J — i  8fi(zi) gM'(z2-Zi)... gM-(Zj-Zj-i)dzi . . .dzj-idzj  (5.A2.7)
j~ 1 £j fj-\ rf
where rt = {(-Ci,-//)u(Zf,Cf)} for i = 1, 2, . . . ,  £ - 1, / /  =n8 !8 l , gM>(z) is a
/ a
normal density with mean nfi and variance ntr  and
{(/j ,cx) , ..., (/j^—! ,cK_i), cK) is a feasible set of critical values for our original 
problem.
Comparing the RHS of equation (5.A2.7) with equation (5.A2.2), we see that 
x f i H )  = jfjO O = *i(//S/<5i) (5.A2.8)
Q-E.D.
Proof of Corollary 5.2 :
Substituting fi = S1 in to equation (5.A2.8) gives
*i*(*i) = *i (S),
and from equation (5.2.3) we have Xi(S) = p. Therefore ■^1*(^1) = p.
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Substituting = - S 1 in to equation (5.A2.8) gives
* ! * ( - * ! )  =  X i i - 8 ) ,
and from equation (5.2.2) we have t c ^ - 8 ) = I -p .  Therefore = I -p .
Proof of Lemma 5.3 :
The expected sample size function for our new problem is given by 
E(N*\n)  =
n * H J  J J — j f M(xl ) f M(x2 - x l ) . . . f M(Xj-Xj_l )dx l ...dXj_ldXj(5.A2.9)
j= i i/O-i* ri*
where s f  = { (-~  , - c / ) u ( - Z / , / / ) u ( c / ,~ ) }  for 7 = 1, 2,
r/* = {(-Q* - l i ' M l i *  ,Ci*)} for i = 
with mean n* fi and variance n*ax2.
c c*) / 1,2, ...,AT-1, and f M(x) is a normal density
2
g 2 8 1
Consider the substitutions z-x = — —  jc,- for i = 1, 2 ,.. . ,  AT, in equation
(5.A2.9). We obtain 
£ ( A T | / / )  =
K r r rJ “ *J (^i) ^i) (5.A2.10)
7=1 SjO-i ^
where Sj = {(-«>,- C j ) v ( - l j 9lj)yj(Cj,°o)} for 7 = 1,2,
rt = {(-q.-ZjOuC//,^)} for i = 1, 2, . . . , K - l ,  gM(x) is a normal density with 
mean nfi' and variance ncr2, and { ( / i ,^ ) , ..., (/*-i c^l is a feasible set of
critical values for our original problem.
Comparing the RHS of equation (5.A2.10) with equation (5.2.5), we have
E(N*\fi) = -2- E ( N \ m') (5.A2.11)
n
where E(N\jl') is the expected sample size function of our original problem under 
a treatment difference of // .
From earlier we have
-2C201 o
n = ——7 n. 
a 2 8 , 2
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Substituting for n* in equation (5.A2.11) and rearranging, we obtain
=  m u ' )  (5 .A 2 . 12)
a  a 2 8 2
and dividing both sides of equation (5.A2.12) by 
(O r^ l- /? )  + 0_1(1 - a / 2)}2/^2^ 2 gives
E(N*\n) = E{N\i i)  
N f  Nf
where, by analogy with equation (5.2.4),
a  2
Nf * = + O 'H l-a /2 )}2
J s x 2
Q.E.D.
Proof of Corollary 5.3 :
(i) Substituting // = 0 in to equation (5.A2.13) gives
E(N*\n=0) = E(N\ii=0) 
N /  Nf
(ii) Substituting ju = 8 l in to equation (5.A2.13) gives
_ E(N\u =S) 
Nf * ~ Nf
(iii) Consider substituting fi' = 8{i/Sl in the expression




From Lemma 5.3, it follows that,
(pin/S^dfi J E(N\ii ) 8 ~l <p{^/8 )dfi' 
N /  ~ Nf
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6. Bayesian Sequential Methods.
6.1 Introduction.
So far we have only considered frequentist sequential designs. Many non- 
frequentists have criticised sequential analysis because it contravenes the 
likelihood principle and relies on a strict adherence to a rather inflexible stopping 
rule. A detailed outline of these criticisms is given in §6.2. In §6.3 we describe 
some sequential procedures proposed by Bayesians and Bayesian decision theorists 
and consider the frequentist properties of one of these designs. We also outline 
the main objections to non-frequentist approaches. In §6.4 we give a frequentist 
defence of sequential analysis.
6.2 The Case Against Sequential Analysis.
All the tests considered so far in this thesis have conformed to the frequentist 
or classical school of statistical inference. In line with the Neyman-Pearson 
approach to hypothesis testing these tests have been designed to satisfy the Type I 
and Type II error constraints. Although a Bayesian decision theory approach was 
employed in §§ 3.6, 4.6 and 5.6 this was not for its own sake, but rather to 
facilitate an efficient method for the computation of optimal frequentist tests.
The debate between different schools of statistical thought has been 
particularly vociferous in the area of sequential analysis. The main debate is 
between conditionalists and unconditionalists. Conditionalists conduct their 
analyses conditional on the data observed but unconditionally over the parameter 
space. Bayesian statisticians are conditionalists. Conversely, unconditionalists 
conduct their analyses conditional on parameter values but unconditionally over 
the sample space. Frequentist statisticians are unconditionalists.
Cornfield (1966) defined a sequential trial to be ‘... any form of data 
collection in which the decision to continue or discontinue further collection 
depends in some sense on the information previously obtained’ and sequential 
analysis to be ‘... any form of analysis in which the conclusion depends not only 
on the data, but also on the stopping rule.’ Conditionalists and unconditionalists 
are agreed on the economic and ethical advantages of sequential trials (described 
in §3.2). They disagree, however, on the relative merits of sequential analysis
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with some conditionalists going as far as Anscombe (1963) in believing that ‘ 
"Sequential analysis" is a hoax’.
At the centre of the argument is the likelihood principle which states that 
inferences should be based on the data observed through the likelihood function 
alone. Conditionalists accept the likelihood principle. For Bayesians, for instance, 
the principle is implicit in Bayes theorem which states that the posterior 
distribution for the parameter of interest is proportional to the product of the 
likelihood function and the prior distribution. There also exist many non-Bayesian 
arguments in support of the likelihood principle; Cornfield (1966) referenced many 
of these arguments, while Anscombe (1963) stated that ‘... the arguments in favour 
of the principle are indeed weighty’.
Berry (1987) gave two consequences of the likelihood principle:
(i) Data which was not observed should not affect inferences;
(ii) Experiments which were not conducted are irrelevant to inferences.
Much of frequentist inference runs contrary to these consequences and sequential 
analysis is no exception. To demonstrate this point we consider an example: 
Suppose we conduct a two-sided hypothesis test on the mean of a normal 
distribution (c.f. §4.2). Let , X2 , ... ~ AT(//,1) and suppose we wish test
H{~: n<  0 vs H0: // = 0 vs i / 1+: // > 0
with Type I error rate a  = 0.05 and Type II error rate p  = 0.1 at = ±0.25. 
Given that + XN) equals 2. lVA is there significant evidence to
reject the null hypothesis in favour of the alternative?
As frequentists we need further information concerning the stopping rule 
employed before being able to answer this question. For instance, was a fixed 
sample size design or a group sequential one used? If the design was group 
sequential how many interim analyses were planned and what were the nominal 
significance levels? As we saw in §4.4 the answers to these questions may lead 
us to radically different conclusions concerning the parameter fi.
Many conditionalists have strongly attacked the reliance of inferences on the 
stopping rule in sequential analysis. Cornfield (1966), for example, has said that 
‘... to most scientists without previous exposure to statistics, as well as to most 
intelligent laymen, any dependence of conclusions on stopping rules ... seems like 
a violation of common sense.’ Discussing a similar example Berry (1987)
- 145 -
remarked that *... it flies in the face of what is generally perceived of as science.’
The emphasis on significance levels in our example demonstrates that 
sequential analysis is inconsistent with consequence (i) of the likelihood principle. 
For a significance level is the probability under the null hypothesis of observing 
something at least as extreme as the observed test statistic (see § 7.4) and hence is 
dependent on what was not observed in addition to what was. Anscombe (1963) 
criticized significance levels as being ‘... strictly irrelevant and possibly 
misleading’ in the context of a clinical trial. He argued further that ‘... consequent 
inferences, beliefs and actions will be perhaps much affected by what was not 
observed, by all the rest of the sample space besides the point in it’ and concluded 
that ‘... absurdity can (and in the present case certainly will sometimes) result.’
Conditionalist criticism of sequential analysis is not confined to its 
contravention of the likelihood principle. On a less philosophical, more practical, 
level Berry (1987) and Freedman & Spiegelhalter (1989) have attacked the 
inflexibility of sequential designs. For example suppose we are conducting a 
clinical trial and we cross a stopping boundary while there are still some patients 
entered on to the experiment who have not yet responded. What should be done 
with the data which will ultimately result from these patients? Frequentists 
following their strict stopping rules cannot use this data directly. Bayesians, on 
the other hand, can easily incorporate these additional responses into their 
posterior distributions and therefore their analyses.
Further the decision to stop a clinical trial is a complex one and, although a 
difference in treatments is obviously important, other factors have to be taken into 
account. Berry (1985), Berger & Berry (1988) and Freedman & Spiegelhalter 
(1989) have wondered what a frequentist would do in the event of an experiment 
being stopped because, for example, one of the treatments is causing undesirable 
side-effects or because a new treatment with a seemingly better success rate has 
been developed. The Bayesian can take the data from such an experiment at face 
value, the frequentist, however, is faced with a problem because his stopping rule 
has been infringed.
Berry (1985), (1987) has pointed to the difficulty many non-statisticians 
experience in understanding significance levels. He suggested that many 
incorrectly regard a P-value as the probability that H0 is true. This is worrying, 
for as Berger & Delampady (1987) have shown for a fixed sample size test, even
- 146 -
with a Bayesian analysis based on a noninformative prior distribution the 
probability of H0 being true may exceed 0.5 when the corresponding P-value is 
smaller than 0.05. Berry (1987) also pointed out that many researchers have 
trouble in understanding why it is necessary to adjust critical values in order to 
compensate for multiple looks at the data. Accordingly they often do not adjust 
critical values. He argued that such an informal approach to interim analyses is 
more in line with the Bayesian approach where the data may be analysed as often 
as one likes without affecting any inferences made. Berry (1987) called for the 
‘... eradication of P-values and significance tests from statistics’ and the adoption 
of more flexible and easily understood Bayesian methods.
Geller & Pocock (1987), Hughes & Pocock (1988) and Freedman & 
Spiegelhalter (1989) have pointed to the difficulty the frequentist experiences in 
calculating an unbiased point estimate for the parameter of interest following a 
sequential experiment. Geller & Pocock also pointed to the difficulty in 
constructing confidence intervals. A review of the literature on estimation 
following a sequential experiment is given in § 7.4. We note here, however, that 
a Bayesian can easily obtain point estimates and confidence intervals from his or 
her posterior distribution.
Geller & Pocock (1987) listed a number of unresolved problems in sequential 
analysis. These include how to proceed when more than two treatments are to be 
compared and how to specify a single clinical endpoint of interest. They also 
discussed other problems relating to the inflexibility of sequential stopping rules 
such as how to conduct an unplanned or a retrospective interim analysis.
We also note two often heard criticisms of sequential analysis and frequentist 
inference in general: the arbitrariness involved in choosing the error rates, a  and 
P, and the failure to incorporate prior information into any analysis even when a 
large body of data may be available from Phase I and Phase n  trials and previous 
studies.
Many frequentists, notably Armitage (1963), have hit back at the main 
criticisms expressed here. We shall give a defence of sequential analysis in §6.4.
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6.3 Bayesian and Bayesian Decision Theoretic Approaches.
A number of Bayesian and Bayesian decision theoretic approaches have been 
proposed in the literature. Here we describe 3 of these approaches and consider 
the frequentist properties of one of them.
Mehta & Cain (1984), Berry (1985) and Freedman & Spiegelhalter (1989) 
have suggested similar procedures where the decision to stop or to continue at 
each analysis is made on the basis of the current posterior distribution for the 
parameter of interest. For example, consider a clinical trial to compare the 
relative efficacies of two treatments, A and B. A maximum of K  groups of n 
pairs of patients are entered on to the trial with the treatments being randomly 
assigned within each pair. Suppose Xj represents the difference in response 
between treatment A and treatment B for the y'th pair and that Xj ~ N(p,G2) with 
a 2 known. Further let the a priori distribution of p  be normal with mean p0 and 
variance g 0 2 . Some simple algebra gives the current distribution of p at stage i 
which is also normal with mean
m
a 2 p0 + g 0 2 ni X  Xj
to = --------2------- —g  + a0 m
and variance
1 2  2  •  * g z + Gq m
The stopping rule of Freedman & Spiegelhalter (1989) is of the general form: 
At analysis i (i = 1, 2 ,. . . ,  K), we stop sampling and conclude that treatment A is 
superior if
P r(//>A A|X ! X J  > 1- f i . (6.3.1)
Similarly we stop sampling and conclude that treatment B is superior if
Pr (/* < , . . . ,  Xin) > l - £ .  (6.3.2)
Here e is suitably small (for example, e -  0.05 or 0.025) and (A5,Aa ) is the 
range of treatment differences for which the experimenter considers A and B to be 
equivalent. (Freedman & Spiegelhalter (1983) described a method for eliciting Aa 
and Ab from clinicians).
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If, for i < K, neither inequality (6.3.1) or (6.3.2) is satisfied, the next group of 
n pairs of patients is entered on to the experiment The trial is terminated at the 
Kth analysis with the posterior distribution for /z summing up the experimenter’s 
current beliefs about the actual treatment difference.
It is easily shown that the stopping rule of Freedman & Spiegelhalter is 
equivalent to stopping to conclude that treatment A is superior when
m
Sin = X Xj > AA 
7=1 ni<702
& 2 Mo <h_ 1 ( l —£ )  I— 5---- !5 O---------- T-— T + -----— ^ G 2G02(G 2+niG02) (6.3.3)
mcF02 ni<r02
and stopping to conclude that treatment B is superior when
.2m
Sin “  X  ^7' <
7=1 ni<jQ2
G Mo ^(1—£) I 5 2 7 2 " 2 \ f£. o a\ —-Z----------— :— y c r 2G02(G 2+niG02) . (6.3.4)
niGQ2 ni<jQ2
As can be seen, these boundaries are symmetric about zero when AB = -A a and 
Mo = 0.
The test proposed by Berry (1985) is a special case of the above method with 
Aa = A# = 0 and prior mean /z0 = 0. From (6.3.3) and (6.3.4), the Berry test 
stops to conclude that treatment A is superior when
2s in > ^ c r2<j02( ( j2+ni(j02)TIIGq
and stops to conclude that treatment B is superior when
2Sin < ~ ^  ^  V<T2G02(G 2+niG02).niGQ
Following McPherson (1982), Berry considered cr02 equal to 0.01 and 0.04.
It is interesting to consider the frequentist properties of the above Bayesian 
procedure. We concentrate on 4 designs considered by Freedman & Spiegelhalter 
(1989), with K  = 5, n = 20, g 2 — 0.5 Aa = AB = 0, e -  0.025 and 
G02 = G 2/n 0 , where n0 = 8, 22, 89 and 800. The different values of n0 in each 
design correspond to differing prior beliefs about //. For example with hq = 8 
these beliefs are diffuse while with n0 = 800 the beliefs are quite concentrated 
around fi = 0. Table 6.1 gives the Type I error, or, the Type II error at 
// = ±0.25, $  and the expected sample sizes under fi -  0 and /z = ±0.25, with 
their corresponding minima given underneath in parentheses, for the 4 designs. 
-Also displayed is the working value of £, £q.05» which would be necessary to give 
a test of size 0.05 for each example.
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Table 6.1. The Type I error, a, Type II error at n = ±0.25, 0, expected sample 
sizes under y, = 0 and fi = ±0.25, together with their corresponding minima in 
parentheses, and the value of e, £0.05’ required to give a test with Type I error 
0.05 for the designs of Freedman & Spiegelhalter (1989) with K  = 5, n = 20, 





a 0.098 0.059 0.010 0.0















e 0.05 0.013 0.022 0.061 0.247
For n0 = 800 the minimum expected sample sizes under // = 0 and 
fi = ±0.25 were not calculated.
From a frequentist perspective Table 6.1 shows some worrying features. 
Designs with n0 "small" (<702 "large") give rise to tests with narrow boundaries 
and, consequently, high Type I errors. For example when n0 = 8 (cr02 = 0.0625) 
the Type I error is (X = 0.098. Obviously for smaller values of nQ, CL will be even 
larger.
Conversely designs with nQ "large" (<702 "small") give rise to tests with wide 
boundaries, low Type I errors and high Type II errors. For example, when 
n0 = 800 (<r02 = 6.25xl0-4) it is almost certain that we will accept the null
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hypothesis regardless of the actual treatment difference. Of course with such a 
precise prior distribution it is unlikely that an experimenter would ever conduct a 
clinical trial.
For certain choices of n0, however, it is possible to obtain a test with 
acceptable size and power under // = ±0.25.
The tests of Freedman & Spiegelhalter (1989) are all very close to optimal in 
terms of minimizing the expected sample size under // = 0 and ^  = ±0.25. 
Indeed they are never more than one percent of the fixed sample size from the 
overall minima. Of course, if we compared the expected sample sizes under 
li -  0 with the minima for inner wedge tests the results would be less impressive. 
A Bayesian inner wedge test could be constructed by stating a range of 
equivalence (AB ,Aa ) and stopping early to accept H0 if
Pr (AB < ^  < Aa | X j, . . . ,  Xin) > 1 —£
for suitably small e. Not only would such an approach improve the efficiency of 
the Bayes procedure under n  = 0, but it may lead to designs like the one with 
jiq = 800 being abandoned before any patients are admitted on to the trial.
The final row of Table 6.1 shows the value of £, £0.05’ required to give a test 
of size a  = 0.05. For instance, when Hq = 22, e0 05 = 0.022. However when 
n0 = 800 it is necessary to consider £0 05 as large as 0.247 in order to compensate 
for the concentrated prior distribution. It is very interesting to note that to obtain 
a test with Type I error 0.05 and power 0.9 at /^  = ±0.25 it would be necessary to 
choose nQ = 1.786 (or <j02 = 0.28) and e0 05 = 0.009.
Freedman & Spiegelhalter only considered designs with K  = 5. A number of 
frequentists, most notably Armitage (1963), have questioned the effect on error 
rates of increasing K  without adjusting critical values. Table 6.2 gives Ct and 0  for 
the 4 designs of Freedman & Spiegelhalter with K  = 5, 10, 50 and 100.
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Table 6.2. The Type I error, Ot, and the Type II error at n -  ±0.25, /J, for the 
designs of Freedman & Spiegelhalter (1989) with nK = 100, Aa = AB = 0, 





a 5 0.098 0.059 0.010 0.0
10 0.122 0.071 0.017 0.0
50 0.166 0.095 0.015 0.0
100 0.179 0.101 0.016 0.0
0 5 0.052 0.071 0.188 0.990
10 0.046 0.065 0.179 0.990
50 0.038 0.055 0.162 0.989
100 0.036 0.052 0.157 0.989
The pattern that emerges from Table 6.2 is clear; increasing K  without 
adjusting the critical values of the stopping rule increases both the size and power 
of any given test. Frequentist concerns about sampling to a forgone conclusion 
(see Armitage et al. (1969), Armitage & McPherson (1971)) are supported by 
Table 6.2. For example, with n0 = 8, the probability of making an error of the 
first kind has increased to 0.179 with 100 analyses. Cornfield (1966) suggested 
that one way of overcoming these problems is to assign a mass of prior 
probability at fi = 0 and fi = ±0.25. Freedman & Spiegelhalter (1989) do not 
discuss this option.
In addition to the possibility of sampling to a forgone conclusion certain 
other criticisms have been voiced over these Bayesian designs. Jennison & 
Turnbull (1989), in response to the discussion of their read paper on repeated 
confidence intervals, have expressed dissatisfaction at the fact that the designs 
require no explicit specification of the ethical and economic costs of admitting 
patients on to a clinical trial. Jennison & Turnbull were also unconvinced about
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the wiseness of specifying a prior distribution for the parameter of interest. They 
pointed to a series of studies conducted by Gilbert, McPeek & Mosteller (1977)
the experimental treatment. Even with the example discussed above where a 
normal prior with zero mean was used, a degree of subjectivity is still necessary in 
specifying the prior variance.
The second approach we consider was first proposed by Anscombe (1963) as 
an alternative to the frequentist designs of Armitage (1960). Anscombe 
considered the usual model with n pairs of patients available for comparing the 
relative efficacies of two treatments, A and B. The difference in response 
between the zth patient on treatment A and the ith patient on treatment B is 
denoted by Xt (i = 1 , . . . , / i ) .  The X;’s are assumed to be independent and 
normally distributed with unknown mean /z and unit variance. Following a 
Bayesian approach, n  is assigned an improper uniform prior distribution.
The Anscombe approach differs from those considered so far in that it 
assumes that a total of N  patients will have their course of treatment affected by 
the trial - either by being entered on to the experiment or by having their 
treatment regimen determined by the results of the trial. After the n pairs of 
patients on the trial have responded we can identify two sources of loss:
i) that arising from n patients receiving the inferior treatment in the clinical trial;
ii) that arising from a wrong decision being made at the conclusion of the trial and 
N - 2 n  patients receiving the inferior treatment
Anscombe argued that both types of loss should be proportional to the actual 
treatment difference fi. Letting x -  X x + X2 + ... + Xn he suggested that loss (i) 
should equal n £ [ |/z |]  and loss (ii) should equal (N-2n) £[max(0,-sg«(jt)/z J. 
Then, as a function of n and x, the total expected loss, R (n ,x ), equals
and the aim is to minimize this loss. Anscombe claimed that to obtain an optimal 
Bayesian solution to this problem would be ‘... possible in principle, if difficult in 
practice, requiring a formidable "backwards induction"’ and he suggested an easy 
to compute near optimal procedure as an alternative. Day (1969) and Chemoff & 
Petkau (1981) have both used dynamic programming to compute the Bayes test 
for this problem and for a group sequential analogy respectively.
where the prior feelings of the clinicians were too optimistic about the efficacy of
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Frequentists have attacked the Anscombe model because of the difficulty 
involved in specifying N  and because of the use of a prior probability distribution.
A third approach is due to Berry & Ho (1988). They considered using 
Bayesian decision theory to obtain a procedure for deciding between a new 
treatment and a control. Their set up is rather different from those we have 
considered so far in that acceptance of the new treatment is only allowed at the 
final stage. The motivation for such a design is that when early results point to 
the superiority of the new treatment testing should continue in order to monitor its 
safety. In §7.3 we will outline the frequentist version of this problem and extend 
our method for the computation of optimal tests to cover it. We now give a brief 
summary of Berry & Ho’s method:
As with earlier problems suppose we have a maximum of K  groups of n pairs of 
patients and that Xt (i = 1 , 2 , ,  nK) denotes the difference in response between 
the patient on the new treatment and the patient on the standard in pair i. It is 
assumed that the X,’s are independent and normally distributed with unknown 
mean p  and known variance c 2 and we wish to decide between
D0: p < 0  and Dl : p > 0 .
Berry & Ho assumed that a priori p  is normally distributed with mean <?0 
and variance r02* They further assumed that a unit sampling cost is incurred for 
each patient entered on to the trial. They suggested a suitable loss function was 
given by: L(D0 , p ) = 0 with L(Dl ,p )  = -M p  for p > 0 and L(Dl ;p ) = L for 
p  < 0. Here M  and L are positive constants under the control of the 
experimenter. The Bayes test for this Bayesian decision problem is computed by 
dynamic programming (c.f. §3.8). Further details of the dynamic programming 
algorithm are given in Berry & Ho (1988).
Frequentist criticisms of this procedure concern the difficulties involved in 
eliciting prior distributions and loss functions from clinicians. To define a loss 
function over the parameter space would seem to be a very complicated task. It is 
difficult to see how such a loss function could be arrived at without the 
introduction of some arbitrariness.
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6.4 A Defence of Sequential Analysis.
In §6.3 we gave a number of frequentist criticisms of other inferential 
approaches to sequential experimentation. We now proceed to defend frequentist 
sequential analysis and, in particular, our optimal group sequential tests. During 
the course of this defence we will address many of the Bayesian criticisms 
outlined in §6.2.
One of the main conditionalist criticisms of sequential analysis in §6.2 
concerned its contravention of the likelihood principle. It is worth underlining the 
point made in §§ 3, 4 and 5 that our optimal group sequential tests are not only 
feasible and efficient from a frequentist perspective, but also Bayes tests for a 
suitable choice of prior distribution, cost function and loss function. Moreover, 
the decision to stop or continue sampling at each stage for the Bayes tests is made 
on the basis of the current distribution for the parameter of interest. It follows 
that the Bayes tests are in accordance with the likelihood principle.
Many of the other frequentist group sequential tests suggested in the literature 
are close to Bayes tests for a suitable decision theory problem. Freedman & 
Spiegelhalter (1989) have shown that, for a suitable choice of prior, the stopping 
rules for their Bayesian procedures are similar to the two-sided tests of Pocock 
(1977) and O’Brien & Fleming (1979). Jennison (1990) pointed to the work of 
Brown, Cohen & Strawdermann (1980) who proved that "admissible" frequentist 
tests are Bayes tests for a suitable choice of decision problem, and suggested that 
‘... good frequentist and Bayes stopping rules should not be too dissimilar.’
Much was made in §6.2 concerning the inflexibility of frequentist stopping 
rules. A good deal of recent research has been devoted to producing more flexible 
procedures. In §3.12 we saw that Lan & DeMets (1983) and Jennison (1987) 
have proposed methods for dealing with unpredictable group sizes and numbers of 
analyses. Our own approach, again outlined in §3.12, attempts to preserve 
optimality while introducing flexibility and is a useful addition to this area.
As was seen in §4.12 Jennison & Turnbull (1984), (1989) have proposed a 
highly flexible procedure called the Repeated Confidence Interval (RCI) method. 
The RCI method enables frequentist inferences to be made even when a trial is 
stopped for reasons other than the crossing of a stopping boundary. Inferences, 
then, are still valid if the trial is stopped because, for example, one of the 
treatments shows unforseen side-effects.. Further it is possible to alter our
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hypotheses during the trial if desired without invalidating inferences. The method 
is easily generalized to the one-sided testing problem. Jennison & Turnbull based 
the calculation of their RCIs on the tests of Pocock (1977) and O’Brien & 
Fleming (1979). A highly efficient as well as flexible procedure could be 
obtained by basing the calculation of RCIs on an optimal test
All the tests we have considered so far have been for normal responses with 
known variance. However simulation studies by both Pocock (1977) and Gould & 
Pecore (1982) have shown that group sequential tests are quite robust to 
departures from both the normality and known variance assumptions. In §7.2 we 
shall consider the generalization of our efficient method for the computation of 
optimal group sequential tests to other distributions.
Criticisms relating to estimation following a sequential test are genuine. 
Research continues in this important area. A review of the literature on estimation 
is given in §7.4.
Conditionalist criticisms concerning the arbitrariness involved in choosing the 
error rates of a test are, to some extent, valid. However frequentist methods are 
not alone in containing a level of arbitrariness and we would advocate the use of 
power calculations at the design stage of any trial in order to decide on an 
appropriate stopping rule and maximum sample size.
Finally we feel it is unfair to argue that frequentists never make use of strong 
prior information when it is available. For example Hughes & Pocock (1988) 
have suggested employing a Bayesian approach to calculate point estimates for the 
parameter of interest following a sequential trial. Also Jennison (1986) advocated 
the use of prior distributions in the design of optimal frequentist tests for the 
bioequivalence problem (see §5.11).
It is perhaps appropriate to end this section with a quote from Anscombe 
(1963) who is very critical of the tests proposed in the book by Armitage (1960), 
but states that the book’s ‘... net effect on medical research will almost certainly 
be good, ... partly because any consideration of sequential designs encourages 
flexibility.’
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7. Further Work and Other Topics. 
7.1 Introduction.
In §7 we consider some suggestions for further work as well as briefly 
mentioning some topics in sequential analysis which have not been looked at so 
far.
In §7.2 we consider the extension of our efficient method for the 
computation of optimal group sequential tests to non-normal responses. In Phase 
II clinical trials it is usually appropriate to consider Bernoulli responses to 
treatments and we propose an approach for computing optimal tests for this 
problem.
In §7.3 we look at the problem considered by Berry & Ho (1988) where a 
new treatment is tested against a standard with early stopping only being permitted 
for the rejection of the new treatment. Berry & Ho considered this problem from 
a Bayesian perspective. We propose extending our method of §§ 3.6-3.8 to obtain 
an efficient method for computing optimal frequentist tests for this problem.
The calculation of P-values, confidence intervals and point estimates 
following a sequential trial is considered in §7.4. Finally, in §7.5, we review the 
literature on stochastic curtailment and its Bayesian counterpart based on 
predictive power.
7.2 Optimal Group Sequential Tests for Non-Normal Data.
So far we have only considered group sequential tests for normal data. With 
group sequential procedures we deal with sums of random variables and so we 
might expect our tests to be robust to departures from normality (by the Central 
Limit Theorem) and the known variance assumption. Simulation studies 
conducted by Pocock (1977) and Gould & Pecore (1982) have demonstrated this 
robustness. Another possibility, suggested by Armitage (1975), is to transform 
non-normal data by taking logs, for example, to facilitate the use of tests designed 
for normal responses.
We have not carried out any studies into the robustness of our own optimal 
group sequential tests. However, on the basis of the work of both Pocock and 
Gould & Pecore, it would seem reasonable to assume that they are fairly robust.
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Our method for computing optimal group sequential tests is easily 
generalized to cases where the data is non-normal. Of particular interest are 
optimal group sequential tests for the binomial distribution. Fleming (1982) and 
Chang, Themeau, Wishart & Cha (1987) considered Phase II trials for anticancer 
drugs. The emphasis in Phase II trials is on screening; we wish to decide whether 
a drug is ineffective and should be discarded or whether it merits further 
investigation in the form of a Phase III trial. In the case of anticancer drugs 
interest typically centres on the parameter p  termed the "regression probability" 
which, according to Chang et aL, is ‘... the probability an eligible patient receiving 
the treatment will experience a tumour regression as precisely defined in the 
protocol’.
Following the notation of Chang et al. (1987) we suppose that a maximum of
N  patients are available for entry on to our Phase II trial. Further let Xt
(i = 1,...,A0 be the random variable representing the response of the ith patient. 
Then the Xf’s are independent Bernoulli random variables with success probability 
p (0 <p<  1), i.e.
Pr(X,- = 1) = p, Pr(X,- = 0) = 1-p.
We consider testing
H o ' P = P o  H i - P = P i
with error probabilities
Pr (.% | p =p0 ) = a  (7.2.1)
P f M o lp ^ i )  = fi (7-2.2)
Here p0 < p x, and and denote the acceptance of H0 and Hl respectively.
Acceptance of H0 would lead us to abandon our investigations into the drug, 
while rejection of H0 in favour of Hl would lead to further studies into the drug’s 
efficacy. Because of the discrete nature of the binomial distribution it will not, in 
general, be possible to obtain stopping rules satisfying (7.2.1) and (7.2.2) exactly. 
Chang et ah suggested that, instead, we should consider tests with Type I error at 
most a  and Type II error at most p.  We shall term such tests "feasible".
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The economic and ethical arguments put forward in §3.2 for introducing 
group sequential designs into Phase HI clinical trials are equally valid for Phase II 
trials. So we shall consider a maximum of K  groups of sizes 
nl ,n 2 -  nx , . . . ,  nK -  nK_x for the above testing problem and stopping rules of 
the form:
At analysis i (1 < i < K - 1),
n;
if £  Xj > bi stop sampling and accept / / j ;
7=1
if 2  Xj < at stop sampling and accept H0\ 
y=i
«<■
if aL < £  Xj < bi continue sampling.
7=1
At analysis K ,
nK
if £  Xj > aK+ 1 stop sampling and accept H i;
7=1
nK
if 2  Xj < aK stop sampling and accept H0.
j= l
Here -1  < at < bt < n{+ 1 (i = 1 , . . . ,  K).
The frequentist properties of our stopping rule may be calculated numerically. 
Equations (7.2.3), (7.2.4) and (7.2.5) give the Type I error, a, Type II error, /?, 
and expected sample size under p , E(N\p), respectively. To ease notation we let 
rrij denote the number of observations in the yth group, i.e. ntj = rij-n j_i 
(y = 2 ,. . .  ,K) and mi = nx.
a  = £ f  £  £  ... E  PtP'(S n -S n h =ij-ij_l ) . . .r r po(Sni=i1)) (7.2.3)
y'=l ij-bj ij-i =fly_i +1 ijsfli + 1
/ = £ (  £  £  ... £  Prpi(Sn - S n._l =ij-ij_1)---PrpS S n =il ))U .2A )
7 - 1  i j —d j - i  + 1  i j - i - d j - i  +  1 i ' i - f l i  +  1
E{N\p) = £  { £  1 ... V  * ,< V - V i  =*7-*7-l)-Prp(5n1 =/i)J (7.2.5)
7= 1  iyG/; iy-i =^7-! +1 l l= f ll  +  l
Here r;- = {(0,a;-)u(fy,«,-)}, for y = 1 ,2 , . . . , /sT, and the distribution of -  5 
(y = 2 , . . . ,  AT) is binomial with parameters and p.
Chang et al. (1987) considered the computation of optimal group sequential 
binomial designs. For instance they considered computing the feasible test which 
minimizes E(N\pQ) + E(N\pi). They noted that the so called exhaustive
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approach to this problem (which considers all possible designs) is both 
computationally inefficient and expensive. For example (see Chang et al. for 
further details) with p 0 = 0.3, p\ = 0.5, K  = 3, /ij = 20, n2 = 15, n3 = 15, 
a  = 0.05 and ft = 0.2, over 300 000 designs have to be considered. Chang et al. 
laid down a number of constraints which must be satisfied by the optimal test, and 
by so doing reduced the number of tests that need be considered to just 15 000.
Clearly it is possible to extend our efficient method for the computation of 
optimal group sequential tests for normally distributed data to binomially 
distributed data. This is achieved by considering the following family of problems 
in Bayesian decision theory:
Suppose there are a maximum of K  groups of sizes m1,m2,. . . ,m ^  of 
independent Bernoulli random variables with success parameter p  available for 
making a decision between:
D0 :p = p 0 and D1: p = p x.
The common prior distribution for p  is given by jc(p q ) = x (P \ ) = 1/2 with 
7r(p) = 0 otherwise, while the common cost of sampling function is given by 
c(Po) = C(P\) = 1 with c(p)  = 0 otherwise. Individual problems within the 
family differ in their loss functions, L(D,p),  which are indexed by a pair of 
parameters, dQ (>0) and ^ (> 0 ) . The general form of L(D,p)  is given by : 
L(Di ,p0) = dQ and L(D0,p1) = dit with L(D,p)  = 0 otherwise.
Suppose for the moment that dQ and dx are fixed and consider a general 
decision rule for the above problem, (B. The general form of (B is given by:
At analysis i (1 <* < ^ -1 ),
«.•
if ^  Xj > bi stop sampling and make decision Dj 
7=1
if ^  Xj < a,- stop sampling and make decision D0 
7=1




if 2  Xj > aK+ 1 stop sampling and make decision D\
7=1
nK
if 2  Xj < aK stop sampling and make decision D0.
7=1
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The risk of ©, r('B,d0,dl ), is defined as the sum of the total expected 
sampling cost plus the total expected loss through making a wrong decision. That 
is,
r iV 'd o ,^ )  = c(p0) E(N\p=p0) n(pQ) + c(pj) E(N\p=p{) K{p{)
+ dQ PrC^o \p=Pi) 7t{p\) + dx P r(^  \p=pQ) 7c(p0)
The Bayes decision rule for our problem, ©*(d0>d1), minimizes this risk over 
the set of all decision rules. We can compute ©*(^0, ^ )  by dynamic 
programming. (We omit details of the dynamic programming algorithm, which is 
a discrete analogy of that for normally distributed data.) Using numerical 
integration we can calculate the errors of ©*(^0,^ ) .  Suppose these errors are 
given by
PrCZ  ^\p=p0) = 8
and
Pr(D0 \p=Pi) = 0,
then clearly
r(©*(</0 »<*i) = ■ j | £ (^Ip=Po) + E{N\p=px) + d0 8  + dx ^ | .
It follows from the definition of the Bayes rule that there can be no other 
decision rule with errors 8  and 0  which attains a lower value of
E(N\p=p0) + E(N\p=p1). By searching over (d0,di) we obtain the feasible test 
which minimizes E(N\p=p0) + E(N\p=Pi).
The main problem with this approach concerns the search over (d0 ,di) to 
obtain a loss function leading to a Bayes test with the required errors. The 
discreteness inherent in our problem means that if we consider a plot of 8  as a 
function of dQ,di we observe a 2-dimensional step function. Similarly a plot of 0  
as a function of d0 and d± would also give a 2-dimensional step function.
However we note that if we fix d0 and increase di then 8  decreases
monotonically. Also if we fix dx and increase d0 then 0  decreases monotonically.
Hence the problem of searching over dQ and dx for the Bayes test with the 
required error rates can be reduced to a series of one-dimensional bisection 
searches.
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As was mentioned earlier, we do not have any results for this proposal. A 
study of it would be worthwhile in order to determine whether, and if so by how 
much, it is more efficient than the approach of Chang et al. (1987).
7.3 The Problem of Berry &  Ho.
Berry & Ho (1988) introduced a Bayesian group sequential procedure for 
comparing an experimental treatment with a standard. The problem they 
considered differed from the one in §3 in that early stopping was only permitted 
for the acceptance of H0 (i.e. the standard treatment is no worse than the 
experimental). Rejection of H0 was only allowed at the final analysis. Such a 
design is attractive as it attempts to stop trials involving unpromising experimental 
treatments as quickly as possible, while it allows trials involving promising 
experimental treatments to continue so that secondary issues may be analysed.
Clearly our improved method for the computation of optimal one-sided group 
sequential tests given in §3 can be extended to this problem. We shall now 
describe this extension: Suppose a maximum of K  groups of n pairs of patients are 
available for entry on to a trial and that Xh the difference in response between the 
ith patient on the new treatment and that on the standard, is normally distributed 
with unknown mean // and known variance a 2. We wish to test
H0: fii<0 vs Hl : fi>  0
with error rates
PrC^I// = 0) = a  (7.3.1)
and
PrCflol// = S) = p. (7.3.2)
Our stopping rule is of the form:
At analysis i (1 < i < K - 1),
if Sin < ct stop entering patients on to the trial and accept H0;
if Sin > Cj enter the next group of n pairs of patients on to the trial.
At analysis K,
if SKn < cK stop entering patients on to the trial and accept H0; 
if SKn > cK stop entering patients on to the trial and accept Hx.
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Clearly, under // < 0, we would like to stop the above experiment and accept 
the null hypothesis as soon after the start of the trial as possible. Consider, for 
example, the minimization of objective function F1: E(N\fi=0) over feasible 
stopping rules of the above form. Below we describe how our improved method 
for the computation of optimal one-sided group sequential tests can be extended to 
this problem.
Consider the following family of problems in Bayesian decision theory:
For the clinical trials problem described earlier we are interested in choosing 
between
D0 : ji<  0 and Dx: fi>  0.
Our family of problems has the common prior distribution for // given by: 
;r(0) = k{8 ) = 1/2 with n(/i)  = 0 otherwise, and the common cost of sampling 
function is given by: c(0) = 1 with c(fi) = 0 otherwise. Individual problems 
within the family differ in terms of their loss functions, L(D;fi), which are 
indexed by a pair of parameters d0 (> 0) and dx (> 0). The general form of 
L (D ,n)  is given by L(DX ,0) = dQ> L(D0 ,8 ) = dl with L(D \fi) = 0 otherwise.
Suppose for the moment that d0 and dl are fixed and consider a general 
decision rule for this problem, rB. The general form of (B is given by:
At analysis i (1 <i < K -1),
if Sin < ct stop entering patients on to the trial and make decision
A »
if Sin > Ci enter the next group of n pairs of patients on to the trial.
At analysis K,
if SKn < cK stop entering patients on to the trial and make decision
A>;
if SKn > cK stop entering patients on to the trial and make decision
A-
The risk of fB, r((B,d0 ,di), is defined as the sum of the total expected 
sampling cost plus the total expected loss through making a wrong decision. That 
is
r(®,c?0^ i )  = c(0)E(A |^=0)^(0) + </0 Pr(A l/*=0)*(0) + dx Pr{D0 \fi=S) tu{8 ).
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The Bayes decision rule for this problem, (B*(d0 ,d i), minimizes this risk 
over the set of all decision rules. We can compute by dynamic
programming (details are omitted although, clearly, the algorithm is similar to 
those described in earlier sections). Using numerical integration we can calculate 
the errors of Suppose these errors are given by
Pr(Dx | // = 0) = a
and
Pr(D0 \fi =  S)  =  0
then clearly
r(®*(</0,*/1),40,d1) = y  + d0 & + dx 0 }.
It follows from the definition of the Bayes rule that there can be no other decision 
rule with errors Ct and 0  which attains a lower value of F1. By searching over 
we obtain a pair of loss parameters, (d0 a^\ d i ^ ^ )  giving rise to a Bayes 
decision theory problem with an associated Bayes rule, with
errors a  and p. It follows that
rCB*(d^a\ d x^ ) , d ^ a\ d ^ )  = ^ { F l + d0W  + d!<«},
and from the definition of the Bayes decision rule there can be no other decision 
rule with errors a  and 0  which attains a lower value of F1 . By equating decisions 
D0 and D l with stopping to accept the hypotheses H0 and Hl we have computed 
the optimal feasible test for our original frequentist problem.
As was made clear in §6.3 there is an increasing emphasis on designs like 
the one considered in this section. There is a strong case to be made, therefore, 
for future research into optimal frequentist tests for this problem. It would also be 
a useful exercise to compare the attained error rates and expected sample sizes of 
our optimal tests with those of the tests proposed by Berry & Ho.
7.4 P-Values, Confidence Intervals and Point Estimation 
Following a Group Sequential Experiment
This thesis has concentrated on designs for group sequential hypothesis tests. 
It would be misleading to pretend that at the end of a clinical trial a simple
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decision to accept or reject the null hypothesis is all that is required. Point 
estimates and confidence intervals for the parameter(s) of interest and P-values 
(also known as observed significance levels) will also be of use in any statistical 
analysis. In a fixed sample size study inferences are made conditional on the 
sample size. In a sequential experiment the parameter of interest can substantially 
influence the final sample size and so it would be inappropriate to make 
inferences conditional on this sample size. Hence a range of new methods have 
been developed and proposed in the literature. All of these methods relate to 
inferences after a one-sided or two-sided hypothesis test.
We begin by considering P-values:
P-values.
A P-value is defined as the probability under the null hypothesis of observing 
something at least as extreme as the observed test statistic. Hence a P-value is a 
useful summary of just how likely the observed data is under H0. In a sequential 
setting the main problem when calculating P-values comes in defining what is 
meant by "at least as extreme as the observed test statistic". Suppose our
in
experiment stops at the zth analysis (1 < i < K) and that Sin = £  Xj is equal to x.
7=1
Then for the two-sided testing problem with no inner wedge Madsen & 
Fairbanks (1983). defined a P-value to be the total probability under /z = 0 of 
stopping and rejecting H0 at analysis j  (j  < i ) and of stopping at analysis i with 
|sj >x, i.e.
2  ^od^n l < C1 ’ •” ’ <Cj- l  ’ ~ Cj )
7=1
+ < C1 . • • • 'l5(i-l)/ll<ci-l
The probabilities in the above expression can be expressed in terms of multiple 
integrals and calculated numerically (see Appendix 5.1). Of course if / = K and 
x = ±cK the P-value is exactly a.
For one-sided tests we define a P-value to be the probability under 
fi = - S  {n = S) of stopping and rejecting H{~ ( H^ )  at analysis j  (j  < i ) and of
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stopping at analysis i with Sin > x, i.e. (under H1 ) the P-value is given by
2  <  c l » ••• » I I <cj - l  » Sjn -  cj )
7=1
+  P r - * ( | S j  <  C l , . . .  , | 5 ( i _ i ) n l  < C i - l  .  Sin > X ) .
Clearly, if i = K and x  = 0, the P-value is exactly a.
Confidence Intervals.
A 100(l-a)%  confidence interval (Cl) for /z is defined to be a set of 
parameter values within which the true value n  lies with probability (1 -a). We 
note that the calculation of a fixed sample size 100(1 -a)%  Cl following a group 
sequential experiment is invalid.
Tsiatis, Rosner & Mehta (1984) have suggested the following approach for
constructing a 100(1 ~a)%  Cl for ji after a sequential test: Suppose our test stops
at analysis i and that the corresponding sum of observations is Sin. Then we term 
the pair ( i , Sin) the stopping time of the test There is obviously a set of 
possible stopping times {(/,£,„): 1 < / < AT} and the first stage in constructing a 
Cl is to order these times. Tsiatis et al. suggested the following (ascending) order 
of stopping times:
(1 ,- ° ° ) ,. . . ,  (1,-Cj),
(2,-oo), . . . ,  (2, - c2),
( K - oo) , . . . , ( K , - ck ) , . . . ,  { K , ck ) , . . . ,  { K , o o ) ,
( l ,c x) , ... , (l,°o).
We use the notation (i,Sin) > (i' ,Sin ) to denote the fact that (/,£,„) is at 
least as large as (i ',S in'). For an observed stopping time (i ,Sin ) and given 
values of and f.i2, we can calculate
>  (*' >s in ) )
and
VrM2((i,Sin) < ( i \S in')).
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Using numerical integration and the bisection search method we obtain ^  and fx2 
such that the above probabilities both equal a/2. Then *s a 100(1 -a)%
Cl for n. The above approach may be used for both one-sided and two-sided tests 
without an inner wedge. The ordering of stopping times when an inner wedge is 
present has not been discussed in the literature.
We note that Jennison & Turnbull (1983) have suggested a similar approach 
for constructing confidence intervals for the probability of success parameter of 
the binomial distribution.
Hughes & Pocock (1988) have suggested a Bayesian approach for obtaining 
confidence intervals following a frequentist design. They suggested assigning ji a 
prior distribution at the start of the trial and then calculating its posterior 
distribution on the basis of the observed data after the experiment has ended. 
From this posterior distribution a suitable 100(1 -a)%  Cl may be constructed.
Point Estimates.
We saw in §6.2 that an outstanding problem in sequential analysis concerns 
the calculation of unbiased point estimates for the parameter(s) of interest after an 
experiment. As an example consider again the two-sided hypothesis test on the 
mean of the normal distribution, //. For a fixed sample size experiment the 
maximum likelihood estimate (m.l.e.) of /*, //, is unbiased, i.e. E(fi) = p. 
However the m.l.e. of fi after a sequential experiment may be substantially biased. 
i.e. E (fi) = // + b(/z), where b(/z) is the bias function. This is a particularly 
acute problem when our test stops early to reject H0.
The reason why m.l.e.’s after a sequential trial are biased concerns the data 
dependent stopping rule; we stop early because there is strong evidence against
H0-
It is relatively simple to calculate a median unbiased point estimate of //, fZ, 
after a sequential trial. Median unbiased estimates are such that med(fZ) = //. 
Jennison & Turnbull (1989) suggested ordering the stopping times of our test as 
with the confidence intervals above. A numerical search method is then used to 
calculate fZ such that
Prp((i,Sin) > ( i \S in')) = 0.5.
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To compute mean unbiased estimates of p Whitehead (1986) suggested 
estimating the bias in fi, b(/2), and then subtracting it from fi. He noted that b(/2) 
could be obtained by numerical integration after a group sequential trial.
Hughes & Pocock (1988) have suggested a Bayesian method for the 
calculation of point estimates analogous to their method for CIs. Their claim is 
that the resulting point estimates, based on a posterior distribution for //, correct 
for any bias which may be present.
7.5 Stochastic Curtailment and Predictive Power.
Stochastic curtailment was initially proposed in the literature by Halperin, 
Lan, Ware, Johnson & DeMets (1982). It is an alternative method to sequential 
analysis which allows a single sample study to be terminated early if there is a 
"high" chance that the fixed sample size test is going to accept or reject the null 
hypothesis.
As an example consider again the fixed sample size one-sided test on the 
mean of the normal distribution, /*, introduced in §3.2. After N j observations we 
reject H0: ji< 0  if the standardized test statistic, is greater than
O-1 (1 —or) and accept Hq otherwise. A suitable choice of Nf gives a test with 
Type II error fi at fi = S.
Suppose that after n ( <Nj )  observations the sum of the observed responses 
equals x . Halperin et al. (1982) suggested stopping the trial and rejecting H0 in 
favour of H 1 if
Pr0(SN/HNf<T2 > 0 -* ( l - a )  | Sn =x) > y (7.5.1)
where y  is suitably large. In other words we reject the null hypothesis after n 
observations if the conditional probability of rejecting it after N  observations is 
"large". The probability on the left hand side of (7.5.1) is easily calculated 
numerically.
Similarly we accept H0 if
Prg iS ^ I ^ N ja 1 < ^ ‘( l - a )  | S„ = *) > y \  (7.5.2)
Halperin et al. proved that under the above "stopping rule" the Type I error 
is bounded above by a jy  and the Type n  error is similarly bounded by p jy  . The
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generalization of stochastic curtailment to two-sided tests with or without early 
acceptance of H0 is obvious.
The Bayesian alternative to stochastic curtailment is known as predictive 
power and was discussed by Spiegelhalter, Freedman & Blackburn (1986). The 
decision to stop or continue the trial after n observations is made on the basis of 
the predicted probability of accepting or rejecting H0. This probability is not 
conditional on any parameter value(s).
Suppose the prior distribution for fi is denoted by k {(i  ). Spiegelhalter et al 
(1986) recommended the use of a noninformative prior - for example a normal 
prior with zero mean and variance r02. Then the current distribution for fi after n 
observations is denoted by k ^ ( h \x ) and the probability of the test based on N  
observations rejecting H0, the predictive power, equals
j  Ptm(Sn > cN | x) 7t {n){n\x) dn,
where cN is the critical value of the Bayes test. We reject H0 if the predictive 
power is sufficiently large and accept H0 if it is sufficiently small. Again the 
integral may be calculated numerically.
Both stochastic curtailment and the Bayesian method based on predictive 
power are important approaches which add a degree of flexibility to experimental 
designs. An interesting suggestion for further research would be to consider the 
efficiency of these designs relative to our optimal group sequential tests.
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